Personale

Recapiti

Italiano

Curriculum

Pubblicazioni

Insegnamenti

Alessandro Maria VANNUCCHI

Ruolo attuale:: Professore Ordinario
SSD:: MEDS-09/B - Malattie del sangue
Afferenza organizzativa:: Dipartimento di Medicina Sperimentale e Clinica

Recapiti

	0554277688
	a.vannucchi(AT)unifi.it

Alessandro Maria VANNUCCHI

Curriculum Titoli di studio

1976-Diploma di Maturità Classica, Pistoia, con il massimo dei voti
29/12/1982-Consegue la Laurea in Medicina e Chirurgia presso l’Università degli Studi di Firenze, con il punteggio di 110/110 e Lode, discutendo la tesi “Studio sulla produzione di trombossano A2 piastrinico nelle sindromi mieloproliferative”, pubblicata in J. Nuclear Medicine and Allied Sciences, 1983; 27:206

1983-Consegue l’abilitazione all’esercizio della professione di medico-chirurgo presso l’Università degli Studi di Firenze; da questa data, iscritto all’Ordine dei Medici della provincia di Pistoia prima e di Firenze attualmente

Specializzazioni

09/07/1985
Consegue la Specializzazione in Ematologia generale (clinica e di laboratorio) presso l’Università degli Studi di Firenze, con il punteggio di 70/70 e Lode, discutendo la tesi “Studio sulla crescita in vitro di colonie megacariocitarie in pazienti con disordini mieloproliferativi”, pubblicata in American Journal of Hematology, 1987; 25:371
Borse di studio, premi e riconoscimenti

1983-1985
Vincitore del concorso pubblico, indetto dal Ministero della Pubblica Istruzione, per l’attribuzione di una borsa di studio triennale (1983-1985) per la frequenza della Scuola di Specializzazione in Ematologia della Università di Firenze

1987-1989
Ottiene una borsa di studio della Associazione Italiana per la lotta contro le Leucemie (AIL) per studi sulla emopoiesi normale e patologica, con particolare interesse per le malattie mieloproliferative croniche e le leucemie mieloidi acute.

1994
Riceve il Premio SIBIOC, della Società Italiana di Biochimica Clinica, per una comunicazione orale presentata, in collaborazione con altri Autori, al 26° Congresso Nazionale della Società Italiana di Biochimica Clinica.

2001
Ottiene il Premio Associazione Italiana per le Leucemie per la migliore comunicazione scientifica come coautore, presentata in Sessione plenaria al 38° Congresso Nazionale della SIE, Firenze

1997
Nomina a Honorary Member della New England Cancer Society per “gli studi condotti su aspetti clinico-biologici del trapianto di midollo osseo applicato alle malattie tumorali”

2006-Selezione per Plenary Scientific Session al 48th Annual Meeting of the American Society of Hematology, Orlando, USA
2006

2007

2008-Press Conference in occasione del 48th Annual Meeting of the American Society of Hematology
Lettura Sessione Educazionale al 48th Annual Meeting of the American Society of Hematology, “Thrombocytosis and thrombosis”
Lettura Sessione Educazionale al 13 Annual Meeting European Society of Hematology, “Stratified management of essential thrombocythemia and polycythemia vera”
-

Brevetti


2007
-
E’ primo inventore, in collaborazione con i Dr. Guglielmelli, Ponziani e Pancrazzi, del Brevetto per Invenzione domanda depositata FI2007A000274, relativo ad “Analisi mutazionale delle malattie mieloproliferative croniche”, descrivente una nuova tecnologia per la determinazione quantitativa delle mutazioni a carico del gene MPL nelle malattie mieloproliferative croniche
•    Posizioni professionali ricoperte
2/05/1990-
29/12/1993-Vincitore del concorso per Assistente di ruolo presso la Divisione di Ematologia, Ospedale di Careggi, Firenze, che ricopre dal 2 maggio 1990. Dal momento dell’assunzione in ruolo, ha prestato servizio in maniera continuativa presso il Servizio Trapianti di Midollo Osseo della Divisione di Ematologia, diretta dal Prof. Pierluigi Rossi Ferrini
30/12/1993-
31/12/1994-Vincitore del concorso per la qualifica di Aiuto Corresponsabile ospedaliero presso la stessa Divisione di Ematologia di Firenze
1.01.1995-Attribuzione della qualifica di Dirigente di I° livello, fascia A
02/02/1998-
a tutt’oggi-Attribuzione dell’incarico di Responsabile del settore organizzativo-gestionale del Laboratorio di Ematologia, con anche la responsabilità di sostituire temporaneamente il Direttore della U.O. di Ematologia. Incarico che riveste tutt’ora

01/11/2002-Viene chiamato a ricoprire il ruolo di Professore di II fascia nel settore disciplinare MED15 dalla Facoltà di Medicina e Chirurgia della Università degli Studi di Firenze, dopo avere ottenuto l’idoneità a professore Associato, settore disciplinare MED15 (Malattie del Sangue) nel 2002 (decreto Rettorale n. 5067 del 2 gennaio 2002) presso l’Università Cattolica del Sacro Cuore, Roma, con il seguente Giudizio Collegiale: “Il candidato ha svolto attività didattica di insegnamento sia nell’ambito della Scuola di Specializzazione in Ematologia sia nel Corso di Laurea in Medicina e Chirurgia, ed ha prestato servizio in Università come Professore a contratto. Ha svolto ottima attività di ricerca, congrua al raggruppamento disciplinare F07G/MED15, ed ha prestato attività clinico-assistenziale in una struttura ematologica. La discussione sui titoli è stata convincente e la prova didattica è risultata di eccellente livello.”
01/11/2005-
a tutt’oggi-Associato Confermato nella Facoltà di Medicina e Chirurgia della Università di Firenze per il settore scientifico-disciplinare MED/15 con Decreto Rettorale 313 sel 20/06/2006, ruolo che riveste attualmente

Esperienze di Ricerca all’estero

03/1987-Observer presso il Laboratorio Investigative Cytology , Department of Pathology, del Memorial Sloan-Kettering Cancer Center, New York, diretto dal Dr. Myron R. Melaned, ove ha collaborato a ricerche su modelli matematici di analisi della cinetica di piastrine radiomarcate e su aspetti della differenziazione e caratterizzazione citofluorimetrica di megacariociti umani e murini purificati

25/10/1988-11/11/1988-Visiting Scientist presso la Division of Haematology del United Medical and Dental Schools of Guy’s and St. Thomas Hospital, University of London, , diretto dal Dr. Thomas C. Pearson, ove si è recato dietro invito del Prof. S. Eridani, responsabile del Laboratorio di Ematologia sperimentale, per svolgere ricerche su originali metodiche di analisi della crescita megacariocitaria in vitro, applicata ai disordini delle sindromi mieloproliferative croniche

01/05/1995-
20/10/1995-Visiting Scientist presso il Laboratory of Hematopoietic Growth Factors del New York Blood Center, New York, diretto dalla Dr. Anna Rita Migliaccio, sotto la supervisione del Dr. John Adamson, ove ha condotto ricerche sulla purificazione e caratterizzazione molecolare di cellule staminali emopoietiche murine ed umane, in particolare su aspetti del differenziamento eritroide; ha inoltre approfondito tematiche relative alla caratterizzazione di cellule staminali umane ottenute da sangue di cordone ombelicale, a fine trapiantologico

Attività di ricerca sperimentale
-
I principali campi di interesse attuali della ricerca sperimentale sono rappresentati dallo studio:
di meccanismi di regolazione della eritropoiesi e della megacariocitopoiesi normale
del fattore di trascrizione GATA-1 nella normale emopoiesi
del modello murino GATA-1low come modello di mielofibrosi umana
di alterazioni molecolari nelle neoplasie mieloproliferative, e delle correlazioni tra genotipo e fenotipo
di marcatori molecolari nelle leucemie acute mieloidi
di profili di espressione genica nelle neoplasie mieloproliferative, e del loro possibile ruolo come marcatori di malattia e di risposta alla terapia
di farmaci con attività selettiva nelle neoplasie mieloproliferative
Attività di ricerca clinica
-

dal 2008--Ha partecipato/partecipa, in qualità di investigatore, a studi clinici controllati, condotti secondo le Good Clinical Practices, sia monocentrici che multicentrici, tra i quali i più recenti:
Studio osservazionale Excell di confronto tra Anagrelide e Idrossiurea in pazienti con trombocitemia essenziale ad alto rischio
Studio del Myeloproliferative Disorders Research Consortium- MPD-RC 102, “An open-label phase ? study of Velcade for injection in subjects with myelofibrosis with myeloid metaplasia”
Studio del Myeloproliferative Disorders Research Consortium- MPD-RC 106, “Research Tisseu Bank”
Studio multicentrico GIMEMA CYTO-PV, “Studio clinico controllato per valutare l’efficacia di terapie citoriduttive a diversa intensità nel prevenire gli eventi cardiovascolari in pazienti affetti da Polcitiemia Vera”
E’ coordinatore nazionale dello studio GIMEMA “CYTO-PV, Substudy CY-S1, “Prospective evaluation of the predicitve role of JAK2V617F allele burden on clinical outcome in patients with polycythemia vera”
E’ coordinatore nazionale dello studio multicentrico, finanziato da AIFA, “A phase1/2 trial of RAD001 in patients with myelofibrosis”

-
Pubblicazioni
-
L’attività scientifica del Prof. A.M. Vannucchi è testimoniata dalle pubblicazioni, riportate nell’allegato Elenco delle Pubblicazioni, che possono essere così suddivise:
-Articoli pubblicati in riviste internazionali                         n. 135
Capitoli o sezioni di libro:                                                   n.   29
Comunicazioni per extenso a congressi nazionali e internazionali:
64

Comunicazioni a congressi internazionali:                           n. 169
Comunicazioni a congressi nazionali:                                  n. 125

Relativamente agli articoli pubblicati in riviste internazionali:
46 articoli come primo autore
17 articoli come ultimo autore
•    Il valore Impact Factor (calcolato sui parametri IF 2007), relativamente agli articoli pubblicati in riviste internazionali, è il seguente:

I.F. totale :       682.98
                                          I.F. medio:            5.69
-
-
Finanziamenti per la ricerca
(elenco parziale)
-
-

1997-1998-Responsabile di un progetto finanziato nell’ambito del Progetto finalizzato “30 ore per la vita” della Associazione Italiana per le Leucemie, per la “caratterizzazione di cellule di eritroleucemia umana”

2002-2004-Responsabile di Unità Operativa nell’ambito dei Progetti di ricerca finalizzata 2001, Ministero Italiano della sanità, “On/off regulation between proliferation and differentiation of hematopoietic stem cell” , progetto dal titolo “The GATA-1low mutant as a model for pathogenesis of human myelofibrosis”
2003-2005-Coordinatore Nazionale di un Programma “Mechanism underlying ex vivo expansion of cord blood hematopoietic stem cells and their proper differentiation toward the megakaryocyte phenotype” nell’ambito del “Progetto Nazionale sulle Cellule staminali”, Ministero della Sanità
2003-Responsabile di un Progetto AIRC dal titolo “Role of GATA-1 transcription factor in the pathogenesis of idiopathic myelofibrosis”
2004-Responsabile di un Progetto AIRC dal titolo “Gene expression profiling of idiopathic myelofibrosis cells: an approach to molecular mechanisms of disease”

2003-2004-Responsabile di Unità Operativa nell’ambito di un finanziamento MIUR, COFIN 2003-4, “Ph-negative chronic myeloproliferative disorders: biological and molecular aspects, diagnosis and complication prevention”, progetto dal titolo “Role of transcription factors GATA1/FOG1 in the abnormal regulation of megakaryocytopoiesis in the pathogenesis of chronic myeloproliferative disorders”.

2005-2007-Responsabile di un Progetto triennale AIRC dal titolo “A molecular approach to the pathogenesis and diagnosis of idiopathic myelofibrosis”

2005-2006-Responsabile di un Progetto finanziato dalla Fondazione Cassa di Risparmio (Firenze) (2005, 2006) “Development of innovative diagnostic approaches in patients with idiopathic myelofibrosis”

2006-2008-Responsabile di Unità Operativa nell’ambito di un Progetto di Ricerca Sanitaria Finalizzata del Ministero Italiano della Sanità, dal titolo “Study of the hemangioblast in idiopathic myelofibrosis”

2007-2008

2007-2009-Responsabile di Unità Operativa nell’ambito di un finanziamento MIUR, COFIN 2007-8, “Genomic and functional analysis of hematopoietic cells in chronic myeloproliferative disorders”, programma dal titolo “Analysis of expression profiling in myelofibrosis: pathogenetic and diagnostic implications”
Responsabile nazionale di un progetto multicentrico finanziato da AIFA, “A phase1/2 trial of RAD001 in patients with myelofibrosis”

2008-2009-Responsabile di un Progetto di ricerca finanziato dall’Istituto Toscano Tumori, “Novel therapeutic targets in the Philadelphia-negative chronic myeloproliferative disorders”

-
Partecipazione a gruppi di studio nazionali ed internazionali

-Membro e responsabile locale del Registro Italiano della Mielofibrosi, http://rimm.it
-Membro e responsabile locale del Registro Italiano della Trombocitemia http://rit.it
Membro del International Working Group for Myelofibrosis Research and Treatment, Houston, USA,
http://www.mpdinfo.org/IWG_MRT/membership_roster.html
-Membro del Myeloproliferative Disorder Research Consortium, Mount Sinai Hospital, New York, http://mpd-rc.negrisud.it
Membro del Comitato Direttivo del Working Party delle Malattie mieloproliferative croniche Ph’-negative del GIMEMA

Membro del WP 9 (chronic Myeloproliferative disorders) del European LeukemiaNet
Attività didattica

1991-1993-Tiene il Corso di “Biologia Molecolare” alla Scuola per Tecnici di Laboratorio Biomedico, Firenze
1994-1995-Tiene il Corso di “Patologia Generale” alla Scuola per Tecnici di Laboratorio Biomedico, Firenze
dal 1992 al 2002
Professore a contratto (titolare del Corso Integrativo “Fisiopatologia del sangue e degli organi emopoietici”) presso la Scuola di Specializzazione in Genetica Medica della Università degli Studi di Firenze

Dal 1994 al 1999-Professore a contratto (titolare del Corso Integrativo “Fisiopatologia clinica e inquadramento nosografico della piastrinopoiesi”) presso la Scuola di Specializzazione in Ematologia dell’Università degli Studi di Firenze

Dal 2000 al 2002-Professore a contratto (Corso “Malattie del sangue. Area: Trapianto di cellule staminali emopoietiche”) presso la Scuola di Specializzazione in Ematologia Generale dell’Università degli Studi di Firenze

Dal 2000 al 2002-Professore a contratto (Corso “Malattie del sangue. Area: Laboratorio di Ematologia diagnostico”) presso la Scuola di Specializzazione in Ematologia Generale dell’Università degli Studi di Firenze

Dal 1999 al 2002-Professore a contratto del Corso “Immunologia” presso la Scuola di Specializzazione in Farmacologia Ospedaliera Università di Firenze

AA 2000-2001-Professore a contratto (settore F07G) per Malattie del Sangue nel Corso Integrato di Specialità Medico Chirurgiche I nel corso di Laurea in Medicina e Chirurgia, Università degli Studi di Firenze
2002-
a tutt’oggi-Insegna Malattie del Sangue nel Corso Integrato di Specialità Medico Chirurgiche I nel corso di Laurea in Medicina e Chirurgia, Università degli Studi di Firenze
2003-
a tutt’oggi-Co-titolare del Corso di Tecniche Diagnostiche in Ematologia al Corso di Laurea triennale in Biotecnologie Mediche, Università degli Studi di Firenze
2005-
a tutt’oggi-Titolare del Corso integrato MED/15 in Diagnostica Oncologia al Corso di Laurea specialistica in Biotecnologie Mediche, Percorso Medico-Diagnostico, Università degli Studi di Firenze
2002-
a tutt’oggi-Insegna alla Scuola di Specializzazione in Ematologia, Università degli Studi di Firenze, Corso di malattie della piastrinopoiesi, Corso di Fisopatologia e clinica delle malattie mieloproliferative croniche
-
2002-
a tutt’oggi-Relatore e correlatore di Tesi di Laurea in Medicina e Chirurgia, Biotecnologie Mediche (corso triennale), e Tesi di Specializzazione in Malattie del Sangue
2004-
a tutt’oggi-Membro del Consiglio dei Docenti del Dottorato in Oncologia Clinica e Sperimentale della Facoltà di Medicina e Chirurgia della Università di Firenze

-
Attivita’ editoriali e organizzative

1991-Traduttore della edizione italiana del testo “Hematology” di W.J. Williams, Mc Graw Hill, edizione del 1991 (capitoli 126-146)
1993-Editore (con A. Grossi & P. Rossi Ferrini) del volume “Disorders of erythropoiesis: therapeutical implications”. Wichtig Ed., Milano, di cui ha curato anche la Prefazione
1993-Revisore per il 34° Congresso Nazionale della Società Italiana di Ematologia
1994-Traduttore della edizione italiana del testo “Malattie della emostasi e della trombosi” di W.E. Hathaway & S.H. Goodnight, Mac Graw Hill
1994-Editore (con P. Rossi Ferrini) del volume “Malattie della emostasi e della trombosi” di W.E. Hathaway & S.H. Goodnight, Mac Graw Hill
1994-Tiene la Segreteria Scientifica del Congresso “Alterazioni della eritropoiesi: implicazioni terapeutiche”, Firenze
2001-Membro del Comitato Organizzatore Locale del 38° Congresso Nazionale della Società Italiana di Ematologia
2003-
Chairman del Symposium on Current Perspectives in Myeloproliferative Disorders, XVIIth Meeting of the International Society of Haematology, Graz, 9 settembre
2003-Moderatore all’Incontro su “Interferone in Ematologia”, Firenze
2004-Organizzatore e Moderatore dell’Incontro Discutiamone Insieme “I fattori trascrizionali che regolano l’emopoiesi normale e patologica”, Firenze
2005-Scientific Committe del Workshop of the European Network on Myelofibrosis-EUMNET, Firenze, 23-24 settembre
2006-Scientific Committe del II International Florence Meeting in Hematology “Focus on Ph’-negative chronic myeloproliferative disorders”, Firenze
2007-Revisore per il 49th Annual Meeting of the American Society of Hematology, ASH, Atlanta
2008-Revisore per il 13th Annual Meeting of the European Hematology Association-EHA, Copenhagen
2008-Revisore per il 34th Annual Meeting of the European Group for Blood and Bone Marrow Transplantation-EBMT, Firenze
2007-Responsabile della creazione del sito web della UF di Ematologia del Dipartimento di Area critica della Facoltà di medicina e Chirurgia della Università di Firenze, www.ematologiafirenze.com
2008-2010-Fa parte del Board Editoriale di Haematologica per il trienno 2008-2010

Dal 2000
a tutt’oggi-Effettua regolarmente attività di Revisore per riviste di argomento ematologico quali Blood, Leukemia, Haematologica, British Journal of Haematology, Stem Cells, Leukemia Research, Annals of Hematology, International Journal of Clinical and Laboratory Hematology

-
Attività clinica
Dal momento dell’ assunzione a ruolo presso la Divisione di Ematologia dell’Ospedale di Careggi, Università degli Studi di Firenze, ha operato in maniera continuativa fino al 2006 presso il Servizio Trapianti di Midollo Osseo, partecipando all’attività di programmazione, esecuzione, e follow-up di tutti i trapianti (autologo, da midollo e da sangue periferico, allogenico, da donatore familiare e non familiare, e da cordone ombelicale) effettuati dal Centro, compresa l’attività di sala operatoria per espianto di midollo da pazienti e donatori, e l’attività di monitoraggio ambulatoriale dei pazienti trapiantati.
Ha inoltre acquisito particolare esperienza nel campo delle malattie mieloproliferative croniche, effettuando attività di diagnostica e monitoraggio terapeutico ambulatoriale presso l’Ambulatorio per pazienti esterni della Divisione di Ematologia di Firenze. Dal Settembre 2006, svolge la propria attività assistenziale nell’Ambulatorio per esterni della SODc di Ematologia della Azienda Ospedaliera-Universitaria Careggi, occupandosi della diagnosi, terapia e follow-up delle diverse patologie ematologiche, ma continuando ad occuparsi in particolare della malattie mieloproliferative croniche. A tal riguardo, ha sviluppato un Percorso Diagnostico Integrato per pazienti con Malattie Mieloproliferative croniche.
Si è interessato della messa a punto di alcune tecniche laboratoristiche utilizzate a scopo diagnostico nei pazienti emopatici; tra queste, lo studio della cinetica piastrinica con piastrine radiomarcate; lo studio della crescita spontanea in vitro di progenitori eritroidi e megacariocitari; la ricerca, mediante tecniche di biologia molecolare, del riarrangiamento genico bcl-1, bcl-2, bcl-6 per pazienti con linfoma non-Hodgkin; una metodica di indagine molecolare (ricerca del mRNA per la citocheratina-19) per la determinazione di micrometastasi midollari in pazienti con neoplasia mammaria avviate alla procedura autotrapiantologica; la determinazione, con tecnica molecolare, del grado di chimerismo in pazienti sottoposti a trapianto allogenico di cellule staminali, in particolare con protocolli non-mieloablativi; la definizione del polimorfismo di geni per citochine, in studi volti a definirne il rapporto con la comparsa di complicazioni post-trapiantologiche. Negli ultimi anni, ha coordinato nell’ambito del laboratorio di Diagnostica Molecolare delle Malattie Mieloproliferative croniche, di cui è responsabile, lo sviluppo di metodologie molecolari avanzate per la ricerca e la quantificazione delle mutazioni del gene JAK2, MPL, cKIT, GATA-1, del riarrangiamento PDGFRalpha-FIPL1, nonchè delle più frequenti anomalie molecolari in apzienti con leucemia Mieloide Acuta, quali le duplicazioni del gene FLT3, le mutazioni di NPM1,
In qualità di Responsabile del settore organizzativo-gestionale del Laboratorio di Ematologia, dal 1998 ha curato la organizzazione funzionale di questo stesso.
-
Appartenenza a società scientifiche

Società Italiana di Ematologia (SIE)
Società Italiana di Ematologia Sperimentale (SIES)
European Hematology Association (EHA)
American Society of Hematology (ASH)
European Cooperative Group for Bone Marrow Transplantation (EBMT)

-
Relazioni e Seminari ad invito
Ha tenuto le seguenti letture ad invito (lista parziale, ultimi 5 anni)
2002-Relazione “Valutazione molecolare dell’infiltrazione midollare nei linfomi follicolari e problemi clinici ad essa correlati” . Meeting “Linfomi follicolari. Un workshop per tante domande”, Firenze, 12 aprile 2002
-Relazione “Biologia molecolare” al Corso Residenziale sui Linfomi, Firenze 6 maggio
2003-Relazione “GATA-1 e mielofibrosi: dal modello animale all’uomo”, Workshop “Il registro Italiano della Mielofibrosi, Pavia 9 maggio
-Relazione “Fisiopatologia dell’eritropoiesi”, Meeting “L’anemia nel periodo perioperatorio”, Firenze 17 maggio
-Relazione “Impaired GATA-1 expression and myelofibrosis in an animal model”. (EHA meeting,). Satellite Symposium “New perspectives in the molecular pathogenesis and treatment of myeloproliferative diseases. Scientific meeting of the European Working Group on Myeloproliferative Diseases”. Lyon, 12 giugno
-Relazione “Clinical aspects of myelofibrosis and GATA-1 mutation”, Symposium on Current Perspectives in Myeloproliferative Disorders, XVIIth Meeting of the International Society of Haematology, Graz, 9 settembre
-Relazione “Terapia cellulare dell’infezione da CMV”, Simposio “Infezioni virali nel paziente trapiantato”, Modena 15 settembre
-Relazione “Insights into the role of GATA-1 in the pathogenesis of myelofibrosis”. 2nd International Congress “Myeloproliferative diseases and Myelodysplastic syndromes”, New York, 16-18 ottobre
-Relazione “Linfomi non-Hodgkin follicolari: La biologia Molecolare”. Incontri FirenzEmatologia, Dicembre 1
2004-Relazione “Regolazione trascrizionale della megacariocitopoiesi”, Discutiamone Insieme SIES, Firenze 24 giugno
-Lettura “Regolazione della eritropoiesi”, VIII Congresso Nazionale SIES, Pavia 15 settembre
-Relazione “Ruolo della biologia molecolare nel monitoraggio dei linfomi”, Corso di Aggiornamento “Progressi nella diagnosi e nel trattamento dei linfomi non-Hodgkin”, Firenze 25 settembre
-Lettura “Impiego della eritropoietina nella terapia delle anemie”, XXXVI Convegno Nazionale di Studi di medicina Trasfusionale, Firenze 3 ottobre
2005-Relazione “Eritro e megacariocitopoiesi nella mielofibrosi idiopatica”, Corso Aggiornementi teorico-pratici in Ematologia, Bologna 22 febbraio
-Lettura “Regolazione dell’eritropoiesi”, 3 Congresso Nazionale della Società Italiana di Citometria Clinica e Sperimentale, Palermo 13 aprile
-Relazione “Fisiologia dell’eritropoiesi”, Stage in Ematologia sulle Sindromi Mielodisplastiche, Blogna 9 maggio
-Relazione “Molecula profiling of hematopoietic stem cells in idiopathic myelofibrosis”, International Symposium on Malignant Stem Cells in Idiopathic Myelofibrosis, Firenze 23 settembre
2006-Relazione “Applicazioni del Bortezomib nella mielofibrosi”, Simposio “L’inibitore del proteasoma nelle neoplasie ematologiche”, Firenze 31 marzo
-Relazione “Fisiologia della eritropoiesi”, Corso teorico-pratico su Le anemie refrattarie, Bologna 8 maggio
-Relazione “La mutazione JAK2V617F nelle sindormi mieloproliferative croniche”, Simposio “Siena 1996-2006: 10 anni di progressi diagnostici e terapeutici”, Siena 19 maggio
-Lettura “Molecular markers in idiopathic myelofibrosis”, European School of Haematology, Madeira Portugal, 16 settembre
-Lettura “Molecular markers of the chronic myeloproliferative disorders” al II International Florence Meeting on Ph’-negative chronic myeloproliferative disorders, Firenze 27 ottobre
2007-Relazione “Correlazione genotipo-fenotipo nelle sindormi mieloproliferative croniche JAK2 positive”, Discutiamone Insieme della SIES, aprile 12
-Relazione “La mutazione di JAK2 nelle malattie mieloproliferative croniche”, Corso Residenziale Argomenti di Ematologia Pratica, Bergamo 25 giugno
-Relazione “Genetic and epigenetic events in the pathogenesis of myelofibrosis”, II Workshop of the Italian registry of Myelofibrosis, Pavia 29 giugno
-Relazione “Genotype and clinical phenotype”, Focus on Myeloproliferative and Myelodysplastic syndromes, Bergamo 21 settembre
-Relazione “Biologia molecolare delle malattie mieloproliferative croniche Ph-negative tipiche”, Meeting Educazionale del 41° Congresso Nazionale della SIE, Bologna 17 ottobre
-Relazione “Bortezomib e mielofibrosi”, Meeting su Terapie innovative del
Mieloma Multiplo, Siena 26 ottobre
-Relazione “Thrombocytosis and thrombosis”, Education Program del 49th ASH Annual Meeting, Atlanta, 9-10 dicembre
-Relazione “Epigenetic regulation in MPDs”, Second Global CML Workshop: Did Dameshek get the Myeloproliferative disease right?, Puerto Rico, 12 dicembre
2008-Seminario “Genetica, epigenetica e patogenesi della mielofibrosi”, presso il Dipartimento di Medicina Clinica e Sperimentale della Università di Padova, su invito del prof. G. Semenzato, Pavia 27 marzo
Lettura “Meccanismi molecolari delle malattie mieloproliferative croniche”, Corso Biotecnologie e Medicina della Accademia delle Biotecnologie, Firenze 15 aprile 2008
Relazione “Clinical relevance of JAK2V617F mutational status and allele burden in myelofibrosis”; 1st Annual Scott Richards Symposium on Myelofibrosis, MD Anderson Cancer center, Houston, Tx
Seminario “Genotipo e fenotipo nelle malattei mieloproliferative croniche”, presso il Dip. Di Ematologia della Università di Bari, su invito della prof. G. Specchia, Bari 28 maggio 2008
Lettura “Stratified management of essential thrombocythemia and polycythemia vera”, Educational program, EHA meeting, Copenhagen

Alessandro Maria VANNUCCHI

Pubblicazioni

Legenda

Contributo su rivista |

Articolo su libro |

Libro |

Contributo in atti di convegno (proceeding) |

Brevetto |

Curatela | Altro

Altro |

Tesi di Dottorato

Guglielmelli, Paola; Mora, Barbara; Gesullo, Francesca; Mannelli, Francesco; Loscocco, Giuseppe Gaetano; Signori, Leonardo; Pessina, Chiara; Colugnat, Ilaria; Aquila, Raffaela; Balliu, Manjola; Maccari, Chiara; Romagnoli, Simone; Paoli, Chiara; Nacca, Elena; Fagiolo, Lorenzo; Maffioli, Margherita; Barbui, Tiziano; Passamonti, Francesco; Vannucchi, Alessandro M. (2024). Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia. AMERICAN JOURNAL OF HEMATOLOGY, vol. 99, pp. 1550-1559, ISSN:0361-8609 DOI

Loscocco, Giuseppe G.; Rotunno, Giada; Mannelli, Francesco; Coltro, Giacomo; Gesullo, Francesca; Pancani, Fabiana; Signori, Leonardo; Maccari, Chiara; Esposito, Maria; Paoli, Chiara; Vannucchi, Alessandro M.; Guglielmelli, Paola (2024). The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis. AMERICAN JOURNAL OF HEMATOLOGY, vol. 99, pp. 68-78, ISSN:0361-8609 DOI

Tefferi, Ayalew; Barosi, Giovanni; Passamonti, Francesco; Hernandez-Boluda, Juan Carlos; Bose, Prithviraj; Döhner, Konstanze; Ellis, Martin; Gangat, Naseema; Garcia, Jacqueline S.; Gisslinger, Heinz; Gotlib, Jason; Guglielmelli, Paola; Gupta, Vikas; Harrison, Claire N.; Hexner, Elizabeth O.; Hobbs, Gabriela S; Kiladjian, Jean-Jacques; Koschmieder, Steffen; Kröger, Nicolaus; Kuykendall, Andrew T; Loscocco, Giuseppe Gaetano; Mascarenhas, John O.; Masarova, Lucia; Mesa, Ruben; Mora, Barbara; Odenike, Olatoyosi; Oh, Stephen T.; Pardanani, Animesh D; Patel, Anand A; Pemmaraju, Naveen; Rambaldi, Alessandro; Rampal, Raajit K.; Sirhan, Shireen; Szuber, Natasha; Talpaz, Moshe; Vachhani, Pankit; Vannucchi, Alessandro M.; Barbui, Tiziano (2024). Proposals for Revised International Working Group-European LeukemiaNet Criteria for Anemia Response in Myelofibrosis. BLOOD, pp. 0-0, ISSN:0006-4971 DOI

Barbui, Tiziano; Carobbio, Alessandra; Guglielmelli, Paola; Ghirardi, Arianna; Fenili, Francesca; Loscocco, Giuseppe Gaetano; De Stefano, Valerio; Ramundo, Francesco; Finazzi, Maria Chiara; Rambaldi, Alessandro; Vannucchi, Alessandro M. (2024). Neutrophil/lymphocyte ratio identifies low‐risk polycythaemia vera patients for early Ropeginterferon alfa‐2b therapy. BRITISH JOURNAL OF HAEMATOLOGY, pp. 0-0, ISSN:0007-1048 DOI

Boldrini, Valentina; Vannucchi, Alessandro M.; Guglielmelli, Paola (2024). A safety evaluation of ruxolitinib for the treatment of polycythemia vera. EXPERT OPINION ON DRUG SAFETY, vol. 23, pp. 1-7, ISSN:1474-0338 DOI

Guglielmelli, Paola; Szuber, Natasha; Gangat, Naseema; Capecchi, Giulio; Maccari, Chiara; Harnois, Michaël; Karrar, Omer; Abdelmagid, Maymona; Balliu, Manjola; Nacca, Elena; Atanasio, Alessandro; Sestini, Ilaria; Désilets, Audrey; Loscocco, Giuseppe Gaetano; Rotunno, Giada; Busque, Lambert; Tefferi, Ayalew; Vannucchi, Alessandro Maria (2024). CALR mutation burden in essential thrombocythemia and disease outcome. BLOOD, vol. 143, pp. 1310-1314, ISSN:1528-0020 DOI

Loscocco, Giuseppe G.; Vannucchi, Margherita; Santi, Raffaella; Amorosi, Andrea; Scarpino, Stefania; Siciliano, Maria Chiara; Guglielmelli, Paola; Tripodo, Claudio; Di Napoli, Arianna; Vannucchi, Alessandro M. (2024). Hepatoid thymic carcinoma in a polycythemia vera patient treated with ropeginterferon Alfa-2b: Clinical, histopathological and molecular correlates. PATHOLOGY RESEARCH AND PRACTICE, vol. 263, pp. 0-0, ISSN:0344-0338 DOI

Barbui, Tiziano; Carobbio, Alessandra; Ghirardi, Arianna; Fenili, Francesca; Finazzi, Maria Chiara; Castelli, Marta; Vannucchi, Alessandro M.; Guglielmelli, Paola; Rambaldi, Alessandro; Gangat, Naseema; Tefferi, Ayalew (2024). Neutrophil-to-lymphocyte ratio as a prognostic indicator of mortality in Polycythemia Vera: insights from a prospective cohort analysis. BLOOD CANCER JOURNAL, vol. 14, pp. 0-0, ISSN:2044-5385 DOI

Barbui, Tiziano; Ghirardi, Arianna; Carobbio, Alessandra; De Stefano, Valerio; Rambaldi, Alessandro; Tefferi, Ayalew; Vannucchi, Alessandro M. (2024). Thrombosis in myeloproliferative neoplasms: a viewpoint on its impact on myelofibrosis, mortality, and solid tumors. BLOOD CANCER JOURNAL, vol. 14, pp. 0-0, ISSN:2044-5385 DOI

Ciolli, Gaia; Pasquini, Andrea; Mannelli, Francesco; Scappini, Barbara; Gianfaldoni, Giacomo; Quinti, Elisa; Fasano, Laura; Caroprese, Jessica; Crupi, Francesca; Vannucchi, Alessandro Maria; Piccini, Matteo (2024). Successful rechallenge with Erwinia chrysanthemi asparaginase after pegaspargase-induced hypertriglyceridemia: a case report. THERAPEUTIC ADVANCES IN HEMATOLOGY, vol. 15, pp. 0-0, ISSN:2040-6207 DOI

Ciolli, Gaia; Piccini, Matteo; Mannelli, Francesco; Gianfaldoni, Giacomo; Scappini, Barbara; Fasano, Laura; Crupi, Francesca; Quinti, Elisa; Pasquini, Andrea; Caroprese, Jessica; Rotunno, Giada; Pancani, Fabiana; Signori, Leonardo; Maccari, Chiara; Vanderwert, Fiorenza I.; Guglielmelli, Paola; Vannucchi, Alessandro M. (2024). Prognostic stratification in venetoclax-based acute myeloid leukemia treatments: the molecular prognostic risk signature tested in a real-world setting. HAEMATOLOGICA, pp. 0-0, ISSN:1592-8721 DOI

Giubbilei, Cristina; D'Angelo, Simona; Fotzi, Ilaria; Mogni, Massimo; Guglielmelli, Paola; Vannucchi, Alessandro Maria; Carrai, Valentina (2024). δβ-Thalassemia and α-Triplication: Is Genetic Retesting Worthwhile in Case of Non-Coherent Phenotype?. HEMOGLOBIN, pp. 1-4, ISSN:0363-0269 DOI

Harrison, Claire N; Mesa, Ruben; Talpaz, Moshe; Al-Ali, Haifa Kathrin; Xicoy, Blanca; Passamonti, Francesco; Palandri, Francesca; Benevolo, Giulia; Vannucchi, Alessandro Maria; Mediavilla, Clemence; Iurlo, Alessandra; Kim, InHo; Rose, Shelonitda; Brown, Patrick; Hernandez, Christopher; Wang, Jia; Kiladjian, Jean-Jacques (2024). Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial. THE LANCET. HAEMATOLOGY, vol. 11, pp. 0-0, ISSN:2352-3026 DOI

Carretta, Chiara; Parenti, Sandra; Bertesi, Matteo; Rontauroli, Sebastiano; Badii, Filippo; Tavernari, Lara; Genovese, Elena; Malerba, Marica; Papa, Elisa; Sperduti, Samantha; Enzo, Elena; Mirabile, Margherita; Pedrazzi, Francesca; Neroni, Anita; Tombari, Camilla; Mora, Barbara; Maffioli, Margherita; Mondini, Marco; Brociner, Marco; Maccaferri, Monica; Tenedini, Elena; Martinelli, Silvia; Bartalucci, Niccolò; Bianchi, Elisa; Casarini, Livio; Potenza, Leonardo; Luppi, Mario; Tagliafico, Enrico; Guglielmelli, Paola; Simoni, Manuela; Passamonti, Francesco; Norfo, Ruggiero; Vannucchi, Alessandro Maria; Manfredini, Rossella; null, null (2024). Chromosome 9p trisomy increases stem cells clonogenic potential and fosters T-cell exhaustion in JAK2-mutant myeloproliferative neoplasms. LEUKEMIA, vol. 38, pp. 2171-2182, ISSN:0887-6924 DOI

Attucci, Irene; Pilerci, Sofia; Messeri, Maria; Pengue, Ludovica; Tomasino, Giulia; Caroti, Leonardo; Vannucchi, Alessandro ; Antonioli, Elisabetta (2024). Carfilzomib‐Induced Thrombotic Microangiopathy—Two Case Reports. CANCER REPORTS, vol. 7, pp. 0-0, ISSN:2573-8348 DOI

Coltro, Giacomo; Capecchi, Giulio; Maffioli, Margherita; Mannelli, Francesco; Mora, Barbara; Atanasio, Alessandro; Iurlo, Alessandra; Maccari, Chiara; Farina, Mirko; Nacca, Elena; Caramella, Marianna; Signori, Leonardo; Borella, Miriam; Bertù, Lorenza; Esposito, Maria; Guglielmelli, Paola; Passamonti, Francesco; Vannucchi, Alessandro Maria (2024). Validation and molecular integration of the RR6 model to predict survival after 6 months of therapy with ruxolitinib. HAEMATOLOGICA, vol. 109, pp. 3398-3403, ISSN:1592-8721 DOI

Harrison, Claire N.; Vannucchi, Alessandro M.; Recher, Christian; Passamonti, Francesco; Gerds, Aaron T.; Hernandez-Boluda, Juan Carlos; Yacoub, Abdulraheem; Sirhan, Shireen; Ellis, Catherine; Patel, Bharat; Strouse, Bryan; Platzbecker, Uwe (2024). Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2. ADVANCES IN THERAPY, vol. 41, pp. 3722-3735, ISSN:0741-238X DOI

Ghirardi, Arianna; Carobbio, Alessandra; Guglielmelli, Paola; Rambaldi, Alessandro; De Stefano, Valerio; Vannucchi, Alessandro M.; Tefferi, Ayalew; Barbui, Tiziano (2024). Age-stratified analysis reveals arterial thrombosis as a predictor for gender-related second cancers in myeloproliferative neoplasms: a case-control study. BLOOD CANCER JOURNAL, vol. 14, pp. 0-0, ISSN:2044-5385 DOI

Tavernari, Lara; Rontauroli, Sebastiano; Norfo, Ruggiero; Mirabile, Margherita; Maccaferri, Monica; Mora, Barbara; Genovese, Elena; Parenti, Sandra; Carretta, Chiara; Bianchi, Elisa; Bertesi, Matteo; Pedrazzi, Francesca; Tenedini, Elena; Martinelli, Silvia; Bochicchio, Maria Teresa; Guglielmelli, Paola; Potenza, Leonardo; Lucchesi, Alessandro; Passamonti, Francesco; Tagliafico, Enrico; Luppi, Mario; Vannucchi, Alessandro Maria; Manfredini, Rossella; null, null (2024). Targeting exhausted cytotoxic T cells through CTLA‐4 inhibition promotes elimination of neoplastic cells in human myelofibrosis xenografts. AMERICAN JOURNAL OF HEMATOLOGY, vol. 99, pp. 1939-1950, ISSN:0361-8609 DOI

Verstovsek, Srdan; Mesa, Ruben; Talpaz, Moshe; Kiladjian, Jean-Jacques; Harrison, Claire N.; Oh, Stephen T.; Vannucchi, Alessandro M.; Rampal, Raajit; Scott, Bart L.; Buckley, Sarah A.; Craig, Adam R.; Roman-Torres, Karisse; Mascarenhas, John O. (2024). Erratum to: Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia. HAEMATOLOGICA, vol. 109, pp. 0-0, ISSN:1592-8721 DOI

Gupta, Vikas; Yacoub, Abdulraheem; Mesa, Ruben A.; Harrison, Claire N.; Vannucchi, Alessandro M.; Kiladjian, Jean-Jacques; Deeg, Hans-Joachim; Fazal, Salman; Foltz, Lynda; Mattison, Ryan J.; Miller, Carole B.; Parameswaran, Vinod; Brown, Patrick; Hernandez, Christopher; Wang, Jia; Talpaz, Moshe (2024). Safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: primary analysis of FREEDOM trial. LEUKEMIA & LYMPHOMA, vol. 65, pp. 1314-1324, ISSN:1042-8194 DOI

Tefferi, Ayalew; Vannucchi, Alessandro M. (2024). Risk models in myelofibrosis—the past, present, and future. AMERICAN JOURNAL OF HEMATOLOGY, vol. 99, pp. 519-522, ISSN:0361-8609 DOI

Gerds, Aaron T.; Harrison, Claire; Kiladjian, Jean-Jacques; Mesa, Ruben; Vannucchi, Alessandro M.; Komrokji, Rami; Bose, Prithviraj; Kremyanskaya, Marina; Mead, Adam J.; Gotlib, Jason; Rose, Shelonitda; Sanabria, Fabian; Marsousi, Niloufar; Giuseppi, Ana Carolina; Jiang, Huijing; Palmer, Jeanne M.; McCaul, Kelly; Ribrag, Vincent; Passamonti, Francesco (2024). Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis. BLOOD ADVANCES, vol. 8, pp. 4511-4522, ISSN:2473-9529 DOI

Harrison, Claire N.; Mesa, Ruben; Talpaz, Moshe; Gupta, Vikas; Gerds, Aaron T.; Perkins, Andrew; Goh, Yeow Tee; Fox, Maria Laura; McLornan, Donal; Palmer, Jeanne; Foltz, Lynda; Vannucchi, Alessandro; Koschmieder, Steffen; Passamonti, Francesco; Lee, Sung-Eun; Ellis, Catherine; Strouse, Bryan; Gonzalez Carreras, Francisco J.; Oh, Stephen T. (2024). Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor–Naive or –Experienced Myelofibrosis Treated With Momelotinib. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, pp. 0-0, ISSN:2152-2650 DOI

Tefferi, Ayalew; Vannucchi, Alessandro Maria; Barbui, Tiziano (2024). Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management. AMERICAN JOURNAL OF HEMATOLOGY, vol. 99, pp. 697-718, ISSN:0361-8609 DOI

Tretti Parenzan, Caterina; Molin, Anna Dal; Longo, Giorgia; Gaffo, Enrico; Buratin, Alessia; Cani, Alice; Boldrin, Elena; Serafin, Valentina; Guglielmelli, Paola; Vannucchi, Alessandro M.; Cazzaniga, Giovanni; Biondi, Andrea; Locatelli, Franco; Meyer, Lueder H.; Buldini, Barbara; te Kronnie, Geertruij; Bresolin, Silvia; Bortoluzzi, Stefania (2024). Functional relevance of circRNA aberrant expression in pediatric acute leukemia with KMT2A:: AFF1 fusion. BLOOD ADVANCES, vol. 8, pp. 1305-1319, ISSN:2473-9529 DOI

Tefferi, Ayalew; Vannucchi, Alessandro M. (2024). CALR mutations possess unique prognostic relevance in myelofibrosis—before and after transplant. BONE MARROW TRANSPLANTATION, vol. 59, pp. 1-3, ISSN:0268-3369 DOI

Sharma, Naman; Loscocco, Giuseppe G.; Gangat, Naseema; Guglielmelli, Paola; Pardanani, Animesh; Vannucchi, Alessandro M.; Alkhateeb, Hassan B.; Tefferi, Ayalew; Ho, Vincent T. (2024). When and how to transplant in myelofibrosis – recent trends. LEUKEMIA & LYMPHOMA, pp. 1-19, ISSN:1042-8194 DOI

Abenavoli, Elisabetta M; Linguanti, Flavia; Anichini, Matilde; Miele, Vittorio; Mungai, Francesco; Palazzo, Marianna; Nassi, Luca; Puccini, Benedetta; Romano, Ilaria; Sordi, Benedetta; Sciagra', Roberto; Simontacchi, Gabriele; Vannucchi, Alessandro M; Berti, Valentina (2024). Texture analysis of 18F-FDG PET/CT and CECT: Prediction of refractoriness of Hodgkin lymphoma with mediastinal bulk involvement. HEMATOLOGICAL ONCOLOGY, vol. 42, pp. 0-0, ISSN:1099-1069 DOI Accesso ONLINE all'editore

Loscocco, Giuseppe G.; Gesullo, Francesca; Capecchi, Giulio; Atanasio, Alessandro; Maccari, Chiara; Mannelli, Francesco; Vannucchi, Alessandro M.; Guglielmelli, Paola (2024). One thousand patients with essential thrombocythemia: the Florence-CRIMM experience. BLOOD CANCER JOURNAL, vol. 14, pp. 0-0, ISSN:2044-5385 DOI

Barbui, Tiziano; Carobbio, Alessandra; De Stefano, Valerio; Alvarez-Larran, Alberto; Ghirardi, Arianna; Carioli, Greta; Fenili, Francesca; Rossi, Elena; Ciceri, Fabio; Bonifacio, Massimiliano; Iurlo, Alessandra; Palandri, Francesca; Benevolo, Giulia; Pane, Fabrizio; Ricco, Alessandra; Carli, Giuseppe; Caramella, Marianna; Rapezzi, Davide; Musolino, Caterina; Siragusa, Sergio; Rumi, Elisa; Patriarca, Andrea; Cascavilla, Nicola; Mora, Barbara; Cacciola, Emma; Calabresi, Laura; Loscocco, Giuseppe Gaetano; Guglielmelli, Paola; Gesullo, Francesca; Betti, Silvia; Ramundo, Francesco; Lunghi, Francesca; Scaffidi, Luigi; Bucelli, Cristina; Cattaneo, Daniele; Vianelli, Nicola; Bellini, Marta; Finazzi, Maria Chiara; Tognoni, Gianni; Rambaldi, Alessandro; Vannucchi, Alessandro Maria (2024). Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes. ANNALS OF HEMATOLOGY, vol. 103, pp. 437-442, ISSN:0939-5555 DOI

Rocca, Bianca; Tosetto, Alberto; Petrucci, Giovanna; Rossi, Elena; Betti, Silvia; Soldati, Denise; Iurlo, Alessandra; Cattaneo, Daniele; Bucelli, Cristina; Dragani, Alfredo; Di Ianni, Mauro; Ranalli, Paola; Palandri, Francesca; Vianelli, Nicola; Beggiato, Eloise; Lanzarone, Giuseppe; Ruggeri, Marco; Carli, Giuseppe; Elli, Elena Maria; Renso, Rossella; Randi, Maria Luigia; Bertozzi, Irene; Loscocco, Giuseppe Gaetano; Ricco, Alessandra; Specchia, Giorgina; Vannucchi, Alessandro M.; Rodeghiero, Francesco; De Stefano, Valerio; Patrono, Carlo; null, null (2024). Long‐term pharmacodynamic and clinical effects of twice‐ versus once‐daily low‐dose aspirin in essential thrombocythemia: The ARES trial. AMERICAN JOURNAL OF HEMATOLOGY, vol. 99, pp. 1462-1474, ISSN:0361-8609 DOI

Gianelli, Umberto; Thiele, Jürgen; Orazi, Attilio; Gangat, Naseema; Vannucchi, Alessandro M; Tefferi, Ayalew; Kvasnicka, Hans Michael (2023). International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms. VIRCHOWS ARCHIV, vol. 482, pp. 53-68, ISSN:0945-6317 DOI

Loscocco, Giuseppe G; Ascani, Stefano; Mannelli, Francesco; Zanelli, Magda; Rotunno, Giada; Santi, Raffaella; Vannucchi, Alessandro M (2023). Concomitant myeloproliferative neoplasm with eosinophilia, B and T cell lymphoblastic lymphoma/leukemia and mast cell proliferation driven by ZMYM2::FGFR1 rearrangement. AMERICAN JOURNAL OF HEMATOLOGY, pp. 1-4, ISSN:0361-8609 DOI

Mascarenhas, John; Gleitz, Hélène F E; Chifotides, Helen T; Harrison, Claire N; Verstovsek, Srdan; Vannucchi, Alessandro Maria; Rampal, Raajit K; Kiladjian, Jean-Jacques; Vainchenker, William; Hoffman, Ronald; Schneider, Rebekka K; List, Alan F (2023). Biological drivers of clinical phenotype in myelofibrosis. LEUKEMIA, vol. 37, pp. 255-264, ISSN:1476-5551 DOI

Mascarenhas, John; Kremyanskaya, Marina; Patriarca, Andrea; Palandri, Francesca; Devos, Timothy; Passamonti, Francesco; Rampal, Raajit K; Mead, Adam J; Hobbs, Gabriella; Scandura, Joseph M; Talpaz, Moshe; Granacher, Nikki; Somervaille, Tim C P; Hoffman, Ronald; Wondergem, Marielle J; Salama, Mohamed E; Colak, Gozde; Cui, Jike; Kiladjian, Jean-Jacques; Vannucchi, Alessandro M; Verstovsek, Srdan; Curto-García, Natalia; Harrison, Claire; Gupta, Vikas (2023). MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis. JOURNAL OF CLINICAL ONCOLOGY, pp. 1-13, ISSN:1527-7755 DOI

Sordi, Benedetta; Vanderwert, Fiorenza; Crupi, Francesca; Gesullo, Francesca; Zanotti, Roberta; Bonadonna, Patrizia; Crosera, Lara; Elena, Chiara; Fiorelli, Nicolas; Ferrari, Jacqueline; Grifoni, Federica; Sciumè, Mariarita; Parente, Roberta; Triggiani, Massimo; Palterer, Boaz; Mecheri, Valentina; Almerigogna, Fabio; Santi, Raffaella; Di Medio, Lisa; Brandi, Maria Luisa; Iorno, Maria Loredana; Ciardetti, Isabella; Bencini, Sara; Annunziato, Francesco; Mannarelli, Carmela; Pieri, Lisa; Guglielmelli, Paola; Mannelli, Francesco; Vannucchi, Alessandro M (2023). Disease correlates and clinical relevance of hereditary α-tryptasemia in patients with systemic mastocytosis. THE JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 151, pp. 485-493, ISSN:1097-6825 DOI

Tefferi, Ayalew; Vannucchi, Alessandro M (2023). JAK2 inhibitor treatment of anemia in myelofibrosis. AMERICAN JOURNAL OF HEMATOLOGY, pp. 1-3, ISSN:1096-8652 DOI

Verstovsek, Srdan; Gerds, Aaron T; Vannucchi, Alessandro M; Al-Ali, Haifa Kathrin; Lavie, David; Kuykendall, Andrew T; Grosicki, Sebastian; Iurlo, Alessandra; Goh, Yeow Tee; Lazaroiu, Mihaela C; Egyed, Miklos; Fox, Maria Laura; McLornan, Donal; Perkins, Andrew; Yoon, Sung-Soo; Gupta, Vikas; Kiladjian, Jean-Jacques; Granacher, Nikki; Lee, Sung-Eun; Ocroteala, Luminita; Passamonti, Francesco; Harrison, Claire N; Klencke, Barbara J; Ro, Sunhee; Donahue, Rafe; Kawashima, Jun; Mesa, Ruben (2023). Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study. THE LANCET, vol. 401, pp. 269-280, ISSN:1474-547X DOI

Verstovsek, Srdan; Kiladjian, Jean-Jacques; Vannucchi, Alessandro M; Mesa, Ruben A; Squier, Peg; Hamer-Maansson, J E; Harrison, Claire (2023). Early intervention in myelofibrosis and impact on outcomes: A pooled analysis of the COMFORT-I and COMFORT-II studies. CANCER, pp. 1-10, ISSN:1097-0142 DOI

Verstovsek, Srdan; Mesa, Ruben A; Gupta, Vikas; Lavie, David; Dubruille, Viviane; Cambier, Nathalie; Platzbecker, Uwe; Hus, Marek; Xicoy, Blanca; Oh, Stephen T; Kiladjian, Jean-Jacques; Vannucchi, Alessandro M; Gerds, Aaron T; Egyed, Miklos; Mayer, Jiri; Sacha, Tomasz; Kawashima, Jun; Morris, Marc; Huang, Mei; Harrison, Claire N (2023). Momelotinib Long-Term Safety and Survival in Myelofibrosis: Integrated Analysis of Phase 3 Randomized-Controlled Trials. BLOOD ADVANCES, pp. 1-31, ISSN:2473-9537 DOI

Bianchi, Elisa; Rontauroli, Sebastiano; Tavernari, Lara; Mirabile, Margherita; Pedrazzi, Francesca; Genovese, Elena; Sartini, Stefano; Dall'Ora, Massimiliano; Grisendi, Giulia; Fabbiani, Luca; Maccaferri, Monica; Carretta, Chiara; Parenti, Sandra; Fantini, Sebastian; Bartalucci, Niccolò; Calabresi, Laura; Balliu, Manjola; Guglielmelli, Paola; Potenza, Leonardo; Tagliafico, Enrico; Losi, Lorena; Dominici, Massimo; Luppi, Mario; Vannucchi, Alessandro Maria; Manfredini, Rossella (2023). Inhibition of ERK1/2 signaling prevents bone marrow fibrosis by reducing osteopontin plasma levels in a myelofibrosis mouse model. LEUKEMIA, pp. 1-12, ISSN:0887-6924 DOI Accesso ONLINE all'editore

Arciprete, Francesca; Verachi, Paola; Martelli, Fabrizio; Valeri, Mauro; Balliu, Manjola; Guglielmelli, Paola; Vannucchi, Alessandro Maria; Migliaccio, Anna Rita; Zingariello, Maria (2023). Inhibition of CXCR1/2 reduces the emperipolesis between neutrophils and megakaryocytes in the Gata1low model of myelofibrosis. EXPERIMENTAL HEMATOLOGY, vol. 121, pp. 30-37, ISSN:0301-472X DOI

Mannelli, Francesco; Crupi, Francesca; Zanotti, Roberta; Pagano, Livio; Rapezzi, Davide; Tanasi, Ilaria; Criscuolo, Marianna; Bonifacio, Massimiliano; Fresa, Alberto; Guglielmelli, Paola; Vannucchi, Alessandro M (2023). The clinical experience of compassionate use program for avapritinib: implications for drug positioning in the therapeutic scenario of systemic mastocytosis. THERAPEUTIC ADVANCES IN HEMATOLOGY, vol. 14, pp. 1-14, ISSN:2040-6207 DOI

Marangoni, Davide; Antonello, Roberta Maria; Coppi, Marco; Palazzo, Marianna; Nassi, Luca; Streva, Noemi; Povolo, Laura; Malentacchi, Francesca; Zammarchi, Lorenzo; Rossolini, Gian Maria; Vannucchi, Alessandro Maria; Bartoloni, Alessandro; Spinicci, Michele (2023). Combination regimen of nirmatrelvir/ritonavir and molnupiravir for the treatment of persistent SARS-CoV-2 infection: A case report and a scoping review of the literature. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, vol. 133, pp. 53-56, ISSN:1878-3511 DOI

Calabresi, Laura; Carretta, Chiara; Romagnoli, Simone; Rotunno, Giada; Parenti, Sandra; Bertesi, Matteo; Bartalucci, Niccolò; Rontauroli, Sebastiano; Chiereghin, Chiara; Castellano, Sara; Gentili, Giulia; Maccari, Chiara; Vanderwert, Fiorenza; Mannelli, Francesco; Della Porta, Matteo; Manfredini, Rossella; Vannucchi, Alessandro Maria; Guglielmelli, Paola (2023). Clonal dynamics and copy number variants by single-cell analysis in leukemic evolution of myeloproliferative neoplasms. AMERICAN JOURNAL OF HEMATOLOGY, vol. 98, pp. 1520-1531, ISSN:0361-8609 DOI

Gupta, Vikas; Mascarenhas, John; Kremyanskaya, Marina; Rampal, Raajit K; Talpaz, Moshe; Kiladjian, Jean-Jacques; Vannucchi, Alessandro M; Verstovsek, Srdan; Colak, Gozde; Dey, Debarshi; Harrison, Claire (2023). Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis. BLOOD ADVANCES, vol. 7, pp. 5421-5432, ISSN:2473-9537 DOI

Atanasio, Alessandro; Bernabini, Sara; Consagra, Angela; Giotti, Irene; Carrai, Valentina; Pelo, Elisabetta; Vannucchi, Alessandro Maria (2023). Testing for rare types of Hereditary Hemochromatosis. A genetic study of two Italian families affected by early onset iron overload. INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, vol. 45, pp. 784-787, ISSN:1751-5521 DOI

g loscocco; am vannucchi (2023). Myeloid sarcoma: more and less than a distinct entity. ANNALS OF HEMATOLOGY, pp. 1-12, ISSN:0939-5555 DOI

Mannelli, Francesco; Guglielmelli, Paola; Fazi, Paola; Crea, Enrico; Piciocchi, Alfonso; Vignetti, Marco; Amadori, Sergio; Pane, Fabrizio; Venditti, Adriano; Vannucchi, Alessandro M (2023). ENABLE: treatment combination including decitabine and venetoclax in acute myeloid leukemia secondary to myeloproliferative neoplasms. FUTURE ONCOLOGY, vol. 19, pp. 103-111, ISSN:1744-8301 DOI

Mannelli, Francesco; Gesullo, Francesca; Mannarelli, Carmela; Vanderwert, Fiorenza; Lazzi, Stefano; Mungai, Francesco; Berti, Valentina; Santi, Raffaella; Guglielmelli, Paola; Vannucchi, Alessandro M (2023). Diagnostic and therapeutic challenges in mast cell sarcoma. AMERICAN JOURNAL OF HEMATOLOGY, vol. 98, pp. 529-532, ISSN:0361-8609 DOI

Coltro, Giacomo; Sant'Antonio, Emanuela; Palumbo, Giuseppe A; Mannelli, Francesco; De Stefano, Valerio; Ruggeri, Marco; Elli, Elena M; Zanotti, Roberta; Borsani, Oscar; Bertozzi, Irene; Duminuco, Andrea; Betti, Silvia; Carli, Giuseppe; Cavalca, Fabrizio; Tanasi, Ilaria; Rumi, Elisa; Randi, Maria L; Garibaldi, Bruno; Loscocco, Giuseppe G; Guglielmelli, Paola; Vannucchi, Alessandro M (2023). Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project. CANCER MEDICINE, vol. 12, pp. 8166-8171, ISSN:2045-7634 DOI

Polverelli, Nicola; Hernández-Boluda, Juan Carlos; Czerw, Tomasz; Barbui, Tiziano; D'Adda, Mariella; Deeg, Hans Joachim; Ditschkowski, Markus; Harrison, Claire; Kröger, Nicolaus Martin; Mesa, Ruben; Passamonti, Francesco; Palandri, Francesca; Pemmaraju, Naveen; Popat, Uday; Rondelli, Damiano; Vannucchi, Alessandro Maria; Verstovsek, Srdan; Robin, Marie; Colecchia, Antonio; Grazioli, Luigi; Damiani, Enrico; Russo, Domenico; Brady, Jessica; Patch, David; Blamek, Slawomir; Damaj, Gandhi Laurent; Hayden, Patrick; McLornan, Donal P; Yakoub-Agha, Ibrahim (2023). Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT. THE LANCET. HAEMATOLOGY, vol. 10, pp. 59-70, ISSN:2352-3026 DOI

Atanasio, A; Vanni, A; Maggi, L; Pilerci, S; Mazzoni, A; Capone, M; Crupi, F; Cicogna, P; Boldrini, V; Tekle, S; Colao, M G; Borella, M; Paoli, C; Rossolini, G M; Vannucchi, A M; Annunziato, F; Guglielmelli, P (2023). Humoral and cellular responses after third dose of SARS-CoV-2 vaccine in myeloproliferative neoplasms patients on ruxolitinib therapy. LEUKEMIA RESEARCH, vol. 131, pp. 107330-107330, ISSN:0145-2126 DOI

Barbui T, Vannucchi AM, De Stefano V, Carobbio A, Ghirardi A, Carioli G, Masciulli A, Rossi E, Ciceri F, Bonifacio M, Iurlo A, Palandri F, Benevolo G, Pane F, Ricco A, Carli G, Caramella M, Rapezzi D, Musolino C, Siragusa S, Rumi E, Patriarca A, Cascavilla N, Mora B, Cacciola E, Mannarelli C, Loscocco GG, Guglielmelli P, Gesullo F, Betti S, Lunghi F, Scaffidi L, Bucelli C, Vianelli N, Bellini M, Finazzi MC, Tognoni G, Rambaldi A (2023). Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera. NEJM EVIDENCE, pp. NEJM Evid 2023; 2 (6)-NEJM Evid 2023; 2 (6), ISSN:2766-5526 DOI

Antonioli, Elisabetta; Pilerci, Sofia; Attucci, Irene; Buda, Gabriele; Gozzetti, Alessandro; Candi, Veronica; Simonetti, Federico; Giudice, Maria Livia Del; Ciofini, Sara; Staderini, Michela; Grammatico, Sara; Buzzichelli, Alessandra; Messeri, Maria; Bocchia, Monica; Galimberti, Sara; Vannucchi, Alessandro M (2023). Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network. FRONTIERS IN ONCOLOGY, vol. 13, pp. 0-0, ISSN:2234-943X DOI

Barbui, Tiziano; Carobbio, Alessandra; Thiele, Juergen; Gangat, Naseema; Rumi, Elisa; Rambaldi, Alessandro; Vannucchi, Alessandro M.; Tefferi, Ayalew; null, null; Jeryczynski, Georg; Müllauer, Leonhard; Vaidya, Rakhee; Sulai, Nanna H.; Pardanani, Animesh; Larson, Dirk R.; Cazzola, Mario; Casetti, Ilaria; Finazzi, Guido; Pieri, Lisa; Gisslinger, Heinz; Gisslinger, Bettina; Rodeghiero, Francesco; Ruggeri, Marco; Randi, Maria Luigia; Bertozzi, Irene; Passamonti, Francesco (2023). The impact of thrombosis on probabilities of death and disease progression in polycythemia vera: a multistate transition analysis of 1,545 patients. BLOOD CANCER JOURNAL, vol. 13, pp. 0-0, ISSN:2044-5385 DOI

Kiladjian, Jean-Jacques; Vannucchi, Alessandro M.; Gerds, Aaron T.; Gupta, Vikas; Verstovsek, Srdan; Egyed, Miklos; Platzbecker, Uwe; Mayer, Jiří; Grosicki, Sebastian; Illés, Árpád; Woźny, Tomasz; Oh, Stephen T.; McLornan, Donal; Kirgner, Ilya; Yoon, Sung-Soo; Harrison, Claire N.; Klencke, Barbara; Huang, Mei; Kawashima, Jun; Mesa, Ruben (2023). Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials. HEMASPHERE, vol. 7, pp. 0-0, ISSN:2572-9241 DOI

Barbui, Tiziano; Carobbio, Alessandra; Vannucchi, Alessandro M.; De Stefano, Valerio (2023). Are the available data sufficient to suggest cytoreductive agents for patients with CHIP and stroke?. BLOOD ADVANCES, vol. 7, pp. 7551-7553, ISSN:2473-9529 DOI

Abenavoli, Elisabetta Maria; Barbetti, Matteo; Linguanti, Flavia; Mungai, Francesco; Nassi, Luca; Puccini, Benedetta; Romano, Ilaria; Sordi, Benedetta; Santi, Raffaella; Passeri, Alessandro; Sciagrà, Roberto; Talamonti, Cinzia; Cistaro, Angelina; Vannucchi, Alessandro Maria; Berti, Valentina (2023). Characterization of Mediastinal Bulky Lymphomas with FDG-PET-Based Radiomics and Machine Learning Techniques. CANCERS, vol. 15, pp. 0-0, ISSN:2072-6694 DOI

Vannucchi, Alessandro Maria; Guglielmelli, Paola (2023). Acute Myocardial Infarction and Chronic Myeloproliferative Neoplasms: Friend and Enemy, Depending on Circumstances. JACC. CARDIOONCOLOGY, vol. 5, pp. 469-471, ISSN:2666-0873 DOI

Mora, Barbara; Maffioli, Margherita; Rumi, Elisa; Guglielmelli, Paola; Caramella, Marianna; Kuykendall, Andrew; Palandri, Francesca; Iurlo, Alessandra; De Stefano, Valerio; Kiladjian, Jean-Jacques; Elli, Elena M; Polverelli, Nicola; Gotlib, Jason; Albano, Francesco; Silver, Richard T; Benevolo, Giulia; Ross, David M; Devos, Timothy; Borsani, Oscar; Barbui, Tiziano; Porta, Matteo G Della; Bertù, Lorenza; Komrokji, Rami; Vannucchi, Alessandro M; Passamonti, Francesco (2023). Incidence of blast phase in myelofibrosis according to anemia severity. EJHAEM, vol. 4, pp. 679-689, ISSN:2688-6146 DOI

Karrar, Omer S; Abdelmagid, Maymona; Vannucchi, Alessandro M; Barbui, Tiziano; Tefferi, Ayalew; Gangat, Naseema (2023). ABO blood group type and risk of venous thrombosis in essential thrombocythemia. BRITISH JOURNAL OF HAEMATOLOGY, vol. 202, pp. 699-703, ISSN:0007-1048 DOI

Carobbio, Alessandra; Vannucchi, Alessandro Maria; Rumi, Elisa; De Stefano, Valerio; Rambaldi, Alessandro; Carli, Giuseppe; Randi, Maria Luigia; Gisslinger, Heinz; Passamonti, Francesco; Thiele, Juergen; Gangat, Naseema; Tefferi, Ayalew; Barbui, Tiziano (2023). Survival expectation after thrombosis and overt-myelofibrosis in essential thrombocythemia and prefibrotic myelofibrosis: a multistate model approach. BLOOD CANCER JOURNAL, vol. 13, pp. 1-3, ISSN:2044-5385 DOI

Mannelli, Francesco; Piccini, Matteo; Bencini, Sara; Gianfaldoni, Giacomo; Peruzzi, Benedetta; Caporale, Roberto; Scappini, Barbara; Fasano, Laura; Quinti, Elisa; Ciolli, Gaia; Pasquini, Andrea; Crupi, Francesca; Pilerci, Sofia; Pancani, Fabiana; Signori, Leonardo; Tarantino, Danilo; Maccari, Chiara; Paradiso, Vivian; Annunziato, Francesco; Guglielmelli, Paola; Vannucchi, Alessandro M (2023). Effect of age and treatment on predictive value of measurable residual disease: implications for clinical management of adult patients with acute myeloid leukemia. HAEMATOLOGICA, pp. 0-0, ISSN:1592-8721 DOI

Mesa, Ruben; Verstovsek, Srdan; Platzbecker, Uwe; Gupta, Vikas; Lavie, David; Giraldo, Pilar; Recher, Christian; Kiladjian, Jean-Jacques; Oh, Stephen T; Gerds, Aaron T; Devos, Timothy; Passamonti, Francesco; Vannucchi, Alessandro M; Egyed, Miklos; Lech-Maranda, Ewa; Pluta, Andrzej; Nilsson, Lars; Shimoda, Kazuya; McLornan, Donal; Kawashima, Jun; Klencke, Barbara; Huang, Mei; Strouse, Bryan; Harrison, Claire (2023). Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib. HAEMATOLOGICA, pp. 0-0, ISSN:1592-8721 DOI

Tefferi, Ayalew; Loscocco, Giuseppe G; Farrukh, Faiqa; Szuber, Natasha; Mannelli, Francesco; Pardanani, Animesh; Hanson, Curtis A; Ketterling, Rhett P; De Stefano, Valerio; Carobbio, Alessandra; Barbui, Tiziano; Guglielmelli, Paola; Gangat, Naseema; Vannucchi, Alessandro M (2023). A globally applicable "triple A" risk model for essential thrombocythemia based on Age, Absolute neutrophil count, and Absolute lymphocyte count. AMERICAN JOURNAL OF HEMATOLOGY, pp. 0-0, ISSN:0361-8609 DOI

Mascarenhas, John; Migliaccio, Anna Rita; Kosiorek, Heidi; Bhave, Rupali; Palmer, Jeanne; Kuykendall, Andrew; Mesa, Ruben; Rampal, Raajit K; Gerds, Aaron T; Yacoub, Abdulraheem; Pettit, Kristen; Talpaz, Moshe; Komrokji, Rami; Kremyanskaya, Marina; Gonzalez, Agapito; Fabris, Frank; Johnson, Kathryn; Dougherty, Mikaela; McGovern, Erin; Arango Ossa, Juan; Domenico, Dylan; Farnoud, Noushin; Weinberg, Rona Singer; Kong, Amy; Najfeld, Vesna; Vannucchi, Alessandro Maria; Arciprete, Francesca; Zingariello, Maria; Falchi, Mario; Salama, Mohamed E; Mead-Harvey, Carolyn; Dueck, Amylou; Varricchio, Lilian; Hoffman, Ronald (2023). A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis. CLINICAL CANCER RESEARCH, vol. 29, pp. 3622-3632, ISSN:1078-0432 DOI

Romagnoli, Simone; Bartalucci, Niccolò; Vannucchi, Alessandro Maria (2023). Resolving complex structural variants via nanopore sequencing. FRONTIERS IN GENETICS, vol. 14, pp. 0-0, ISSN:1664-8021 DOI

Paggi, Riccardo; Mariotti, Francesca; Mencarini, Jessica; Bresci, Silvia; Campolmi, Irene; Bartalesi, Filippo; Borchi, Beatrice; Nassi, Luca; Sordi, Benedetta; Vannucchi, Alessandro Maria; Bartoloni, Alessandro (2023). Orbital Infiltration in a Patient with Waldenström Macroglobulinemia: Need for Multidisciplinary Approach and Comparison with the Literature. MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, vol. 15, pp. e2023028-0, ISSN:2035-3006 DOI Accesso ONLINE all'editore

Shomali, William; Colucci, Philomena; George, Tracy I; Kiladjian, Jean-Jacques; Langford, Cheryl; Patel, Jay L; Reiter, Andreas; Vannucchi, Alessandro M; Gotlib, Jason (2023). Comprehensive response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: a proposal from the MLN International Working Group. LEUKEMIA, vol. 37, pp. 981-987, ISSN:0887-6924 DOI

Guglielmelli, Paola; Maccari, Chiara; Sordi, Benedetta; Balliu, Manjola; Atanasio, Alessandro; Mannarelli, Carmela; Capecchi, Giulio; Sestini, Ilaria; Coltro, Giacomo; Loscocco, Giuseppe Gaetano; Rotunno, Giada; Angori, Eva; Borri, Filippo C; Tefferi, Ayalew; Vannucchi, Alessandro M (2023). Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis. BLOOD CANCER JOURNAL, vol. 13, pp. 21-21, ISSN:2044-5385 DOI

Barbui, Tiziano; Ghirardi, Arianna; Carobbio, Alessandra; Masciulli, Arianna; Carioli, Greta; Rambaldi, Alessandro; Finazzi, Maria Chiara; Bellini, Marta; Rumi, Elisa; Vanni, Daniele; Borsani, Oscar; Passamonti, Francesco; Mora, Barbara; Brociner, Marco; Guglielmelli, Paola; Paoli, Chiara; Alvarez-Larran, Alberto; Triguero, Ana; Garrote, Marta; Pettersson, Helna; Andréasson, Björn; Barosi, Giovanni; Vannucchi, Alessandro Maria (2022). Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score. BLOOD CANCER JOURNAL, vol. 12, pp. 156-156, ISSN:2044-5385 DOI

Loscocco, Giuseppe G; Guglielmelli, Paola; Mannelli, Francesco; Mora, Barbara; Mannarelli, Carmela; Rotunno, Giada; Pancani, Fabiana; Maccari, Chiara; Bartalucci, Niccolò; Romagnoli, Simone; Coltro, Giacomo; Passamonti, Francesco; Vannucchi, Alessandro M (2022). SF3B1 mutations in primary and secondary myelofibrosis: Clinical, molecular and prognostic correlates. AMERICAN JOURNAL OF HEMATOLOGY, vol. 97, pp. E347-E349, ISSN:1096-8652 DOI

Mascarenhas, John; Kremyanskaya, Marina; Patriarca, Andrea; Harrison, Claire; Bose, Prithviraj; Rampal, Raajit K; Palandri, Francesca; Devos, Timothy; Passamonti, Francesco; Hobbs, Gabriela; Talpaz, Moshe; Vannucchi, Alessandro; Kiladjian, Jean-Jacques; Verstovsek, Srdan; Hoffman, Ron; Salama, Mohamed E; Chen, Dong; Taverna, Pietro; Chang, Alex; Colak, Gozde; Klein, Sandra; Gupta, Vikas (2022). MPN-375 BET Inhibitor Pelabresib (CPI-0610) Combined With Ruxolitinib in Patients With Myelofibrosis - JAK Inhibitor-Naïe or With Suboptimal Response to Ruxolitinib - Preliminary Data From the MANIFEST Study. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol. 22 Suppl 2, pp. 335-336, ISSN:2152-2669 DOI

Passamonti, Francesco; Harrison, Claire N; Mesa, Ruben A; Kiladjian, Jean-Jacques; Vannucchi, Alessandro M; Verstovsek, Srdan (2022). Anemia in myelofibrosis: Current and emerging treatment options. CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY, vol. 180, pp. 103862-103862, ISSN:1879-0461 DOI

Verstovsek, Srdan; Al-Ali, Haifa Kathrin; Mascarenhas, John; Perkins, Andrew; Vannucchi, Alessandro Maria; Mohan, Sanjay R; Scott, Bart L; Woszczyk, Dariusz; Koschmieder, Steffen; García-Delgado, Regina; László, Rejtő; McGreivy, Jesse S; Rothbaum, Wayne P; Kiladjian, Jean-Jacques (2022). BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis. FUTURE ONCOLOGY, pp. 4059-4069, ISSN:1744-8301 DOI

Zappasodi, Patrizia; Cattaneo, Chiara; Valeria Ferretti, Virginia; Mina, Roberto; José María Ferreri, Andrés; Merli, Francesco; Oberti, Margherita; Krampera, Mauro; Romano, Alessandra; Zerbi, Caterina; Ferrari, Jacqueline; Cavo, Michele; Salvini, Marco; Bertù, Lorenza; Stefano Fracchiolla, Nicola; Marchesi, Francesco; Massaia, Massimo; Marasco, Vincenzo; Cairoli, Roberto; Maria Scattolin, Anna; Maria Vannucchi, Alessandro; Gambacorti-Passerini, Carlo; Musto, Pellegrino; Gherlinzoni, Filippo; Cuneo, Antonio; Pinto, Antonello; Trentin, Livio; Bocchia, Monica; Galimberti, Sara; Coviello, Elisa; Chiara Tisi, Maria; Morotti, Alessandro; Falini, Brunangelo; Turrini, Mauro; Tafuri, Agostino; Billio, Atto; Gentile, Massimo; Massimo Lemoli, Roberto; Venditti, Adriano; Giovanni Della Porta, Matteo; Lanza, Francesco; Rigacci, Luigi; Tosi, Patrizia; Mohamed, Sara; Corso, Alessandro; Luppi, Mario; Giuliani, Nicola; Busca, Alessandro; Pagano, Livio; Bruno, Raffaele; Antonio Grossi, Paolo; Corradini, Paolo; Passamonti, Francesco; Arcaini, Luca (2022). Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV. HEMATOLOGICAL ONCOLOGY, vol. 40, pp. 846-856, ISSN:1099-1069 DOI

Loscocco GG, Santi R, Mannarelli C, Mannelli F, Gesullo F, Coltro G, Guglielmelli P, Gianelli U, Vannucchi AM (2022). Clinical, Molecular, and Histopathological Correlates in a Series of 24 Consecutive Cases of Suspected Myeloproliferative Neoplasms with a JAK2V617F Variant Allele Frequency≤ 1%. In: American Society of Hematology (ASH) 2022, Blood, pp. 9714-9716. DOI

Guglielmelli P, Irushani Vanderwert F, Romagnoli S, Coltro G, Loscocco GG, Mannelli F, Calabresi L, Gentili G, Rotunno G, Bartalucci N, Boldrini V, Sant'Antonio E, Tarantino D, Pieraccioli M, Vannucchi AM (2022). Molecular Characterization of Response/Loss-of-Response to Ruxolitinib in Patients with Myelofibrosis. In: American Society of Hematology (ASH) 2022, Blood, pp. 832-833. DOI

Duncavage, Eric J; Bagg, Adam; Hasserjian, Robert P; DiNardo, Courtney D; Godley, Lucy A; Iacobucci, Ilaria; Jaiswal, Siddhartha; Malcovati, Luca; Vannucchi, Alessandro M; Patel, Keyur P; Arber, Daniel A; Arcila, Maria E; Bejar, Rafael; Berliner, Nancy; Borowitz, Michael J; Branford, Susan; Brown, Anna L; Cargo, Catherine A; Döhner, Hartmut; Falini, Brunangelo; Garcia-Manero, Guillermo; Haferlach, Torsten; Hellström-Lindberg, Eva; Kim, Annette S; Klco, Jeffery M; Komrokji, Rami S; Loh, Mignon L; Loghavi, Sanam; Mullighan, Charles G; Ogawa, Seishi; Tefferi, Ayalew; Papaemmanuil, Elli; Reiter, Andreas; Ross, David Morrall; Savona, Michael R; Shimamura, Akiko; Skoda, Radek C; Sole, Francesc; Stone, Richard M; Orazi, Attilio; Walter, Matthew J; Wu, David; Ebert, Benjamin L; Cazzola, Mario (2022). Genomic Profiling for Clinical Decision Making in Myeloid Neoplasms and Acute Leukemia. BLOOD, vol. 140, pp. 2228-2247, ISSN:0006-4971 DOI

Vannucchi, Alessandro Maria; Guglielmelli, Paola (2022). Molecular prognostication in Ph-negative MPNs in 2022. HEMATOLOGY, vol. 2022, pp. 225-234, ISSN:1520-4391 DOI

Reiter, Andreas; Schwaab, Juliana; DeAngelo, Daniel J; Gotlib, Jason R; Deininger, Michael W; Pettit, Kristen M; Álvarez-Twose, Iván; Vannucchi, Alessandro M; Panse, Jens Peter; Platzbecker, Uwe; Hermine, Olivier; Dybedal, Ingunn; Lin, Hui-Min; Rylova, Svetlana N; Ehlert, Katrin Maria; Dimitrijević, Saša; Radia, Deepti H (2022). Efficacy and Safety of Avapritinib in Previously Treated Patients with Advanced Systemic Mastocytosis. BLOOD ADVANCES, pp. 1-45, ISSN:2473-9529 DOI Accesso ONLINE all'editore

Arber, Daniel A; Orazi, Attilio; Hasserjian, Robert P; Borowitz, Michael J; Calvo, Katherine R; Kvasnicka, Hans-Michael; Wang, Sa A; Bagg, Adam; Barbui, Tiziano; Branford, Susan; Bueso-Ramos, Carlos E; Cortes, Jorge E; Dal Cin, Paola; DiNardo, Courtney D; Dombret, Hervé; Duncavage, Eric J; Ebert, Benjamin L; Estey, Elihu H; Facchetti, Fabio; Foucar, Kathryn; Gangat, Naseema; Gianelli, Umberto; Godley, Lucy A; Gökbuget, Nicola; Gotlib, Jason; Hellström-Lindberg, Eva; Hobbs, Gabriela S; Hoffman, Ronald; Jabbour, Elias J; Kiladjian, Jean-Jacques; Larson, Richard A; Le Beau, Michelle M; Loh, Mignon L-C; Löwenberg, Bob; Macintyre, Elizabeth; Malcovati, Luca; Mullighan, Charles G; Niemeyer, Charlotte; Odenike, Olatoyosi M; Ogawa, Seishi; Orfao, Alberto; Papaemmanuil, Elli; Passamonti, Francesco; Porkka, Kimmo; Pui, Ching-Hon; Radich, Jerald P; Reiter, Andreas; Rozman, Maria; Rudelius, Martina; Savona, Michael R; Schiffer, Charles A; Schmitt-Graeff, Annette; Shimamura, Akiko; Sierra, Jorge; Stock, Wendy A; Stone, Richard M; Tallman, Martin S; Thiele, Jürgen; Tien, Hwei-Fang; Tzankov, Alexandar; Vannucchi, Alessandro M; Vyas, Paresh; Wei, Andrew H; Weinberg, Olga K; Wierzbowska, Agnieszka; Cazzola, Mario; Döhner, Hartmut; Tefferi, Ayalew (2022). International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. BLOOD, vol. 140, pp. 1200-1228, ISSN:1528-0020 DOI

Barbui, Tiziano; Carobbio, Alessandra; Ghirardi, Arianna; Iurlo, Alessandra; De Stefano, Valerio; Sobas, Marta Anna; Rumi, Elisa; Elli, Elena Maria; Lunghi, Francesca; Gasior Kabat, Mercedes; Cuevas, Beatriz; Guglielmelli, Paola; Bonifacio, Massimiliano; Marchetti, Monia; Alvarez-Larran, Alberto; Fox, Laura; Bellini, Marta; Daffini, Rosa; Benevolo, Giulia; Carreno-Tarragona, Gonzalo; Patriarca, Andrea; Al-Ali, Haifa Kathrin; Andrade-Campos, Maria Marcio Miguel; Palandri, Francesca; Harrison, Claire; Foncillas, Maria Angeles; Osorio, Santiago; Koschmieder, Steffen; Magro Mazo, Elena; Kiladjian, Jean-Jacques; Bolaños Calderón, Estefanía; Heidel, Florian H; Quiroz Cervantes, Keina; Griesshammer, Martin; Garcia-Gutierrez, Valentin; Sanchez, Alberto Marin; Hernandez-Boluda, Juan Carlos; Lopez Abadia, Emma; Carli, Giuseppe; Sagues Serrano, Miguel; Kusec, Rajko; Xicoy Cirici, Blanca; Guenova, Margarita; Navas Elorza, Begona; Angona, Anna; Cichocka, Edyta; Kulikowska de Nałęcz, Anna; Cattaneo, Daniele; Bucelli, Cristina; Betti, Silvia; Borsani, Oscar; Cavalca, Fabrizio; Carbonell, Sara; Curto-Garcia, Natalia; Benajiba, Lina; Rambaldi, Alessandro; Vannucchi, Alessandro Maria (2022). Breakthrough infections in MPN-COVID vaccinated patients. BLOOD CANCER JOURNAL, vol. 12, pp. 154-154, ISSN:2044-5385 DOI

Aspite, Silvia; Schepis, Filippo; Roccarina, Davide; Gitto, Stefano; Citone, Michele; Di Bonaventura, Chiara; Bianchini, Marcello; Arena, Umberto; Vannucchi, Alessandro M; Guglielmelli, Paola; Campani, Francesca; Fanelli, Fabrizio; Marra, Fabio; Vizzutti, Francesco (2022). Portosystemic shunt is an effective treatment for complications of portal hypertension in hepatic myeloid metaplasia and improves nutritional status. LIVER INTERNATIONAL, vol. 42, pp. 419-424, ISSN:1478-3223 DOI

Barbui, Tiziano; Iurlo, Alessandra; Masciulli, Arianna; Carobbio, Alessandra; Ghirardi, Arianna; Carioli, Greta; Sobas, Marta Anna; Elli, Elena Maria; Rumi, Elisa; De Stefano, Valerio; Lunghi, Francesca; Marchetti, Monia; Daffini, Rosa; Gasior Kabat, Mercedes; Cuevas, Beatriz; Fox, Maria Laura; Andrade-Campos, Marcio Miguel; Palandri, Francesca; Guglielmelli, Paola; Benevolo, Giulia; Harrison, Claire; Foncillas, Maria Angeles; Bonifacio, Massimiliano; Alvarez-Larran, Alberto; Kiladjian, Jean-Jacques; Bolaños Calderón, Estefanía; Patriarca, Andrea; Quiroz Cervantes, Keina; Griessammer, Martin; Garcia-Gutierrez, Valentin; Marin Sanchez, Alberto; Magro Mazo, Elena; Ruggeri, Marco; Hernandez-Boluda, Juan Carlos; Osorio, Santiago; Carreno-Tarragona, Gonzalo; Sagues Serrano, Miguel; Kusec, Rajko; Navas Elorza, Begona; Angona, Anna; Xicoy Cirici, Blanca; Lopez Abadia, Emma; Koschmieder, Steffen; Cattaneo, Daniele; Bucelli, Cristina; Cichocka, Edyta; Masternak Kulikowska de Nałęcz, Anna; Cavalca, Fabrizio; Borsani, Oscar; Betti, Silvia; Benajiba, Lina; Bellini, Marta; Curto-Garcia, Natalia; Rambaldi, Alessandro; Vannucchi, Alessandro Maria (2022). Second versus first wave of COVID-19 in patients with MPN. LEUKEMIA, vol. 36, pp. 897-900, ISSN:0887-6924 DOI

Guglielmelli, Paola; Kiladjian, Jean-Jacques; Vannucchi, Alessandro M; Duan, Minghui; Meng, Haitao; Pan, Ling; He, Guangsheng; Verstovsek, Srdan; Boyer, Françoise; Barraco, Fiorenza; Niederwieser, Dietger; Pungolino, Ester; Liberati, Anna Marina; Harrison, Claire; Roussou, Pantelia; Wroclawska, Monika; Karumanchi, Divyadeep; Sinclair, Karen; Te Boekhorst, Peter A W; Gisslinger, Heinz (2022). Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50 × 109/L to <100 × 109/L) at baseline: the final analysis of EXPAND. THERAPEUTIC ADVANCES IN HEMATOLOGY, vol. 13, pp. 1-13, ISSN:2040-6207 DOI

Loscocco, Giuseppe G; Santi, Raffaella; Carrai, Valentina; Coltro, Giacomo; Mannelli, Francesco; Guglielmelli, Paola; Vannucchi, Alessandro M (2022). Concomitant JAK2 mutated myeloproliferative neoplasms and hereditary hemochromatosis. INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, pp. 1-2, ISSN:1751-5521 DOI

Passamonti F.; Palandri F.; Saydam G.; Callum J.; Devos T.; Guglielmelli P.; Vannucchi A.M.; Zor E.; Zuurman M.; Gilotti G.; Zhang Y.; Griesshammer M. (2022). Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study. THE LANCET. HAEMATOLOGY, vol. 9, pp. e480-e492, ISSN:2352-3026 DOI

Mannelli, Francesco; Bencini, Sara; Coltro, Giacomo; Loscocco, Giuseppe G; Peruzzi, Benedetta; Rotunno, Giada; Maccari, Chiara; Gesullo, Francesca; Borella, Miriam; Paoli, Chiara; Caporale, Roberto; Mannarelli, Carmela; Annunziato, Francesco; Guglielmelli, Paola; Vannucchi, Alessandro M (2022). Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis. AMERICAN JOURNAL OF HEMATOLOGY, vol. 97, pp. 846-855, ISSN:0361-8609 DOI

Kulasekararaj, Austin G; Griffin, Morag; Langemeijer, Saskia; Usuki, Kensuke; Kulagin, Alexander; Ogawa, Masayo; Yu, Ji; Mujeebuddin, Arshad; Nishimura, Jun-Ichi; Lee, Jong Wook; Peffault de Latour, Régis, 301/302 Study Group: Aigul Latypova, Wilma Barcellini, Fiorenza Barraco, Donald Beam, Peter Bettelheim, Elena Borisenkova, Andres Brodsky, Benedict Carnley, Jaroslav Cermak, Tsai‐Yun Chen, Lee Ping Chew, Teng Keat Chew, Chul Won Choi, Yunsuk Choi, Joo Seop Chung, Sophie De Guibert, Timothy Devos, Yuri Dunaev, Jadwiga Dwilewicz‐Trojaczek, Yoko Edahiro, Iliya Elykomov, Maria Ines Engelberger, Fabrizio Pomponi, Wolfgang Fuereder, Nobuharu Fujii, Shinichiro Fujiwara, Piero Galieni, Anna Gaya Valls, Stéphane Girault, David Gomez Almaguer, F. Ataulfo Gonzalez Fernandez, Sergey Gritsaev, Eren Gunduz, Chattree Hantaweepant, Hiroshi Harada, Martin Höglund, Wei‐Han Huang, Azlan Husin, Takayuki Ikezoe, Ken Ishiyama, Yoshikazu Ito, Jun Ho Jang, Deog‐Yeon Jo, Ka‐Won Kang, James Kennedy, Hyo Jung Kim, Jeong‐A Kim, Jin Seok Kim, Fumihiko Kimura, Masayoshi Kobune, Hiroshi Kosugi, Alexander Kulagin, Austin Kulasekararaj, Kuan‐Ming Lai, Loree Larratt, Gyeong‐Won Lee, Jae Hoon Lee, Je‐Hwan Lee, Jong Wook Lee, Chien‐Chin Lin, Elena Lukina, Elena Martynova, Itaru Matsumura, Galina Meike, Sandra Fátima Menosi Gualandro, Natalia Minaeva, Yasuo Mori, Kimio Morita, Fernanda Maria Morselli Ramalho, Yeung‐Chul Mun, Petra Muus, Alexander Myasnikov, Kensuke Naito, Haruhiko Ninomiya, Ayako Nogami, Rosario Notaro, Emilio Ojeda Gutierrez, Masaya Okada, Shinichiro Okamoto, Tatiana Olkhovik, Fabrizio Pane, Ronald Paquette, Joon Seong Park, Régis Peffault de la Tour, Caroline Piatek, Agnieszka Piekarska, Marcos Laercio Pontes Reis, Tatiana Pospelova, Vadim Ptushkin, Alexander Roeth, Ponlapat Rojnuckarin, Viviani de Lourdes Rosa Pessoa, Blanca Rossi, Sinari Salleh, Marco Aurelio Salvino de Araujo, Desmond Samuel, Natalya Saraeva, Hubert Schrezenmeier, Yury Shatokhin, Tatiana Shelekhova, Sang Kyun Sohn, Katerina Steinerova, Kazutaka Sunami, Sharifah Shahnaz Syed Abdul Kadir, Shinobu Tamura, Koen Theunissen, See Guan Toh, Akihiro Tomita, José Miguel Torregrosa Diaz, Yasutaka Ueda, Kensuke Usuki, Alessandro Maria Vannucchi, Pongtep Viboonjuntra, Iige Viigimaa, Svetlana Volkova, Ming‐Chung Wang, Jong‐Ho Won, Lily Lee Lee Wong, Voon Fei Wong, Eng Soo Yap, Su‐Peng Yeh, Ho‐Young Yhim, Yuji Yonemura, Sung‐Soo Yoon, and Andrey Zhuravkov (2022). Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies. EUROPEAN JOURNAL OF HAEMATOLOGY, vol. 109, pp. 205-214, ISSN:0902-4441 DOI

Kuykendall, Andrew T; Sun, Libo; Mascarenhas, John; Kiladjian, Jean-Jacques; Vannucchi, Alessandro M; Wang, Julia; Xia, Qi; Zhu, Eugene; Feller, Faye; Rizo, Aleksandra; Bussolari, Jacqueline; Wan, Ying; Komrokji, Rami (2022). Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data. ANNALS OF HEMATOLOGY, vol. 101, pp. 139-146, ISSN:0939-5555 DOI

Mora, Barbara; Guglielmelli, Paola; Kuykendall, Andrew; Rumi, Elisa; Maffioli, Margherita; Palandri, Francesca; De Stefano, Valerio; Caramella, Marianna; Salmoiraghi, Silvia; Kiladjian, Jean-Jacques; Gotlib, Jason; Iurlo, Alessandra; Cervantes, Francisco; Ruggeri, Marco; Silver, Richard T; Albano, Francesco; Benevolo, Giulia; Ross, David M; Della Porta, Matteo G; Devos, Timothy; Rotunno, Giada; Komrokji, Rami S; Casetti, Ilaria C; Merli, Michele; Brociner, Marco; Caramazza, Domenica; Auteri, Giuseppe; Barbui, Tiziano; Cattaneo, Daniele; Bertù, Lorenza; Arcaini, Luca; Vannucchi, Alessandro M; Passamonti, Francesco (2022). Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients. LEUKEMIA, vol. 36, pp. 2453-2460, ISSN:0887-6924 DOI

Guglielmelli, Paola; Coltro, Giacomo; Mannelli, Francesco; Rotunno, Giada; Loscocco, Giuseppe G; Mannarelli, Carmela; Maccari, Chiara; Paoli, Chiara; Romagnoli, Simone; Bartalucci, Niccolò; Vannucchi, Alessandro M (2022). ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera. BLOOD ADVANCES, vol. 6, pp. 2927-2931, ISSN:2473-9537 DOI

Genovese, Elena; Mirabile, Margherita; Rontauroli, Sebastiano; Sartini, Stefano; Fantini, Sebastian; Tavernari, Lara; Maccaferri, Monica; Guglielmelli, Paola; Bianchi, Elisa; Parenti, Sandra; Carretta, Chiara; Mallia, Selene; Castellano, Sara; Colasante, Corrado; Balliu, Manjola; Bartalucci, Niccolò; Palmieri, Raffaele; Ottone, Tiziana; Mora, Barbara; Potenza, Leonardo; Passamonti, Francesco; Voso, Maria Teresa; Luppi, Mario; Vannucchi, Alessandro Maria; Tagliafico, Enrico; Manfredini, Rossella; On Behalf Of The Mynerva MYeloid NEoplasms Research Venture Airc, null (2022). The Response to Oxidative Damage Correlates with Driver Mutations and Clinical Outcome in Patients with Myelofibrosis. ANTIOXIDANTS, vol. 11, pp. 1-15, ISSN:2076-3921 DOI

Mascarenhas, John; Harrison, Claire N; Kiladjian, Jean-Jacques; Komrokji, Rami S; Koschmieder, Steffen; Vannucchi, Alessandro M; Berry, Tymara; Redding, Denise; Sherman, Laurie; Dougherty, Souria; Peng, Lixian; Sun, Libo; Huang, Fei; Wan, Ying; Feller, Faye M; Rizo, Aleksandra; Verstovsek, Srdan (2022). Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design. FUTURE ONCOLOGY, vol. 18, pp. 2393-2402, ISSN:1744-8301 DOI

Harrison, Claire; Heidel, Florian H; Vannucchi, Alessandro M; Kiladjian, Jean-Jacques; Hayat, Amjad; Passamonti, Francesco; Conneally, Eibhlin; Kindler, Thomas; Martino, Bruno; Lipka, Daniel B; Stefanelli, Tommaso; Roussou, Pantelia; Germano, Davide; Ewan, Jacqueline; Ribrag, Vincent (2022). A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis. HEMASPHERE, vol. 6, pp. 1-4, ISSN:2572-9241 DOI

Mascarenhas, John; Kosiorek, Heidi E; Prchal, Josef T; Rambaldi, Alessandro; Berenzon, Dmitriy; Yacoub, Abdulraheem; Harrison, Claire N; McMullin, Mary Frances; Vannucchi, Alessandro M; Ewing, Joanne; O'Connell, Casey L; Kiladjian, Jean-Jacques; Mead, Adam J; Winton, Elliott F; Leibowitz, David S; De Stefano, Valerio; Arcasoy, Murat O; Kessler, Craig M; Catchatourian, Rosalind; Rondelli, Damiano; Silver, Richard T; Bacigalupo, Andrea; Nagler, Arnon; Kremyanskaya, Marina; Levine, Max F; Arango Ossa, Juan E; McGovern, Erin; Sandy, Lonette; Salama, Mohamad E; Najfeld, Vesna; Tripodi, Joseph; Farnoud, Noushin; Penson, Alexander V; Weinberg, Rona Singer; Price, Leah; Goldberg, Judith D; Barbui, Tiziano; Marchioli, Roberto; Tognoni, Gianni; Rampal, Raajit K; Mesa, Ruben A; Dueck, Amylou C; Hoffman, Ronald (2022). A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia. BLOOD, vol. 139, pp. 2931-2941, ISSN:0006-4971 DOI

Francesca Gorini , Michele Santoro , Anna Pierini , Lorena Mezzasalma , Silvia Baldacci , Elena Bargagli , Alessandra Boncristiano , Maurizia Rossana Brunetto , Paolo Cameli , Francesco Cappelli , Giancarlo Castaman , Barbara Coco , Maria Alice Donati , Renzo Guerrini , Silvia Linari , Vittoria Murro , Iacopo Olivotto , Paola Parronchi , Francesca Pochiero , Oliviero Rossi , Barbara Scappini , Andrea Sodi , Alessandro Maria Vannucchi , Alessio Coi (2022). Orphan Drug Use in Patients With Rare Diseases: A Population-Based Cohort Study. FRONTIERS IN PHARMACOLOGY, vol. 13, pp. 0-0, ISSN:1663-9812 DOI

Gangat, Naseema; Singh, Amritpal; Szuber, Natasha; Begna, Kebede; Elliott, Michelle; Wolanskyj-Spinner, Alexandra; Hanson, Curtis A; Pardanani, Animesh; De Stefano, Valerio; Barbui, Tiziano; Vannucchi, Alessandro M; Tefferi, Ayalew (2022). Site-specific venous thrombosis in essential thrombocythemia: Impact on subsequent vascular events and survival. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, vol. 20, pp. 2439-2443, ISSN:1538-7933 DOI

Loscocco, Giuseppe G; Vannucchi, Alessandro M (2022). Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives. INTERNATIONAL JOURNAL OF HEMATOLOGY, vol. 115, pp. 626-644, ISSN:0925-5710 DOI

Rothenberg, Marc E; Roufosse, Florence; Faguer, Stanislas; Gleich, Gerald J; Steinfeld, Jonathan; Yancey, Steven W; Mavropoulou, Eleni; Kwon, Namhee, HES Mepolizumab Study Group: Gabriel Ricardo García, Adriana Sosso, Luis Wehbe, Anahí Yañez, Daniël Blockmans, Florence Roufosse, Martti Anton Antila, Daniela Blanco, Sergio Grava, Marina Andrade Lima, Andreia Luisa Francisco Pez, Stanislas Faguer, Mohamed A Hamidou, Jean-Emmanuel Kahn, Guillaume Lefévre, Knut Brockow, Peter M Kern, Andreas J Reiter, Bastian Walz, Tobias Welte, Fabrizio Pane, Alessandro M Vannucchi, Ruth Cerino-Javier, Alfredo Gazca-Aguilar, Dante D Hernández-Colín, Héctor Glenn Valdéz-López, Izabela R Kupryś-Lipińska, Jacek Musial, Witold Prejzner, Eniko Mihaly, Viola Popov, Mihnea Tudor Zdrenghea, Sergey V Gritsaev, Vladimir Ivanov, Nikolay Tsyba, Aránzazu Alonso, Maria Cinta Cid Xutgla, Maria Laura Fox, Regina Garcia Delgado, Jesús María Hernández Rivas, Guillermo Sanz Santillana, Ana Isabel González, Andrew J Wardlaw, Praveen Akuthota, Joseph H Butterfield, Geoffrey L Chupp, John B Cox, Gerald J Gleich, Devi Jhaveri, Marc E Rothenberg (2022). Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. IN PRACTICE, vol. 10, pp. 2367-2374.e3, ISSN:2213-2198 DOI

Thiele, Jürgen; Kvasnicka, Hans Michael; Orazi, Attilio; Gianelli, Umberto; Gangat, Naseema; Vannucchi, Alessandro M; Barbui, Tiziano; Arber, Daniel A; Tefferi, Ayalew (2022). The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms. AMERICAN JOURNAL OF HEMATOLOGY, pp. 1200-1228, ISSN:0361-8609 DOI

Carobbio, Alessandra; Vannucchi, Alessandro Maria; De Stefano, Valerio; Masciulli, Arianna; Guglielmelli, Paola; Loscocco, Giuseppe Gaetano; Ramundo, Francesco; Rossi, Elena; Kanthi, Yogendra; Tefferi, Ayalew; Barbui, Tiziano (2022). Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera. BLOOD CANCER JOURNAL, vol. 12, pp. 1-6, ISSN:2044-5385 DOI

Mesa, Ruben; Harrison, Claire; Oh, Stephen T; Gerds, Aaron T; Gupta, Vikas; Catalano, John; Cervantes, Francisco; Devos, Timothy; Hus, Marek; Kiladjian, Jean-Jacques; Lech-Maranda, Ewa; McLornan, Donal; Vannucchi, Alessandro M; Platzbecker, Uwe; Huang, Mei; Strouse, Bryan; Klencke, Barbara; Verstovsek, Srdan (2022). Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis. LEUKEMIA, vol. 36, pp. 2261-2268, ISSN:0887-6924 DOI

Gangat, Naseema; Szuber, Natasha; Jadoon, Yamna; Farrukh, Faiqa; Begna, Kebede; Elliott, Michelle A; Wolanskyj-Spinner, Alexandra P; Hanson, Curtis A; Pardanani, Animesh D; De Stefano, Valerio; Barbui, Tiziano; Vannucchi, Alessandro Maria; Tefferi, Ayalew (2022). 1.5 million platelet count limit at essential thrombocythemia diagnosis: correlations and relevance to vascular events. BLOOD ADVANCES, vol. 6, pp. 3835-3839, ISSN:2473-9529 DOI

Marchetti, M; Vannucchi, AM; Griesshammer, M; Harrison, C; Koschmieder, S; Gisslinger, H; Alvarez-Larran, A; De Stefano, V; Guglielmelli, P; Palandri, F; Passamonti, F; Barosi, G; Silver, RT; Hehlmann, R; Kiladjian, JJ; Barbui, T (2022). Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. THE LANCET. HAEMATOLOGY, vol. 9, pp. E301-E311, ISSN:2352-3026 DOI

Harrison, Claire N; Gupta, Vikas K; Gerds, Aaron T; Rampal, Raajit; Verstovsek, Srdan; Talpaz, Moshe; Kiladjian, Jean-Jacques; Mesa, Ruben; Kuykendall, Andrew T; Vannucchi, Alessandro M; Palandri, Francesca; Grosicki, Sebastian; Devos, Timothy; Jourdan, Eric; Wondergem, Marielle J; Al-Ali, Haifa Kathrin; Buxhofer-Ausch, Veronika; Alvarez-Larrán, Alberto; Patriarca, Andrea; Kremyanskaya, Marina; Mead, Adam J; Akhani, Sanjay; Sheikine, Yuri; Colak, Gozde; Mascarenhas, John (2022). Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis. FUTURE ONCOLOGY, vol. 18, pp. 2987-2997, ISSN:1479-6694 DOI

Harrison, Claire N; Schaap, Nicolaas; Vannucchi, Alessandro M; Kiladjian, Jean-Jacques; Passamonti, Francesco; Zweegman, Sonja; Talpaz, Moshe; Verstovsek, Srdan; Rose, Shelonitda; Zhang, Jun; Sy, Oumar; Mesa, Ruben A (2022). Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts. BRITISH JOURNAL OF HAEMATOLOGY, vol. 198, pp. 317-327, ISSN:1365-2141 DOI

Mascarenhas, John; Passamonti, Francesco; Burbury, Kate; El-Galaly, Tarec Christoffer; Gerds, Aaron; Gupta, Vikas; Higgins, Brian; Wonde, Kathrin; Jamois, Candice; Kovic, Bruno; Huw, Ling-Yuh; Katakam, Sudhakar; Maffioli, Margherita; Mesa, Ruben; Palmer, Jeanne; Bellini, Marta; Ross, David M; Vannucchi, Alessandro M; Yacoub, Abdulraheem (2022). The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study. BLOOD ADVANCES, vol. 6, pp. 1162-1174, ISSN:2473-9537 DOI

Pemmaraju, Naveen; Harrison, Claire; Gupta, Vikas; Verstovsek, Srdan; Scott, Bart; Oh, Stephen T; Palandri, Francesca; Al-Ali, Haifa Kathrin; Sobas, Marta; McMullin, Mary Frances; Mesa, Ruben; Buckley, Sarah; Roman-Torres, Karisse; Vannucchi, Alessandro; Yacoub, Abdulraheem (2022). Risk-adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis. EJHAEM, vol. 3, pp. 1346-1351, ISSN:2688-6146 DOI

Farrukh F.; Guglielmelli P.; Loscocco G.G.; Pardanani A.; Hanson C.A.; De Stefano V.; Barbui T.; Gangat N.; Vannucchi A.M.; Tefferi A. (2022). Deciphering the individual contribution of absolute neutrophil and monocyte counts to thrombosis risk in polycythemia vera and essential thrombocythemia. AMERICAN JOURNAL OF HEMATOLOGY, vol. 97, pp. E35-E37, ISSN:0361-8609 DOI

Szuber, Natasha; Toliopoulos, Panagiota; Busque, Lambert; Cerquozzi, Sonia; Foltz, Lynda; Gupta, Vikas; Tefferi, Ayalew; Vannucchi, Alessandro Maria; Hillis, Christopher; Leber, Brian; Maze, Dawn; Prchal, Jaroslav; Olney, Harold J; Sirhan, Shireen (2022). Perioperative management of myeloproliferative neoplasms: A pan-Canadian physician survey and international expert opinion. AMERICAN JOURNAL OF HEMATOLOGY, vol. 97, pp. E466-E469, ISSN:0361-8609 DOI

Guglielmelli P.; Ghirardi A.; Carobbio A.; Masciulli A.; Maccari C.; Mora B.; Rumi E.; Triguero A.; Finazzi M.C.; Pettersson H.; Paoli C.; Mannelli F.; Vanni D.; Rambaldi A.; Passamonti F.; Alvarez-Larran A.; Andreasson B.; Vannucchi A.M.; Barbui T. (2022). Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: Update of the ERNEST Study. BLOOD ADVANCES, vol. 6, pp. 373-375, ISSN:2473-9529 DOI

Barbui, Tiziano; Carobbio, Alessandra; Ghirardi, Arianna; Iurlo, Alessandra; Sobas, Marta Anna; Elli, Elena Maria; Rumi, Elisa; De Stefano, Valerio; Lunghi, Francesca; Marchetti, Monia; Daffini, Rosa; Gasior Kabat, Mercedes; Cuevas, Beatriz; Fox, Maria Laura; Andrade-Campos, Marcio Miguel; Palandri, Francesca; Guglielmelli, Paola; Benevolo, Giulia; Harrison, Claire; Foncillas, Maria-Angeles; Bonifacio, Massimiliano; Alvarez-Larran, Alberto; Kiladjian, Jean-Jacques; Bolaños Calderón, Estefanía; Patriarca, Andrea; Quiroz Cervantes, Keina; Griesshammer, Martin; Garcia-Gutierrez, Valentin; Marin Sanchez, Alberto; Magro Mazo, Elena; Carli, Giuseppe; Hernandez-Boluda, Juan Carlos; Osorio, Santiago; Carreno-Tarragona, Gonzalo; Sagues Serrano, Miguel; Kusec, Rajko; Navas Elorza, Begona; Angona, Anna; Xicoy Cirici, Blanca; Lopez Abadia, Emma; Koschmieder, Steffen; Cattaneo, Daniele; Bucelli, Cristina; Cichocka, Edyta; de Nałęcz, Anna Kulikowska; Cavalca, Fabrizio; Borsani, Oscar; Betti, Silvia; Bellini, Marta; Curto-Garcia, Natalia; Rambaldi, Alessandro; Vannucchi, Alessandro Maria (2022). Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID-19. AMERICAN JOURNAL OF HEMATOLOGY, vol. 97, pp. E470-E473, ISSN:0361-8609 DOI

Coltro, Giacomo; Mannelli, Francesco; Loscocco, Giuseppe Gaetano; Mannarelli, Carmela; Rotunno, Giada; Maccari, Chiara; Pancani, Fabiana; Atanasio, Alessandro; Vannucchi, Alessandro Maria; Guglielmelli, Paola (2022). Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis. BLOOD CANCER JOURNAL, vol. 12, pp. 1-7, ISSN:2044-5385 DOI

Gerds, Aaron; Verstovsek, Srdan; Vannucchi, Alessandro; Al-Ali, Haifa Kathrin; Lavie, David; Kuykendall, Andrew; Grosicki, Sebastian; Iurlo, Alessandra; Goh, Yeow Tee; Lazaroiu, Mihaela; Egyed, Miklos; Fox, Maria Laura; McLornan, Donal; Perkins, Andrew; Yoon, Sung-Soo; Gupta, Vikas; Kiladjian, Jean-Jacques; Donahue, Rafe; Kawashima, Jun; Mesa, Ruben (2022). MPN-483 Thrombocytopenic Myelofibrosis (MF) Patients Previously Treated With a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) [MOMENTUM]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol. 22 Suppl 2, pp. 340-340, ISSN:2152-2669 DOI

Vannucchi A.M.; Sordi B.; Morettini A.; Nozzoli C.; Poggesi L.; Pieralli F.; Bartoloni A.; Atanasio A.; Miselli F.; Paoli C.; Loscocco G.G.; Fanelli A.; Para O.; Berni A.; Tassinari I.; Zammarchi L.; Maggi L.; Mazzoni A.; Scotti V.; Falchetti G.; Malandrino D.; Luise F.; Millotti G.; Bencini S.; Capone M.; Piccinni M.P.; Annunziato F.; Guglielmelli P.; Mannelli F.; Coltro G.; Fantoni D.; Borella M.; Ravenda E.; Peruzzi B.; Caporale R.; Cosmi L.; Liotta F.; Lombardelli L.; Logiodice F.; Vanni A.; Salvati L.; Lazzeri C.; Bonizzoli M.; Peris A.; Cianchi G.; Bosi A.; Pucatti M.; Fontanari P.; Benemei S.; MatucciCerinic M.; Turco L. (2021). Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study. LEUKEMIA, pp. 1121-1133, ISSN:0887-6924 DOI

Zampieri, Mattia; Allinovi, Marco; Olivotto, Iacopo; Antonioli, Elisabetta; Gabriele, Martina; Argirò, Alessia; Fumagalli, Carlo; Nardi, Giulia; Di Mario, Carlo; Vannucchi, Alessandro M; Perfetto, Federico; Cappelli, Francesco (2021). Ventricular tachyarrhythmias and sudden cardiac death in light-chain amyloidosis: a clash of cardio-toxicities?. BRITISH JOURNAL OF HAEMATOLOGY, vol. 193, pp. e27-e31, ISSN:0007-1048 DOI

Romagnoli S.; Bartalucci N.; Gesullo F.; Balliu M.; Bonifacio S.; Fernandez A.G.L.; Mannelli F.; Bolognini D.; Pelo E.; Mecucci C.; Guglielmelli P.; Vannucchi A.M. (2021). Nanopore sequencing for the screening of myeloid and lymphoid neoplasms with eosinophilia and rearrangement of PDGFRα, PDGFRβ, FGFR1 or PCM1-JAK2. BIOMARKER RESEARCH, vol. 9, pp. 83-86, ISSN:2050-7771 DOI

Barbui T.; De Stefano V.; Alvarez-Larran A.; Iurlo A.; Masciulli A.; Carobbio A.; Ghirardi A.; Ferrari A.; Cancelli V.; Elli E.M.; Andrade-Campos M.M.; Kabat M.G.; Kiladjian J.-J.; Palandri F.; Benevolo G.; Garcia-Gutierrez V.; Fox M.L.; Foncillas M.A.; Morcillo C.M.; Rumi E.; Osorio S.; Papadopoulos P.; Bonifacio M.; Cervantes K.S.Q.; Serrano M.S.; Carreno-Tarragona G.; Sobas M.A.; Lunghi F.; Patriarca A.; Elorza B.N.; Angona A.; Mazo E.M.; Koschmieder S.; Carli G.; Cuevas B.; Hernandez-Boluda J.C.; Abadia E.L.; Cirici B.X.; Guglielmelli P.; Garrote M.; Cattaneo D.; Daffini R.; Cavalca F.; Bellosillo B.; Benajiba L.; Curto-Garcia N.; Bellini M.; Betti S.; Harrison C.; Rambaldi A.; Vannucchi A.M. (2021). Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19. BLOOD CANCER JOURNAL, vol. 11, pp. 21-31, ISSN:2044-5385 DOI

Cervantes, Francisco; Ross, David M; Radinoff, Atanas; Palandri, Francesca; Myasnikov, Alexandr; Vannucchi, Alessandro M; Zachee, Pierre; Gisslinger, Heinz; Komatsu, Norio; Foltz, Lynda; Mannelli, Francesco; Passamonti, Francesco; Gilotti, Geralyn; Sadek, Islam; Tiwari, Ranjan; Zor, Evren; Al-Ali, Haifa Kathrin (2021). Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study. LEUKEMIA, vol. 35, pp. 3626-3626, ISSN:0887-6924 DOI

Pardanani A.; Tefferi A.; Masszi T.; Mishchenko E.; Drummond M.; Jourdan E.; Vannucchi A.; Jurgutis M.; Ribrag V.; Rambaldi A.; Koh L.P.; Rose S.; Zhang J.; Harrison C. (2021). Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis. BRITISH JOURNAL OF HAEMATOLOGY, vol. 195, pp. 244-248, ISSN:0007-1048 DOI

Harrison C.N.; Schaap N.; Vannucchi A.M.; Kiladjian J.-J.; Jourdan E.; Silver R.T.; Schouten H.C.; Passamonti F.; Zweegman S.; Talpaz M.; Verstovsek S.; Tang D.; Abraham P.; Lord-Bessen J.; Rose S.; Guo S.; Liao W.; Mesa R.A. (2021). Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial. HEMASPHERE, vol. 5, pp. 1-11, ISSN:2572-9241 DOI

Fantini S.; Rontauroli S.; Sartini S.; Mirabile M.; Bianchi E.; Badii F.; Maccaferri M.; Guglielmelli P.; Ottone T.; Palmieri R.; Genovese E.; Carretta C.; Parenti S.; Mallia S.; Tavernari L.; Salvadori C.; Gesullo F.; Maccari C.; Zizza M.; Grande A.; Salmoiraghi S.; Mora B.; Potenza L.; Rosti V.; Passamonti F.; Rambaldi A.; Voso M.T.; Mecucci C.; Tagliafico E.; Luppi M.; Vannucchi A.M.; Manfredini R. (2021). Increased plasma levels of lncrnas linc01268, gas5 and malat1 correlate with negative prognostic factors in myelofibrosis. CANCERS, vol. 13, pp. 4744-4765, ISSN:2072-6694 DOI

Passamonti, Francesco; Romano, Alessandra; Salvini, Marco; Merli, Francesco; Porta, Matteo G Della; Bruna, Riccardo; Coviello, Elisa; Romano, Ilaria; Cairoli, Roberto; Lemoli, Roberto; Farina, Francesca; Venditti, Adriano; Busca, Alessandro; Ladetto, Marco; Massaia, Massimo; Pinto, Antonio; Arcaini, Luca; Tafuri, Agostino; Marchesi, Francesco; Fracchiolla, Nicola; Bocchia, Monica; Armiento, Daniele; Candoni, Anna; Krampera, Mauro; Luppi, Mario; Cardinali, Valeria; Galimberti, Sara; Cattaneo, Chiara; La Barbera, Elettra Ortu; Mina, Roberto; Lanza, Francesco; Visani, Giuseppe; Musto, Pellegrino; Petrucci, Luigi; Zaja, Francesco; Grossi, Paolo A; Bertù, Lorenza; Pagano, Livio; Corradini, Paolo; ITA-HEMA-COV Investigators*: Enrico Derenzini, Monia Marchetti, Anna M Scattolin, Alessandro Corso, Patrizia Tosi, Filippo Gherlinzoni, Carlo Gambacorti Passerini, Michele Cavo, Carmen Fava, Mauro Turrini, Carlo Visco, Patrizia Zappasodi, Michele Merli, Barbara Mora, Alessandro M Vannucchi (2021). COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies. BRITISH JOURNAL OF HAEMATOLOGY, vol. 195, pp. 371-377, ISSN:1365-2141 DOI

Piccini, Matteo; Pilerci, Sofia; Merlini, Marta; Grieco, Pietro; Scappini, Barbara; Bencini, Sara; Peruzzi, Benedetta; Caporale, Roberto; Signori, Leonardo; Pancani, Fabiana; Vannucchi, Alessandro Maria; Gianfaldoni, Giacomo (2021). Venetoclax-Based Regimens for Relapsed/Refractory Acute Myeloid Leukemia in a Real-Life Setting: A Retrospective Single-Center Experience. JOURNAL OF CLINICAL MEDICINE, vol. 10, pp. 1684-1695, ISSN:2077-0383 DOI

Galata G.; Garcia-Montero A.C.; Kristensen T.; Dawoud A.A.Z.; Munoz-Gonzalez J.I.; Meggendorfer M.; Guglielmelli P.; Hoade Y.; Alvarez-Twose I.; Gieger C.; Strauch K.; Ferrucci L.; Tanaka T.; Bandinelli S.; Schnurr T.M.; Haferlach T.; Broesby-Olsen S.; Vestergaard H.; Moller M.B.; Bindslev-Jensen C.; Vannucchi A.M.; Orfao A.; Radia D.; Reiter A.; Chase A.J.; Cross N.C.P.; Tapper W.J. (2021). Genome-wide association study identifies novel susceptibility loci for KIT D816V positive mastocytosis. AMERICAN JOURNAL OF HUMAN GENETICS, vol. 108, pp. 284-294, ISSN:0002-9297 DOI

Tanasi, Ilaria; Bonifacio, Massimiliano; Pizzolato, Miriam; Irene Grifoni, Federica; Sciumè, Mariarita; Elena, Chiara; Benvenuti, Pietro; Mannelli, Francesco; Parente, Roberta; Schena, Donatella; Scaffidi, Luigi; Bonadonna, Patrizia; Papayannidis, Cristina; Rondoni, Michela; Criscuolo, Marianna; Vannucchi, Alessandro M.; Triggiani, Massimo; Martinelli, Giovanni; Krampera, Mauro; Zanotti, Roberta (2021). Familial occurrence of systemic and cutaneous mastocytosis in an adult multicentre series. BRITISH JOURNAL OF HAEMATOLOGY, vol. 193, pp. 845-848, ISSN:0007-1048 DOI

Todisco G.; Creignou M.; Galli A.; Guglielmelli P.; Rumi E.; Roncador M.; Rizzo E.; Nannya Y.; Pietra D.; Elena C.; Bono E.; Molteni E.; Rosti V.; Catricala S.; Sarchi M.; Dimitriou M.; Ungerstedt J.; Vannucchi A.M.; Hellstrom-Lindberg E.; Ogawa S.; Cazzola M.; Malcovati L. (2021). Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2 P95-mutated neoplasms. LEUKEMIA, vol. 35, pp. 2371-2381, ISSN:0887-6924 DOI

Tosetto A.; Rocca B.; Petrucci G.; Betti S.; Soldati D.; Rossi E.; Timillero A.; Cavalca V.; Porro B.; Iurlo A.; Cattaneo D.; Bucelli C.; Dragani A.; Di Ianni M.; Ranalli P.; Palandri F.; Vianelli N.; Beggiato E.; Lanzarone G.; Ruggeri M.; Carli G.; Elli E.M.; Priolo S.; Randi M.L.; Bertozzi I.; Loscocco G.G.; Ricco A.; Specchia G.; Vannucchi A.M.; Rodeghiero F.; De Stefano V.; Patrono C. (2021). Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia. CLINICAL PHARMACOLOGY & THERAPEUTICS, pp. 1-11, ISSN:0009-9236 DOI

Coltro G.; Loscocco G.G.; Vannucchi A.M. (2021). Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities. ELSEVIER, vol. 365, pp. 1-69, ISSN:0922-3444 DOI

Martelli F.; Verachi P.; Zingariello M.; Mazzarini M.; Vannucchi A.M.; Lonetti A.; Bacci B.; Sarli G.; Migliaccio A.R. (2021). hGATA1 Under the Control of a μLCR/β-Globin Promoter Rescues the Erythroid but Not the Megakaryocytic Phenotype Induced by the Gata1 low Mutation in Mice. FRONTIERS IN GENETICS, vol. 12, pp. 720552-720571, ISSN:1664-8021 DOI

Chiusolo P.; Bregante S.; Giammarco S.; Lamparelli T.; Casarino L.; Dominietto A.; Raiola A.M.; Metafuni E.; Di Grazia C.; Gualandi F.; Sora F.; Laurenti L.; Sica S.; Barosi G.; Guolo F.; Rossi M.; Rossi E.; Vannucchi A.; Signori A.; De Stefano V.; Bacigalupo A.; Angelucci E. (2021). Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen. AMERICAN JOURNAL OF HEMATOLOGY, vol. 96, pp. 234-240, ISSN:0361-8609 DOI

Verstovsek, Srdan; Mesa, Ruben; Talpaz, Moshe; Kiladjian, Jean-Jacques; Harrison, Claire N; Oh, Stephen T; Vannucchi, Alessandro M; Rampal, Raajit; Scott, Bart L; Buckley, Sarah A; Craig, Adam R; Roman-Torres, Karisse; Mascarenhas, John O (2021). Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia. HAEMATOLOGICA, pp. 1-21, ISSN:1592-8721 DOI

Gotlib J.; Reiter A.; Radia D.H.; Deininger M.W.; George T.I.; Panse J.; Vannucchi A.M.; Platzbecker U.; Alvarez-Twose I.; Mital A.; Hermine O.; Dybedal I.; Hexner E.O.; Hicks L.K.; Span L.; Mesa R.; Bose P.; Pettit K.M.; Heaney M.L.; Oh S.T.; Sen J.; Lin H.-M.; Mar B.G.; DeAngelo D.J. (2021). Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial. NATURE MEDICINE, vol. 27, pp. 2192-2199, ISSN:1078-8956 DOI

Vannucchi A.M.; Mortara A.; D'alessio A.; Morelli M.; Tedeschi A.; Festuccia M.B.; Monforte A.D.; Capochiani E.; Selleri C.; Simonetti F.; Saracino A.; Rapezzi D.; Badagliacca M.R.; Falasca K.; Molteni A.; Palazzolo R.; Schettino G.; Bocchia M.; Turrini M.; Ascierto P.A.; Zuurman M.; Paley C.; Coco P.; Saglio G. (2021). Jak inhibition with ruxolitinib in patients with covid‐19 and severe pneumonia: Multicenter clinical experience from a compassionate use program in italy. JOURNAL OF CLINICAL MEDICINE, vol. 10, pp. 3752-3764, ISSN:2077-0383 DOI

Loscocco G.G.; Coltro G.; Guglielmelli P.; Vannucchi A.M. (2021). Integration of molecular information in risk assessment of patients with myeloproliferative neoplasms. CELLS, vol. 10, pp. 1962-1984, ISSN:2073-4409 DOI

Gangat N.; Guglielmelli P.; Betti S.; Farrukh F.; Carobbio A.; Barbui T.; Vannucchi A.M.; De Stefano V.; Tefferi A. (2021). Cerebral venous thrombosis and myeloproliferative neoplasms: A three-center study of 74 consecutive cases. AMERICAN JOURNAL OF HEMATOLOGY, vol. 96, pp. 1580-1586, ISSN:0361-8609 DOI

Bartalucci N.; Romagnoli S.; Vannucchi A.M. (2021). A blood drop through the pore: nanopore sequencing in hematology. TRENDS IN GENETICS, pp. 1-15, ISSN:0168-9525 DOI

Vanderwert, Fiorenza Irushani; Sordi, Benedetta; Mannelli, Francesco; Palterer, Boaz; Gesullo, Francesca; Mecheri, Valentina; Santi, Raffaella; Mannarelli, Carmela; Crupi, Francesca; Zanotti, Roberta; Grifoni, Federica Irene; Elena, Chiara; Parente, Roberta; Triggiani, Massimo; Lisa, Pieri; Almerigogna, Fabio; Guglielmelli, Paola; Vannucchi, Alessandro (2021). Screening for Hereditary Alpha-Tryptasemia in Subjects with Systemic Mastocytosis (SM) and Non-SM Mast Cell Activation Symptoms. BLOOD, vol. 138, pp. 1500-1502, ISSN:0006-4971 DOI Accesso ONLINE all'editore

Zampieri M.; Cappelli F.; Allinovi M.; Olivotto I.; Antonioli E.; Tassetti L.; Zocchi C.; Andrei V.; Di Mario C.; Nozzoli C.; Curciarello G.; Ciciani A.M.; Bergesio F.; Vannucchi A.M.; Perfetto F. (2021). Incidence of light chain amyloidosis in Florence metropolitan area, Italy: a population-based study. AMYLOID, vol. 28, pp. 211-212, ISSN:1350-6129 DOI

Gleich, Gerald J; Roufosse, Florence; Chupp, Geoffrey; Faguer, Stanislas; Walz, Bastian; Reiter, Andreas; Yancey, Steven W; Bentley, Jane H; Steinfeld, Jonathan; HES Mepolizumab Study Group: Gabriel Ricardo García, Pablo Pascale, Luis Wehbe, Daniël Blockmans, Florence Roufosse, Martti Anton Antila, Daniela Blanco, Andreia Luisa Francisco Pez, Stanislas Faguer, Jean-Emmanuel Kahn, Guillaume Lefévre, Antoine Neel, Peter M Kern, Andreas J Reiter, Bastian Walz, Tobias Welte, Fabrizio Pane, Alessandro M Vannucchi, Ruth Cerino-Javier, Dante D Hernández-Colín, Héctor Glenn Valdéz-López, Izabela R Kupryś-Lipińska, Jacek Musial, Eniko Mihaly, Viola Maria Popov, Vladimir Ivanov, Nikolay Tsyba, Maria C Cid, Maria Laura Fox, Guillermo Sanz Santillana, Andrew J Wardlaw, Praveen Akuthota, Joseph H Butterfield, Geoffrey L Chupp, Gerald J Gleich, Devi Jhaveri, Marc E Rothenberg (2021). Safety and Efficacy of Mepolizumab in Hypereosinophilic Syndrome: An Open-Label Extension Study. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. IN PRACTICE, vol. 9, pp. 4431-4440.e1, ISSN:2213-2198 DOI

Coltro G.; Vannucchi A.M. (2021). The safety of JAK kinase inhibitors for the treatment of myelofibrosis. EXPERT OPINION ON DRUG SAFETY, vol. 20, pp. 139-154, ISSN:1474-0338 DOI

Guglielmelli, Paola; Mazzoni, Alessio; Maggi, Laura; Kiros, Seble Tekle; Zammarchi, Lorenzo; Pilerci, Sofia; Rocca, Arianna; Spinicci, Michele; Borella, Miriam; Bartoloni, Alessandro; Rossolini, Gian Maria; Annunziato, Francesco; Vannucchi, Alessandro M (2021). Impaired response to first SARS-CoV-2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib. AMERICAN JOURNAL OF HEMATOLOGY, pp. 1-1, ISSN:0361-8609 DOI

Cervantes F.; Ross D.M.; Radinoff A.; Palandri F.; Myasnikov A.; Vannucchi A.M.; Zachee P.; Gisslinger H.; Komatsu N.; Foltz L.; Mannelli F.; Passamonti F.; Gilotti G.; Sadek I.; Tiwari R.; Zor E.; Al-Ali H.K. (2021). Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study. LEUKEMIA, vol. 35, pp. 3455-3465, ISSN:0887-6924 DOI

Loscocco G.G.; Antonioli E.; Romano I.; Vergoni F.; Rotunno G.; Mannelli F.; Guglielmelli P.; Vannucchi A.M. (2021). Lenalidomide: A double-edged sword for concomitant multiple myeloma and post-essential thrombocythemia myelofibrosis. AMERICAN JOURNAL OF HEMATOLOGY, vol. 96, pp. 749-754, ISSN:0361-8609 DOI

Passamonti F.; Gupta V.; Martino B.; Foltz L.; Zaritskey A.; Al-Ali H.K.; Tavares R.; Maffioli M.; Raanani P.; Giraldo P.; Griesshammer M.; Guglielmelli P.; Bouard C.; Paley C.; Tiwari R.; Vannucchi A.M. (2021). Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low-, intermediate-1-, intermediate-2-, and high-risk myelofibrosis in JUMP, a Phase 3b, expanded-access study. HEMATOLOGICAL ONCOLOGY, vol. 39, pp. 558-566, ISSN:0278-0232 DOI

Balliu M.; Calabresi L.; Bartalucci N.; Romagnoli S.; Maggi L.; Manfredini R.; Lulli M.; Guglielmelli P.; Vannucchi A.M. (2021). Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, CALR-mutated MPNs. BLOOD ADVANCES, vol. 5, pp. 2184-2195, ISSN:2473-9529 DOI

Chowdhury O.; O'Sullivan J.; Barkas N.; Wang G.; Buck G.; Hamblin A.; Tefferi A.; Al-Ali H.K.; Barosi G.; Devos T.; Gisslinger H.; Jiang Q.; Kiladjian J.-J.; Mesa R.; Passamonti F.; Ribrag V.; Schiller G.; Vannucchi A.M.; Zhou D.; McMullin M.F.; Zhong J.; Gale R.P.; Mead A.J.; Catalano J.; Stevenson W.; Gastl G.; Linkesch W.; Van Droogenbroeck J.; Mineur P.; Gupta V.; Turner A.; Nevill T.; Li J.; Shen Z.; Liu T.; Bordessoule D.; Natarajan-Ame S.; Recher C.; Demory J.L.; Schlenk R.; Griesshammer M.; Cazzola M.; Saglio G.; Specchia G.; Rambaldi A.; Pane F.; Zweegman S.; te Boekhorst P.; Raymakers R.; Abdulkadyrov K.; Sokolova M.; Salogub G.; Zaritskiy A.; Cervantes F.; Boluda J.C.H.; Ojeda E.; Tesfa D.; Nilsson L.; Drummond M.; Reilly J.; Harrison C.; Milojkovic D.; Rivera C.; Besa E.; Deeg H.J.; Mascarenhas J.; Prchal J.; Tiu R.; Talpaz M.; Wang J.C.; Rampal R.; Rondelli D.; McCaul K.; Brown R.; Komatsu N.; Ohyashiki K.; Ando K.; Kawabata H.; Takenaka K.; Hata T.; Vardiman J. (2021). Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide. LEUKEMIA, vol. 35, pp. 1197-1202, ISSN:0887-6924 DOI

Gangat, Naseema; Guglielmelli, Paola; Al‐Kali, Aref; Wolanskyj‐Spinner, Alexandra P.; Camoriano, John; Patnaik, Mrinal M.; Pardanani, Animesh; Hanson, Curtis A.; Vannucchi, Alessandro M.; Tefferi, Ayalew (2021). Pregnancy in patients with myelofibrosis: Mayo–Florence series of 24 pregnancies in 16 women. BRITISH JOURNAL OF HAEMATOLOGY, vol. 195, pp. 133-137, ISSN:0007-1048 DOI

Attardi, Enrico; Pilerci, Sofia; Attucci, Irene; Buzzichelli, Alessandra; Messeri, Maria; Staderini, Michela; Vannucchi, Alessandro M; Antonioli, Elisabetta (2021). Ninety-Minute Daratumumab Infusions for Relapsed and Refractory Multiple Myeloma: Two Years of Italian Single-Center Observational Study. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol. 21, pp. e850-e852, ISSN:2152-2650 DOI

Barbui T.; Vannucchi A.M.; Alvarez-Larran A.; Iurlo A.; Masciulli A.; Carobbio A.; Ghirardi A.; Ferrari A.; Rossi G.; Elli E.; Andrade-Campos M.M.; Kabat M.G.; Kiladjian J.-J.; Palandri F.; Benevolo G.; Garcia-Gutierrez V.; Fox M.L.; Foncillas M.A.; Morcillo C.M.; Rumi E.; Osorio S.; Papadopoulos P.; Bonifacio M.; Cervantes K.S.Q.; Serrano M.S.; Carreno-Tarragona G.; Sobas M.A.; Lunghi F.; Patriarca A.; Elorza B.N.; Angona A.; Mazo E.M.; Koschmieder S.; Ruggeri M.; Cuevas B.; Hernandez-Boluda J.C.; Abadia E.L.; Cirici B.X.; Guglielmelli P.; Garrote M.; Cattaneo D.; Daffini R.; Cavalca F.; Bellosillo B.; Benajiba L.; Curto-Garcia N.; Bellini M.; Betti S.; De Stefano V.; Harrison C.; Rambaldi A. (2021). High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. LEUKEMIA, vol. 35, pp. 485-493, ISSN:0887-6924 DOI

Mannelli, Francesco; Gianfaldoni, Giacomo; Guglielmelli, Paola; Buccisano, Francesco; Caporale, Roberto; Chiarini, Marco; Rossi, Giuseppe; Venditti, Adriano; Fazi, Paola; Crea, Enrico; Piciocchi, Alfonso; Voso, Maria Teresa; Vignetti, Marco; Amadori, Sergio; Vannucchi, Alessandro Maria (2021). AMELIORATE: early intensification in FLT3-mutated acute myeloid leukemia based on peripheral blast clearance – MYNERVA-GIMEMA AML1919 trial. FUTURE ONCOLOGY, vol. 17, pp. 3787-3796, ISSN:1479-6694 DOI

Tefferi A.; Szuber N.; Pardanani A.; Hanson C.A.; Vannucchi A.M.; Barbui T.; Gangat N. (2021). Extreme thrombocytosis in low-risk essential thrombocythemia: Retrospective review of vascular events and treatment strategies. AMERICAN JOURNAL OF HEMATOLOGY, vol. 96, pp. E182-E184, ISSN:0361-8609 DOI

Zanelli, Magda; Loscocco, Giuseppe G.; Sabattini, Elena; Zizzo, Maurizio; Sanguedolce, Francesca; Panico, Luigi; Fanni, Daniela; Santi, Raffaella; Caprera, Cecilia; Rossi, Cristiana; Soriano, Alessandra; Cavazza, Alberto; Giunta, Alessandro; Mecucci, Cristina; Vannucchi, Alessandro M.; Pileri, Stefano A.; Ascani, Stefano (2021). T-Cell Lymphoblastic Lymphoma Arising in the Setting of Myeloid/Lymphoid Neoplasms with Eosinophilia: LMO2 Immunohistochemistry as a Potentially Useful Diagnostic Marker. CANCERS, vol. 13, pp. 1-17, ISSN:2072-6694 DOI

Tefferi A.; Vannucchi A.M.; Barbui T. (2021). Polycythemia vera: historical oversights, diagnostic details, and therapeutic views. LEUKEMIA, vol. 35, pp. 3339-3351, ISSN:0887-6924 DOI

Guglielmelli P.; Gangat N.; Coltro G.; Lasho T.L.; Loscocco G.G.; Finke C.M.; Morsia E.; Sordi B.; Szuber N.; Hanson C.A.; Pardanani A.; Vannucchi A.M.; Tefferi A. (2021). Mutations and thrombosis in essential thrombocythemia. BLOOD CANCER JOURNAL, vol. 11, pp. 77-80, ISSN:2044-5385 DOI

Gangat N.; Guglielmelli P.; Szuber N.; Begna K.H.; Patnaik M.M.; Litzow M.R.; Al-Kali A.; Foran J.M.; Palmer J.M.; Alkhateeb H.; Elliott M.A.; Hanson C.A.; Pardanani A.; Mannelli F.; Vannucchi A.M.; Tefferi A. (2021). Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases. AMERICAN JOURNAL OF HEMATOLOGY, vol. 96, pp. 781-789, ISSN:0361-8609 DOI

Mascarenhas J.; Komrokji R.S.; Palandri F.; Martino B.; Niederwieser D.; Reiter A.; Scott B.L.; Baer M.R.; Hoffman R.; Odenike O.; Vannucchi A.M.; Bussolari J.; Zhu E.; Rose E.; Sherman L.; Dougherty S.; Sun L.; Huang F.; Wan Y.; Feller F.M.; Rizo A.; Kiladjian J.-J. (2021). Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis. JOURNAL OF CLINICAL ONCOLOGY, vol. 39, pp. 2881-2892, ISSN:1527-7755 DOI

Rambaldi A.; Iurlo A.; Vannucchi A.M.; Martino B.; Guarini A.; Ruggeri M.; von Bubnoff N.; De Muro M.; McMullin M.F.; Luciani S.; Martinelli V.; Nogai A.; Rosti V.; Ricco A.; Bettica P.; Manzoni S.; Di Tollo S. (2021). Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program. BLOOD CANCER JOURNAL, vol. 11, pp. 53-59, ISSN:2044-5385 DOI

Rontauroli S.; Castellano S.; Guglielmelli P.; Zini R.; Bianchi E.; Genovese E.; Carretta C.; Parenti S.; Fantini S.; Mallia S.; Tavernari L.; Sartini S.; Mirabile M.; Mannarelli C.; Gesullo F.; Pacilli A.; Pietra D.; Rumi E.; Salmoiraghi S.; Mora B.; Villani L.; Grilli A.; Rosti V.; Barosi G.; Passamonti F.; Rambaldi A.; Malcovati L.; Cazzola M.; Bicciato S.; Tagliafico E.; Vannucchi A.M.; Manfredini R. (2021). Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis. BLOOD ADVANCES, vol. 5, pp. 1452-1462, ISSN:2473-9529 DOI

Loscocco G.G.; Guglielmelli P.; Gangat N.; Rossi E.; Mannarelli C.; Betti S.; Maccari C.; Ramundo F.; Jadoon Y.; Gesullo F.; Ceglie S.; Paoli C.; Pardanani A.; De Stefano V.; Tefferi A.; Vannucchi A.M. (2021). Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients. AMERICAN JOURNAL OF HEMATOLOGY, vol. 96, pp. 1472-1480, ISSN:0361-8609 DOI

Verstovsek S.; Chen C.-C.; Egyed M.; Ellis M.; Fox L.; Goh Y.T.; Gupta V.; Harrison C.; Kiladjian J.-J.; Lazaroiu M.C.; Mead A.; McLornan D.; McMullin M.F.; Oh S.T.; Perkins A.; Platzbecker U.; Scheid C.; Vannucchi A.; Yoon S.-S.; Kowalski M.M.; Mesa R.A. (2021). MOMENTUM: Momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic. FUTURE ONCOLOGY, vol. 17, pp. 1449-1458, ISSN:1479-6694 DOI

Loscocco G.G.; Rotunno G.; Mannelli L.; Mannelli F.; Vergoni F.; Guglielmelli P.; Vannucchi A.M. (2021). BRAFV600E mutation in the wrong place: a case of concomitant polycythemia vera, hairy cell leukemia, and thyroid adenoma. TUMORI, vol. 107, pp. NP28-NP32, ISSN:0300-8916 DOI

Mesa R.A.; Schaap N.; Vannucchi A.M.; Kiladjian J.-J.; Passamonti F.; Zweegman S.; Talpaz M.; Verstovsek S.; Rose S.; Abraham P.; Lord-Bessen J.; Tang D.; Guo S.; Ye X.; Harrison C.N. (2021). Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial. HEMASPHERE, vol. 5, pp. 1-10, ISSN:2572-9241 DOI

Barbui T.; Vannucchi A.M.; De Stefano V.; Masciulli A.; Carobbio A.; Ferrari A.; Ghirardi A.; Rossi E.; Ciceri F.; Bonifacio M.; Iurlo A.; Palandri F.; Benevolo G.; Pane F.; Ricco A.; Carli G.; Caramella M.; Rapezzi D.; Musolino C.; Siragusa S.; Rumi E.; Patriarca A.; Cascavilla N.; Mora B.; Cacciola E.; Mannarelli C.; Loscocco G.G.; Guglielmelli P.; Betti S.; Lunghi F.; Scaffidi L.; Bucelli C.; Vianelli N.; Bellini M.; Finazzi M.C.; Tognoni G.; Rambaldi A. (2021). Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial. THE LANCET. HAEMATOLOGY, vol. 8, pp. e175-e184, ISSN:2352-3026 DOI

Barbui T.; Iurlo A.; Masciulli A.; Carobbio A.; Ghirardi A.; Rossi G.; Harrison C.; Alvarez-Larran A.; Elli E.M.; Kiladjian J.-J.; Gasior Kabat M.; Marin Sanchez A.; Palandri F.; Andrade-Campos M.M.; Vannucchi A.M.; Carreno-Tarragona G.; Papadopoulos P.; Quiroz Cervantes K.; Angeles Foncillas M.; Fox M.L.; Sagues Serrano M.; Rumi E.; Osorio S.; Benevolo G.; Patriarca A.; Navas Elorza B.; Garcia-Gutierrez V.; Magro Mazo E.; Lunghi F.; Bonifacio M.; De Stefano V.; Hernandez-Boluda J.C.; Lopez Abadia E.; Angona A.; Xicoy Cirici B.; Ruggeri M.; Koschmieder S.; Sobas M.A.; Cuevas B.; Cattaneo D.; Daffini R.; Bellini M.; Curto-Garcia N.; Garrote M.; Cavalca F.; Benajiba L.; Bellosillo B.; Guglielmelli P.; Borsani O.; Betti S.; Salmoiraghi S.; Rambaldi A. (2021). Long-term follow-up of recovered MPN patients with COVID-19. BLOOD CANCER JOURNAL, vol. 11, pp. 1-4, ISSN:2044-5385 DOI

Barbui T.; De Stefano V.; Carobbio A.; Iurlo A.; Alvarez-Larran A.; Cuevas B.; Ferrer Marin F.; Vannucchi A.M.; Palandri F.; Harrison C.; Sibai H.; Griesshammer M.; Bonifacio M.; Elli E.M.; Trotti C.; Koschmieder S.; Carli G.; Benevolo G.; Ianotto J.-C.; Goel S.; Falanga A.; Betti S.; Cattaneo D.; Arellano-Rodrigo E.; Mannelli L.; Vianelli N.; Doyle A.; Gupta V.; Wille K.; Tremblay D.; Mascarenhas J. (2021). Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients. LEUKEMIA, vol. 35, pp. 2989-2993, ISSN:0887-6924 DOI

Guglielmelli P.; Loscocco G.G.; Mannarelli C.; Rossi E.; Mannelli F.; Ramundo F.; Coltro G.; Betti S.; Maccari C.; Ceglie S.; Chiusolo P.; Paoli C.; Barbui T.; Tefferi A.; De Stefano V.; Vannucchi A.M. (2021). JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis. BLOOD CANCER JOURNAL, vol. 11, pp. 199-208, ISSN:2044-5385 DOI

Peruzzi, Benedetta; Bencini, Sara; Capone, Manuela; Mazzoni, Alessio; Maggi, Laura; Salvati, Lorenzo; Vanni, Anna; Orazzini, Chiara; Nozzoli, Carlo; Morettini, Alessandro; Poggesi, Loredana; Pieralli, Filippo; Peris, Adriano; Bartoloni, Alessandro; Vannucchi, Alessandro Maria; Liotta, Francesco; Caporale, Roberto; Cosmi, Lorenzo; Annunziato, Francesco (2020). Quantitative and qualitative alterations of circulating myeloid cells and plasmacytoid DC in SARS-CoV-2 infection. IMMUNOLOGY, pp. 0-0, ISSN:0019-2805 DOI

Gupta V.; Wolleschak D.; Hasselbalch H.; Vannucchi A.M.; Koschmieder S.; Cervantes F.; Li Y.; Dong T.; Wroclawska M.; Bharathy S.; Harrison C. (2020). Safety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis: A phase 1b/2 dose-finding study. BLOOD ADVANCES, vol. 4, pp. 3063-3071, ISSN:2473-9529 DOI

Coltro G.; Rotunno G.; Mannelli L.; Mannarelli C.; Fiaccabrino S.; Romagnoli S.; Bartalucci N.; Ravenda E.; Gelli E.; Sant'Antonio E.; Patnaik M.M.; Tefferi A.; Vannucchi A.M.; Guglielmelli P. (2020). RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features. BLOOD ADVANCES, vol. 4, pp. 3677-3687, ISSN:2473-9529 DOI

Coltro, Giacomo; Antelo, Guadalupe; Lasho, Terra L; Finke, Christy M; Pardanani, Animesh; Gangat, Naseema; Carr, Ryan M; Binder, Moritz; Mangaonkar, Abhishek A; Ketterling, Rhett; Fernandez-Zapico, Martin E; Robertson, Keith D; Bosi, Alberto; Vannucchi, Alessandro M; Tefferi, Ayalew; Patnaik, Mrinal M (2020). Phenotypic Correlates and Prognostic Outcomes of TET2 Mutations in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Comprehensive Study of 504 Adult Patients. AMERICAN JOURNAL OF HEMATOLOGY, pp. 222-230, ISSN:0361-8609 DOI

Coltro, Giacomo; Mannelli, Francesco; Vergoni, Federica; Santi, Raffaella; Massi, Daniela; Siliani, Luisa Margherita; Marzullo, Antonella; Bonifacio, Stefania; Pelo, Elisabetta; Pacilli, Annalisa; Paoli, Chiara; Franci, Annalisa; Calabresi, Laura; Bosi, Alberto; Vannucchi, Alessandro Maria; Guglielmelli, Paola (2020). Extramedullary blastic transformation of primary myelofibrosis in the form of disseminated myeloid sarcoma: a case report and review of the literature. CLINICAL AND EXPERIMENTAL MEDICINE, pp. 203-210, ISSN:1591-8890 DOI

Rocca, Bianca; Tosetto, Alberto; Betti, Silvia; Soldati, Denise; Petrucci, Giovanna; Rossi, Elena; Timillero, Andrea; Cavalca, Viviana; Porro, Benedetta; Iurlo, Alessandra; Cattaneo, Daniele; Bucelli, Cristina; Dragani, Alfredo; Di Ianni, Mauro; Ranalli, Paola; Palandri, Francesca; Vianelli, Nicola; Beggiato, Eloise; Lanzarone, Giuseppe; Ruggeri, Marco; Carli, Giuseppe; Elli, Elena Maria; Carpenedo, Monica; Bertozzi, Irene; Paoli, Chiara; Randi, Maria L; Ricco, Alessandra; Specchia, Giorgina; Vannucchi, Alessandro Maria; Rodeghiero, Francesco; Patrono, Carlo; De Stefano, Valerio (2020). A randomized, double-blind trial of three aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia. BLOOD, pp. 1-33, ISSN:0006-4971 DOI

Harrison C.N.; Schaap N.; Vannucchi A.M.; Kiladjian J.-J.; Jourdan E.; Silver R.T.; Schouten H.C.; Passamonti F.; Zweegman S.; Talpaz M.; Verstovsek S.; Rose S.; Shen J.; Berry T.; Brownstein C.; Mesa R.A. (2020). Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure. AMERICAN JOURNAL OF HEMATOLOGY, vol. 95, pp. 594-603, ISSN:0361-8609 DOI

Quattrocchi A.; Maiorca C.; Billi M.; Tomassini S.; De Marinis E.; Cenfra N.; Equitani F.; Gentile M.; Ceccherelli A.; Banella C.; Mecarocci S.; Scerpa M.C.; Pisano S.; Pacilli A.; Di Cristofano C.; Mancini M.; Guglielmelli P.; Vannucchi A.M.; Noguera N.; Grignani F.; Cimino G.; Nervi C. (2020). Genetic lesions disrupting calreticulin 3′-untranslated region in JAK2 mutation-negative polycythemia vera. AMERICAN JOURNAL OF HEMATOLOGY, vol. 95, pp. E263-E267, ISSN:0361-8609 DOI

Gerds A.T.; Savona M.R.; Scott B.L.; Talpaz M.; Egyed M.; Harrison C.N.; Yacoub A.; Vannucchi A.; Mead A.J.; Kiladjian J.-J.; O'Sullivan J.; Garcia-Gutierrez V.; Bose P.; Rampal R.K.; Miller C.B.; Palmer J.; Oh S.T.; Buckley S.A.; Mould D.R.; Ito K.; Tyavanagimatt S.; Smith J.A.; Roman-Torres K.; Devineni S.; Craig A.R.; Mascarenhas J.O. (2020). Determining the recommended dose of pacritinib: Results from the PAC203 dose-finding trial in advanced myelofibrosis. BLOOD ADVANCES, vol. 4, pp. 5825-5835, ISSN:2473-9529 DOI

Palandri F.; Piciocchi A.; De Stefano V.; Breccia M.; Finazzi G.; Iurlo A.; Fazi P.; Soddu S.; Martino B.; Siragusa S.; Albano F.; Passamonti F.; Vignetti M.; Vannucchi A.M. (2020). How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy—a GIMEMA MPN WP survey. LEUKEMIA, vol. 34, pp. 2805-2808, ISSN:0887-6924 DOI

Calvani, Maura; Dabraio, Annalisa; Bruno, Gennaro; De Gregorio, Veronica; Coronnello, Marcella; Bogani, Costanza; Ciullini, Sara; Marca, Giancarlo la; Vignoli, Marina; Chiarugi, Paola; Nardi, Margherita; Vannucchi, Alessandro Maria; Filippi, Luca; Favre, Claudio (2020). β3-Adrenoreceptor Blockade Reduces Hypoxic Myeloid Leukemic Cells Survival and Chemoresistance. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 21, pp. 1-18, ISSN:1422-0067 DOI

Vannucchi A.M. (2020). To be, or not to be. BLOOD, vol. 135, pp. 1617-1618, ISSN:0006-4971 DOI

Zingariello M.; Rosti V.; Vannucchi A.M.; Guglielmelli P.; Mazzarini M.; Barosi G.; Genova M.L.; Migliaccio A.R. (2020). Shared and Distinctive Ultrastructural Abnormalities Expressed by Megakaryocytes in Bone Marrow and Spleen From Patients With Myelofibrosis. FRONTIERS IN ONCOLOGY, vol. 10, pp. 1-12, ISSN:2234-943X DOI

Loscocco G.G.; Mannelli F.; Mannelli L.; Vergoni F.; Gesullo F.; Rotunno G.; Guglielmelli P.; Vannucchi A.M. (2020). A case of aleukemic mast cell leukemia with an underlying myeloproliferative neoplasm: Morphological and molecular characteristics of a highly aggressive disease. AMERICAN JOURNAL OF HEMATOLOGY, vol. 95, pp. 1622-1624, ISSN:0361-8609 DOI

Tefferi A.; Guglielmelli P.; Lasho T.L.; Coltro G.; Finke C.M.; Loscocco G.G.; Sordi B.; Szuber N.; Rotunno G.; Pacilli A.; Hanson C.A.; Ketterling R.P.; Pardanani A.; Gangat N.; Vannucchi A.M. (2020). Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. BRITISH JOURNAL OF HAEMATOLOGY, vol. 189, pp. 291-302, ISSN:0007-1048 DOI

Sant'Antonio E.; Guglielmelli P.; Pieri L.; Primignani M.; Randi M.L.; Santarossa C.; Rumi E.; Cervantes F.; Delaini F.; Carobbio A.; Betti S.; Rossi E.; Lavi N.; Harrison C.N.; Curto-Garcia N.; Gisslinger H.; Gisslinger B.; Specchia G.; Ricco A.; Vianelli N.; Polverelli N.; Koren-Michowitz M.; Ruggeri M.; Girodon F.; Ellis M.; Iurlo A.; Mannelli F.; Mannelli L.; Sordi B.; Loscocco G.G.; Cazzola M.; De Stefano V.; Barbui T.; Tefferi A.; Vannucchi A.M. (2020). Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases. AMERICAN JOURNAL OF HEMATOLOGY, vol. 95, pp. 156-166, ISSN:0361-8609 DOI

Mannelli L.; Guglielmelli P.; Vannucchi A.M. (2020). Stem cell transplant for the treatment of myelofibrosis. EXPERT REVIEW OF HEMATOLOGY, vol. 13, pp. 363-374, ISSN:1747-4086 DOI

Bartalucci N.; Guglielmelli P.; Vannucchi A.M. (2020). Polycythemia vera: the current status of preclinical models and therapeutic targets. EXPERT OPINION ON THERAPEUTIC TARGETS, vol. 24, pp. 615-628, ISSN:1472-8222 DOI

Guglielmelli P.; Carobbio A.; Rumi E.; De Stefano V.; Mannelli L.; Mannelli F.; Rotunno G.; Coltro G.; Betti S.; Cavalloni C.; Finazzi M.C.; Thiele J.; Cazzola M.; Vannucchi A.M.; Barbui T. (2020). Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis. BLOOD CANCER JOURNAL, vol. 10, pp. 21-28, ISSN:2044-5385 DOI

Loscocco G.G.; Malandrino D.; Barchiesi S.; Berni A.; Poggesi L.; Guglielmelli P.; Vannucchi A.M. (2020). The HScore for secondary hemophagocytic lymphohistiocytosis, calculated without a marrow biopsy, is consistently low in patients with COVID-19. INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, vol. 42, pp. e270-e273, ISSN:1751-5521 DOI

Barbui T.; Vannucchi A.M.; Guglielmelli P.; de Stefano V.; Rambaldi A. (2020). An agenda for future research projects in polycythemia vera and essential thrombocythemia. HAEMATOLOGICA, vol. 105, pp. 1999-2003, ISSN:0390-6078 DOI

Alessandra Carobbio, Paola Guglielmelli, Elisa Rumi, Chiara Cavalloni, Valerio De Stefano, Silvia Betti, Alessandro Rambaldi, Maria Chiara Finazzi, Juergen Thiele, Alessandro M. Vannucchi, Ayalew Tefferi,Tiziano Barbui (2020). A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis. BLOOD CANCER JOURNAL, vol. 10, pp. 100-107, ISSN:2044-5385 DOI Accesso ONLINE all'editore

Guglielmelli P.; Pacilli A.; Coltro G.; Mannelli F.; Mannelli L.; Contini E.; Rotunno G.; Bartalucci N.; Fiaccabrino S.; Sordi B.; Loscocco G.G.; Paoli C.; Vannucchi A.M. (2020). Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms. AMERICAN JOURNAL OF HEMATOLOGY, vol. 95, pp. E23-E26, ISSN:0361-8609 DOI

Lagi F.; Piccica M.; Graziani L.; Vellere I.; Botta A.; Tilli M.; Ottino L.; Borchi B.; Pozzi M.; Bartalesi F.; Mencarini J.; Spinicci M.; Zammarchi L.; Pieralli F.; Zagli G.; Nozzoli C.; Romagnoli S.; Bartoloni A.; Campolmi I.; Di Lauria N.; Millotti G.; Basile G.; Meli M.; Rogasi P.G.; Bartolozzi D.; Corsi P.; Mazzetti M.; Farese A.; Bresci S.; Cavallo A.; Trotta M.; Corti G.; Morettini A.; Poggesi L.; de Gaudio A.R.; Peris A.; Fontanari P.; Parronchi P.; Almerigogna F.; Annunziato F.; Liotta F.; Cosmi L.; Vultaggio A.; Matucci A.; Angileri M.; Ipponi A.; Cecchi M.; Benemei S.; Vannucchi A.M.; Matucci-Cerinic; Turco L. (2020). Early experience of an infectious and tropical diseases unit during the coronavirus disease (COVID-19) pandemic, Florence, Italy, February to March 2020. EUROSURVEILLANCE, vol. 25, pp. 6-11, ISSN:1025-496X DOI

Mora B.; Guglielmelli P.; Rumi E.; Maffioli M.; Barraco D.; Rambaldi A.; Caramella M.; Komrokji R.S.; Kiladjian J.-J.; Gotlib J.; Iurlo A.; Cervantes F.; Devos T.; Palandri F.; De Stefano V.; Ruggeri M.; Silver R.T.; Albano F.; Benevolo G.; Cavalloni C.; Uccella S.; Accetta R.; Siracusa C.; Agnoli S.; Merli M.; Barbui T.; Bertu L.; Cazzola M.; Vannucchi A.M.; Passamonti F. (2020). Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group. AMERICAN JOURNAL OF HEMATOLOGY, vol. 95, pp. E1-E3, ISSN:0361-8609 DOI

Loscocco G.G.; Guglielmelli P.; Vannucchi A.M. (2020). Impact of mutational profile on the management of myeloproliferative neoplasms: A short review of the emerging data. ONCOTARGETS AND THERAPY, vol. 13, pp. 12367-12382, ISSN:1178-6930 DOI

Guglielmelli P.; Vannucchi A.M. (2020). Current management strategies for polycythemia vera and essential thrombocythemia. BLOOD REVIEWS, vol. 42, pp. 100714-100722, ISSN:0268-960X DOI

Breccia M.; Piciocchi A.; De Stefano V.; Finazzi G.; Iurlo A.; Fazi P.; Soddu S.; Martino B.; Palandri F.; Siragusa S.; Albano F.; Passamonti F.; Vignetti M.; Vannucchi A.M. (2020). COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey. LEUKEMIA, vol. 34, pp. 2813-2814, ISSN:0887-6924 DOI

De Stefano, Valerio; Ghirardi, Arianna; Masciulli, Arianna; Carobbio, Alessandra; Palandri, Francesca; Vianelli, Nicola; Rossi, Elena; Betti, Silvia; Di Veroli, Ambra; Iurlo, Alessandra; Cattaneo, Daniele; Finazzi, Guido; Bonifacio, Massimiliano; Scaffidi, Luigi; Patriarca, Andrea; Rumi, Elisa; Casetti, Ilaria Carola; Stephenson, Clemency Imogen Methven; Guglielmelli, Paola; Elli, Elena Maria; Palova, Miroslava; Rapezzi, Davide; Erez, Daniel; Gomez, Montse; Wille, Kai; Perez-Encinas, Manuel; Lunghi, Francesca; Angona, Anna; Fox, María-Laura; Beggiato, Eloise; Benevolo, Giulia; Carli, Giuseppe; Cacciola, Rossella; McMullin, Mary Frances; Tieghi, Alessia; Recasens, Valle; Isfort, Susanne; Marchetti, Monia; Griesshammer, Martin; Alvarez-Larran, Alberto; Vannucchi, Alessandro Maria; Rambaldi, Alessandro; Barbui, Tiziano (2020). Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer. A case-control study. BLOOD, vol. 135, pp. 381-386, ISSN:0006-4971 DOI Accesso ONLINE all'editore

Coltro, Giacomo; Mangaonkar, Abhishek A; Lasho, Terra L; Finke, Christy M; Pophali, Prateek; Carr, Ryan; Gangat, Naseema; Binder, Moritz; Pardanani, Animesh; Fernandez-Zapico, Martin; Robertson, Keith D; Bosi, Alberto; Droin, Nathalie; Vannucchi, Alessandro M; Tefferi, Ayalew; Hunter, Anthony; Padron, Eric; Solary, Eric; Patnaik, Mrinal M (2019). Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients. LEUKEMIA, pp. 78-85, ISSN:0887-6924 DOI

Bolognini D.; Bartalucci N.; Mingrino A.; Vannucchi A.M.; Magi A. (2019). NANOR: A user-friendly R package to analyze and compare nanopore sequencing data. PLOS ONE, vol. 14, pp. 1-12, ISSN:1932-6203 DOI Accesso ONLINE all'editore

Bridgford, Jessica L; Lee, Su Min; Lee, Christine Mei Mei; Guglielmelli, Paola; Rumi, Elisa; Pietra, Daniela; Wilcox, Stephen; Chhabra, Yash; Rubin, Alan F; Cazzola, Mario; Vannucchi, Alessandro M.; Brooks, Andrew J; Call, Matthew Edwin; Call, Melissa Joy (2019). Novel Drivers and Modifiers of MPL-dependent Oncogenic Transformation Identified by Deep Mutational Scanning. BLOOD, pp. 1-14, ISSN:0006-4971 DOI Accesso ONLINE all'editore

Marchetti, Monia; Ghirardi, Arianna; Masciulli, Arianna; Carobbio, Alessandra; Palandri, Francesca; Vianelli, Nicola; Rossi, Elena; Betti, Silvia; Di Veroli, Ambra; Iurlo, Alessandra; Cattaneo, Daniele; Finazzi, Guido; Bonifacio, Massimiliano; Scaffidi, Luigi; Patriarca, Andrea; Rumi, Elisa; Casetti, Ilaria Carola; Stephenson, Clemency; Guglielmelli, Paola; Elli, Elena Maria; Palova, Miroslava; Rapezzi, Davide; Erez, Daniel; Gomez, Montse; Wille, Kai; Perez-Encinas, Manuel; Lunghi, Francesca; Angona, Anna; Fox, Maria Laura; Beggiato, Eloise; Benevolo, Giulia; Carli, Giuseppe; Cacciola, Rossella; McMullin, Mary Frances; Tieghi, Alessia; Recasens, Valle; Isfort, Susanne; Pane, Fabrizio; De Stefano, Valerio; Griesshammer, Martin; Alvarez-Larran, Alberto; Vannucchi, Alessandro Maria; Rambaldi, Alessandro; Barbui, Tiziano (2019). Second cancers in MPN: Survival analysis from an international study. AMERICAN JOURNAL OF HEMATOLOGY, pp. 1-19, ISSN:0361-8609 DOI

Barbui T.; De Stefano V.; Falanga A.; Finazzi G.; Martinelli I.; Rodeghiero F.; Vannucchi A.M.; Barosi G. (2019). Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper. BLOOD CANCER JOURNAL, vol. 9, pp. 1-10, ISSN:2044-5385 DOI Accesso ONLINE all'editore

Vannucchi A.M.; Te Boekhorst P.A.W.; Harrison C.N.; He G.; Caramella M.; Niederwieser D.; Boyer-Perrard F.; Duan M.; Francillard N.; Molloy B.; Wroclawska M.; Gisslinger H. (2019). EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis. HAEMATOLOGICA, vol. 104, pp. 947-954, ISSN:0390-6078 DOI Accesso ONLINE all'editore

Barbui T.; Thiele J.; Gisslinger H.; Orazi A.; Vannucchi A.M.; Gianelli U.; Beham-Schmid C.; Tefferi A. (2019). Comments on pre-fibrotic myelofibrosis and how should it be managed. BRITISH JOURNAL OF HAEMATOLOGY, vol. 186, pp. 358-360, ISSN:0007-1048 DOI Accesso ONLINE all'editore

Ferrari, Alberto; Carobbio, Alessandra; Masciulli, Arianna; Ghirardi, Arianna; Finazzi, Guido; De Stefano, Valerio; Vannucchi, Alessandro Maria; Barbui, Tiziano (2019). Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis. HAEMATOLOGICA, pp. 1-19, ISSN:0390-6078 DOI

Mannelli F.; Gesullo F.; Rotunno G.; Pacilli A.; Bencini S.; Annunziato F.; Zanotti R.; Scaffidi L.; Giona F.; Santopietro M.; Grifoni F.; Pieri L.; Guglielmelli P.; Vannucchi A.M. (2019). Myelodysplasia as assessed by multiparameter flow cytometry refines prognostic stratification provided by genotypic risk in systemic mastocytosis. AMERICAN JOURNAL OF HEMATOLOGY, vol. 94, pp. 845-852, ISSN:0361-8609 DOI Accesso ONLINE all'editore

Rotunno G.; Mannarelli C.; Brogi G.; Pacilli A.; Gesullo F.; Mannelli F.; Fiaccabrino S.; Sordi B.; Paoli C.; Marone I.; Rumi E.; Manfredini R.; Barosi G.; Cazzola M.; Vannucchi A.M.; Guglielmelli P. (2019). Spectrum of ASXL1 mutations in primary myelofibrosis: Prognostic impact of the ASXL1 p.G646Wfs∗12 mutation. BLOOD, vol. 133, pp. 2802-2808, ISSN:0006-4971 DOI Accesso ONLINE all'editore

Salati S.; Genovese E.; Carretta C.; Zini R.; Bartalucci N.; Prudente Z.; Pennucci V.; Ruberti S.; Rossi C.; Rontauroli S.; Enzo E.; Calabresi L.; Balliu M.; Mannarelli C.; Bianchi E.; Guglielmelli P.; Tagliafico E.; Vannucchi A.M.; Manfredini R. (2019). Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants. SCIENTIFIC REPORTS, vol. 9, pp. 10558-10571, ISSN:2045-2322 DOI Accesso ONLINE all'editore

Loscocco G.G.; Mannelli F.; Guglielmelli P.; Paoli C.; Marone I.; Cucci R.; Coltro G.; Sordi B.; Albano F.; Breccia M.; De Stefano V.; Finazzi G.; Iurlo A.; Martino B.; Palandri F.; Passamonti F.; Siragusa S.; Mannelli L.; Fantoni D.; Fazi P.; Amadori S.; Vignetti M.; Barbui T.; Vannucchi A.M. (2019). Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative. AMERICAN JOURNAL OF HEMATOLOGY, vol. 94, pp. E239-E242, ISSN:0361-8609 DOI Accesso ONLINE all'editore

Vannucchi A.M.; Guglielmelli P. (2019). The JAK2 46/1 (GGCC) MPN-predisposing haplotype: A risky haplotype, after all. AMERICAN JOURNAL OF HEMATOLOGY, vol. 94, pp. 283-285, ISSN:0361-8609 DOI Accesso ONLINE all'editore

Magi, Alberto; Bolognini, Davide; Bartalucci, Niccoló; Mingrino, Alessandra; Semeraro, Roberto; Giovannini, Luna; Bonifacio, Stefania; Parrini, Daniela; Pelo, Elisabetta; Mannelli, Francesco; Guglielmelli, Paola; Vannucchi, Alessandro Maria (2019). Nano-GLADIATOR: real-time detection of copy number alterations from nanopore sequencing data. BIOINFORMATICS, pp. 1-9, ISSN:1367-4803 DOI

Molin A.D.; Bresolin S.; Gaffo E.; Tretti C.; Boldrin E.; Meyer L.H.; Guglielmelli P.; Vannucchi A.M.; Kronnie G.; Bortoluzzi S. (2019). Circ RNAs are here to stay: A perspective on the MLL recombinome. FRONTIERS IN GENETICS, vol. 10, pp. 88-95, ISSN:1664-8021 DOI Accesso ONLINE all'editore

Mora B.; Rumi E.; Guglielmelli P.; Barraco D.; Maffioli M.; Rambaldi A.; Caramella M.; Komrokji R.; Gotlib J.; Kiladjian J.J.; Cervantes F.; Devos T.; Palandri F.; Stefano V.D.; Ruggeri M.; Silver R.T.; Benevolo G.; Albano F.; Cavalloni C.; Pietra D.; Barbui T.; Rotunno G.; Cazzola M.; Vannucchi A.M.; Giorgino T.; Passamonti F. (2019). Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients. CANCER MEDICINE, vol. 8, pp. 4089-4092, ISSN:2045-7634 DOI Accesso ONLINE all'editore

Paola Guglielmelli, MD PhD, Niccolò Bartalucci, PhDBSc, Elisa Contini, PhD, Giada Rotunno, PhD, Annalisa Pacilli, PhD, Simone Romagnoli, BSc, Lara Mannelli, MD, Francesco Mannelli, MD, Giacomo Coltro, MD, Alessandro Pancrazzi, PhD, Valentina Ariu, BSci, Sara Fiaccabrino, Roberto Semeraro, Alberto Magi, PhD, Carmela Mannarelli, PhD, Francesca Gesullo, BSci, Chiara Paoli, PhD, Alessandro M. Vannucchi, MD (2019). Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs). BLOOD, pp. 0-0, ISSN:0006-4971

Bartalucci, N; Mannelli, F; Contini, E; Romagnoli, S; Gianfaldoni, G; Scappini, B; Pelo, E; Pancani, F; Magi, A; Bosi, A; Guglielmelli, P; Vannucchi, AM (2019). THIRD GENERATION SEQUENCING OF NORMAL KARYOTYPE ACUTE MYELOID LEUKEMIA: IMPLICATIONS FOR PROGNOSIS. In: HAEMATOLOGICA, FERRATA STORTI FOUNDATION, vol. 104, pp. 12-12.

Yacoub, Abdulraheem; Mascarenhas, John; Kosiorek, Heidi; Prchal, Josef T.; Berenzon, Dmitry; Baer, Maria R.; Ritchie, Ellen; Silver, Richard T.; Kessler, Craig; Winton, Elliott; Finazzi, Maria Chiara; Rambaldi, Alessandro; Vannucchi, Alessandro M.; Leibowitz, David; Rondelli, Damiano; Arcasoy, Murat O.; Catchatourian, Rosalind; Vadakara, Joseph; Rosti, Vittorio; Hexner, Elizabeth; Kremyanskaya, Marina; Sandy, Lonette; Tripodi, Joseph; Najfeld, Vesna; Farnoud, Noushin; Papaemmanuil, Elli; Salama, Mohamed; Singer-Weinberg, Rona; Rampal, Raajit; Goldberg, Judith D.; Barbui, Tiziano; Mesa, Ruben; Dueck, Amylou C.; Hoffman, Ronald (2019). Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. BLOOD, vol. 134, pp. 1498-1509, ISSN:0006-4971 DOI

Bartalucci, Niccolò; Romagnoli, Simone; Contini, Elisa; Marseglia, Giuseppina; Magi, Alberto; Guglielmelli, Paola; Pelo, Elisabetta; Vannucchi, Alessandro M (2019). Long Reads, Short Time: Feasibility of Prenatal Sample Karyotyping by Nanopore Genome Sequencing. CLINICAL CHEMISTRY, vol. 65, pp. 1605-1608-1608, ISSN:0009-9147 DOI

Barbui, Tiziano; Ghirardi, Arianna; Masciulli, Arianna; Carobbio, Alessandra; Palandri, Francesca; Vianelli, Nicola; De Stefano, Valerio; Betti, Silvia; Di Veroli, Ambra; Iurlo, Alessandra; Cattaneo, Daniele; Delaini, Federica; Bonifacio, Massimiliano; Scaffidi, Luigi; Patriarca, Andrea; Rumi, Elisa; Casetti, Ilaria Carola; Stephenson, Clemency; Guglielmelli, Paola; Elli, Elena Maria; Palova, Miroslava; Bertolotti, Laura; Erez, Daniel; Gomez, Montse; Wille, Kai; Perez-Encinas, Manuel; Lunghi, Francesca; Angona, Anna; Fox, Maria Laura; Beggiato, Eloise; Benevolo, Giulia; Carli, Giuseppe; Cacciola, Rossella; McMullin, Mary Frances; Tieghi, Alessia; Recasens, Valle; Marchetti, Monia; Griesshammer, Martin; Alvarez-Larran, Alberto; Vannucchi, Alessandro Maria; Finazzi, Guido (2019). Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study. LEUKEMIA, vol. 33, pp. 1996-2005, ISSN:1476-5551 DOI

Mannelli F.; Gesullo F.; Rotunno G.; Pacilli A.; Pieri L.; Guglielmelli P.; Vannucchi A.M. (2019). Validation of the Mayo alliance prognostic system for mastocytosis. BLOOD CANCER JOURNAL, vol. 9, pp. 18-21, ISSN:2044-5385 DOI Accesso ONLINE all'editore

Mascarenhas J.; Kosiorek H.; Prchal J.; Yacoub A.; Berenzon D.; Baer M.R.; Ritchie E.; Silver R.T.; Kessler C.; Winton E.; Finazzi M.C.; Rambaldi A.; Vannucchi A.M.; Leibowitz D.; Rondelli D.; Arcasoy M.O.; Catchatourian R.; Vadakara J.; Rosti V.; Hexner E.; Kremyanskaya M.; Sandy L.; Tripodi J.; Najfeld V.; Farnoud N.; Salama M.E.; Weinberg R.S.; Rampal R.; Goldberg J.D.; Mesa R.; Dueck A.C.; Hoffman R. (2019). A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis. LEUKEMIA, pp. 1-5, ISSN:0887-6924 DOI Accesso ONLINE all'editore

Barosi G.; Passamonti F.; Accorsi P.; Pane F.; Vannucchi A.M.; Velati C.; Gale R.P.; Tura S.; Barbui T. (2018). Response to “Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions” by Heidel et al. LEUKEMIA, vol. 32, pp. 2727-2728, ISSN:0887-6924 DOI Accesso ONLINE all'editore

Barbui T.; Passamonti F.; Accorsi P.; Pane F.; Vannucchi A.M.; Velati C.; Gale R.P.; Tura S.; Barosi G. (2018). Evidence- and consensus-based recommendations for phlebotomy in polycythemia vera. LEUKEMIA, vol. 32, pp. 2077-2081, ISSN:0887-6924 DOI Accesso ONLINE all'editore

De Stefano V.; Rossi E.; Carobbio A.; Ghirardi A.; Betti S.; Finazzi G.; Vannucchi A.M.; Barbui T. (2018). Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases. BLOOD CANCER JOURNAL, vol. 8, pp. 112-118, ISSN:2044-5385 DOI

Barbui T.; Finazzi G.; Vannucchi A.M.; De Stefano V. (2018). Targeting myeloid cells to prevent recurrent stroke in general population: the lesson of hydroxyurea in myeloproliferative neoplasms. BLOOD CANCER JOURNAL, vol. 8, pp. 103-105, ISSN:2044-5385 DOI Accesso ONLINE all'editore

Barbui T.; De Stefano V.; Ghirardi A.; Masciulli A.; Finazzi G.; Vannucchi A.M. (2018). Different effect of hydroxyurea and phlebotomy on prevention of arterial and venous thrombosis in Polycythemia Vera. BLOOD CANCER JOURNAL, vol. 8, pp. 1-4, ISSN:2044-5385 DOI Accesso ONLINE all'editore

Pacilli A.; Rotunno G.; Mannarelli C.; Fanelli T.; Pancrazzi A.; Contini E.; Mannelli F.; Gesullo F.; Bartalucci N.; Fattori G.C.; Paoli C.; Vannucchi A.M.; Guglielmelli P. (2018). Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea. BLOOD CANCER JOURNAL, vol. 8, pp. 122-131, ISSN:2044-5385 DOI Accesso ONLINE all'editore

Mora B.; Giorgino T.; Guglielmelli P.; Rumi E.; Maffioli M.; Rambaldi A.; Caramella M.; Komrokji R.; Gotlib J.; Kiladjian J.J.; Cervantes F.; Devos T.; Palandri F.; De Stefano V.; Ruggeri M.; Silver R.T.; Benevolo G.; Albano F.; Cavalloni C.; Barraco D.; Pietra D.; Barbui T.; Rotunno G.; Vannucchi A.M.; Passamonti F. (2018). Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. LEUKEMIA RESEARCH, vol. 69, pp. 100-102, ISSN:0145-2126 DOI Accesso ONLINE all'editore

Barraco D.; Mora B.; Guglielmelli P.; Rumi E.; Maffioli M.; Rambaldi A.; Caramella M.; Komrokji R.; Gotlib J.; Kiladjian J.J.; Cervantes F.; Devos T.; Palandri F.; De Stefano V.; Ruggeri M.; Silver R.T.; Benevolo G.; Albano F.; Merli M.; Pietra D.; Barbui T.; Rotunno G.; Cazzola M.; Giorgino T.; Vannucchi A.M.; Passamonti F. (2018). Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. BLOOD CANCER JOURNAL, vol. 8, pp. 89-92, ISSN:2044-5385 DOI Accesso ONLINE all'editore

Pardanani A.; Shah S.; Mannelli F.; Elala Y.C.; Guglielmelli P.; Lasho T.L.; Patnaik M.M.; Gangat N.; Ketterling R.P.; Reichard K.K.; Hanson C.A.; Vannucchi A.M.; Tefferi A. (2018). Mayo alliance prognostic system for mastocytosis: Clinical and hybrid clinical-molecular models. BLOOD ADVANCES, vol. 2, pp. 2964-2972, ISSN:2473-9529 DOI Accesso ONLINE all'editore

Tefferi A.; Guglielmelli P.; Pardanani A.; Vannucchi A.M. (2018). Myelofibrosis Treatment Algorithm 2018. BLOOD CANCER JOURNAL, vol. 8, pp. 72-78, ISSN:2044-5385 DOI Accesso ONLINE all'editore

De Stefano V.; Carobbio A.; Di Lazzaro V.; Guglielmelli P.; Iurlo A.; Finazzi M.C.; Rumi E.; Cervantes F.; Elli E.M.; Randi M.L.; Griesshammer M.; Palandri F.; Bonifacio M.; Hernandez-Boluda J.-C.; Cacciola R.; Miroslava P.; Carli G.; Beggiato E.; Ellis M.H.; Musolino C.; Gaidano G.; Rapezzi D.; Tieghi A.; Lunghi F.; Loscocco G.G.; Cattaneo D.; Cortelezzi A.; Betti S.; Rossi E.; Finazzi G.; Censori B.; Cazzola M.; Bellini M.; Arellano-Rodrigo E.; Bertozzi I.; Sadjadian P.; Vianelli N.; Scaffidi L.; Gomez M.; Cacciola E.; Vannucchi A.M.; Barbui T. (2018). Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms. BLOOD CANCER JOURNAL, vol. 8, pp. 25-36, ISSN:2044-5385 DOI Accesso ONLINE all'editore

Tefferi, Ayalew; Guglielmelli, Paola; Nicolosi, Maura; Mannelli, Francesco; Mudireddy, Mythri; Bartalucci, Niccolo; Finke, Christy M; Lasho, Terra L; Hanson, Curtis A; Ketterling, Rhett P; Begna, Kebede H; Naseema Gangat, null; Pardanani, Animesh; Vannucchi, Alessandro M (2018). GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. LEUKEMIA, vol. 32, pp. 1631-1642, ISSN:1476-5551 DOI Accesso ONLINE all'editore

Chorzalska A.; Morgan J.; Ahsan N.; Treaba D.O.; Olszewski A.J.; Petersen M.; Kingston N.; Cheng Y.; Lombardo K.; Schorl C.; Yu X.; Zini R.; Pacilli A.; Tepper A.; Coburn J.; Hryniewicz-Jankowska A.; Zhao T.C.; Oancea E.; Reagan J.L.; Liang O.; Kotula L.; Quesenberry P.J.; Gruppuso P.A.; Manfredini R.; Vannucchi A.M.; Dubielecka P.M. (2018). Bone marrow-specific loss of ABI1 induces myeloproliferative neoplasm with features resembling, human myelofibrosis. BLOOD, vol. 132, pp. 2053-2066, ISSN:0006-4971 DOI Accesso ONLINE all'editore

De Stefano V.; Rocca B.; Tosetto A.; Soldati D.; Petrucci G.; Beggiato E.; Bertozzi I.; Betti S.; Carli G.; Carpenedo M.; Cattaneo D.; Cavalca V.; Dragani A.; Elli E.; Finazzi G.; Iurlo A.; Lanzarone G.; Lissandrini L.; Palandri F.; Paoli C.; Rambaldi A.; Ranalli P.; Randi M.L.; Ricco A.; Rossi E.; Ruggeri M.; Specchia G.; Timillero A.; Turnu L.; Vianelli N.; Vannucchi A.M.; Rodeghiero F.; Patrono C. (2018). The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B 2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting. BLOOD CANCER JOURNAL, vol. 8, pp. 49-57, ISSN:2044-5385 DOI Accesso ONLINE all'editore

Finazzi G.; Vannucchi A.M.; Barbui T. (2018). Prefibrotic myelofibrosis: treatment algorithm 2018. BLOOD CANCER JOURNAL, vol. 8, pp. 104-108, ISSN:2044-5385 DOI Accesso ONLINE all'editore

Barbui T.; Tefferi A.; Vannucchi A.M.; Passamonti F.; Silver R.T.; Hoffman R.; Verstovsek S.; Mesa R.; Kiladjian J.-J.; Hehlmann R.; Reiter A.; Cervantes F.; Harrison C.; Mc Mullin M.F.; Hasselbalch H.C.; Koschmieder S.; Marchetti M.; Bacigalupo A.; Finazzi G.; Kroeger N.; Griesshammer M.; Birgegard G.; Barosi G. (2018). Philadelphia chromosome-negative classical myeloproliferative neoplasms: Revised management recommendations from European LeukemiaNet. LEUKEMIA, vol. 32, pp. 1057-1069, ISSN:0887-6924 DOI Accesso ONLINE all'editore

Tefferi, Ayalew; Mudireddy, Mythri; Mannelli, Francesco; Begna, Kebede H; Patnaik, Mrinal M; Hanson, Curtis A; Ketterling, Rhett P; Gangat, Naseema; Yogarajah, Meera; De Stefano, Valerio; Passamonti, Francesco; Rosti, Vittorio; Finazzi, Maria Chiara; Rambaldi, Alessandro; Bosi, Alberto; Guglielmelli, Paola; Pardanani, Animesh; Vannucchi, Alessandro M (2018). Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. LEUKEMIA, pp. 280-290, ISSN:1476-5551 DOI

Tefferi A.; Guglielmelli P.; Lasho T.L.; Gangat N.; Ketterling R.P.; Pardanani A.; Vannucchi A.M. (2018). MIPSS701 version 2.0: Mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis. JOURNAL OF CLINICAL ONCOLOGY, vol. 36, pp. 1769-1770, ISSN:0732-183X DOI Accesso ONLINE all'editore

Mora B.; Giorgino T.; Guglielmelli P.; Rumi E.; Maffioli M.; Rambaldi A.; Caramella M.; Komrokji R.; Gotlib J.; Kiladjian J.J.; Cervantes F.; Devos T.; Palandri F.; De Stefano V.; Ruggeri M.; Silver R.T.; Benevolo G.; Albano F.; Cavalloni C.; Barraco D.; Merli M.; Pietra D.; Casalone R.; Barbui T.; Rotunno G.; Cazzola M.; Vannucchi A.M.; Passamonti F. (2018). Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC project. HAEMATOLOGICA, vol. 103, pp. e392-e394, ISSN:0390-6078 DOI Accesso ONLINE all'editore

Rossi C.; Zini R.; Rontauroli S.; Ruberti S.; Prudente Z.; Barbieri G.; Bianchi E.; Salati S.; Genovese E.; Bartalucci N.; Guglielmelli P.; Tagliafico E.; Rosti V.; Barosi G.; Vannucchi A.M.; Manfredini R. (2018). Role of TGF-β1/miR-382-5p/SOD2 axis in the induction of oxidative stress in CD34+ cells from primary myelofibrosis. MOLECULAR ONCOLOGY, vol. 12, pp. 2102-2123, ISSN:1574-7891 DOI Accesso ONLINE all'editore

Grinfeld J.; Nangalia J.; Baxter E.J.; Wedge D.C.; Angelopoulos N.; Cantrill R.; Godfrey A.L.; Papaemmanuil E.; Gundem G.; MacLean C.; Cook J.; O'Neil L.; O'Meara S.; Teague J.W.; Butler A.P.; Massie C.E.; Williams N.; Nice F.L.; Andersen C.L.; Hasselbalch H.C.; Guglielmelli P.; McMullin M.F.; Vannucchi A.M.; Harrison C.N.; Gerstung M.; Green A.R.; Campbell P.J. (2018). Classification and personalized prognosis in myeloproliferative neoplasms. THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 379, pp. 1416-1430, ISSN:0028-4793 DOI Accesso ONLINE all'editore

Barbui, Tiziano; Thiele, Jürgen; Gisslinger, Heinz; Kvasnicka, Hans Michael; Vannucchi, Alessandro M; Guglielmelli, Paola; Orazi, Attilio; Tefferi, Ayalew (2018). The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. BLOOD CANCER JOURNAL, vol. 8, pp. 15-25, ISSN:2044-5385 DOI

Avanzini, Maria Antonietta; Abbonante, Vittorio; Catarsi, Paolo; Dambruoso, Irene; Mantelli, Melissa; Poletto, Valentina; Lenta, Elisa; Guglielmelli, Paola; Croce, Stefania; Cobianchi, Lorenzo; Jemos, Basilio; Campanelli, Rita; Bonetti, Elisa; Di Buduo, Christian Andrea; Salmoiraghi, Silvia; Villani, Laura; Massa, Margherita; Boni, Marina; Zappatore, Rita; Iurlo, Alessandra; Rambaldi, Alessandro; Vannucchi, Alessandro Maria; Bernasconi, Paolo; Balduini, Alessandra; Barosi, Giovanni; Rosti, Vittorio* (2018). The spleen of patients with myelofibrosis harbors defective mesenchymal stromal cells. AMERICAN JOURNAL OF HEMATOLOGY, pp. 00-23, ISSN:0361-8609 DOI Accesso ONLINE all'editore

Loscocco, Giuseppe G; Piccini, Matteo; Vergoni, Federica; Vannucchi, Alessandro M; Bosi, Alberto (2018). A case of disseminated Blastic Plasmocytoid Dendritic Cell Neoplasm. AMERICAN JOURNAL OF HEMATOLOGY, pp. 25-28, ISSN:0361-8609 DOI

Tefferi, Ayalew*; Vannucchi, Alessandro M.; Barbui, Tiziano (2018). Essential thrombocythemia treatment algorithm 2018. BLOOD CANCER JOURNAL, vol. 8, pp. 2-7, ISSN:2044-5385 DOI Accesso ONLINE all'editore

Tefferi, Ayalew*; Vannucchi, Alessandro M.; Barbui, Tiziano (2018). Polycythemia vera treatment algorithm 2018. BLOOD CANCER JOURNAL, vol. 8, pp. 3-9, ISSN:2044-5385 DOI Accesso ONLINE all'editore

Koren-Michowitz, Maya; Lavi, Noa; Ellis, Martin H.; Vannucchi, Alessandro M.; Mesa, Ruben; Harrison, Claire N. (2017). Management of extreme thrombocytosis in myeloproliferative neoplasms: an international physician survey. ANNALS OF HEMATOLOGY, vol. 96, pp. 87-92, ISSN:0939-5555 DOI Accesso ONLINE all'editore

Vannucchi, Alessandro Maria; Verstovsek, Srdan; Guglielmelli, Paola; Griesshammer, Martin; Burn, Timothy C.; Naim, Ahmad; Paranagama, Dilan; Marker, Mahtab; Gadbaw, Brian; Kiladjian, Jean-Jacques (2017). Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study. ANNALS OF HEMATOLOGY, pp. 1-8, ISSN:0939-5555 DOI Accesso ONLINE all'editore

Geyer, Holly L; Kosiorek, Heidi; Dueck, Amylou C.; Scherber, Robyn; Slot, Stefanie; Zweegman, Sonja; te Boekhorst, Peter A. W.; Senyak, Zhenya; Schouten, Harry C.; Sackmann, Federico; Fuentes, Ana Kerguelen; Hernández-Maraver, Dolores; Pahl, Heike L.; Griesshammer, Martin; Stegelmann, Frank; Döhner, Konstanze; Lehmann, Thomas; Bonatz, Karin; Reiter, Andreas; Boyer, Francoise; Etienne, Gabriel; Ianotto, Jean-Christophe; Ranta, Dana; Roy, Lydia; Cahn, Jean-Yves; Harrison, Claire N.; Radia, Deepti; Muxi, Pablo; Maldonado, Norman; Besses, Carlos; Cervantes, Francisco; Johansson, Peter L.; Barbui, Tiziano; Barosi, Giovanni; Vannucchi, Alessandro M.; Paoli, Chiara; Passamonti, Francesco; Andreasson, Bjorn; Ferrari, Maria L.; Rambaldi, Alessandro; Samuelsson, Jan; Cannon, Keith; Birgegard, Gunnar; Xiao, Zhijian; Xu, Zefeng; Zhang, Yue; Sun, Xiujuan; Xu, Junqing; Kiladjian, Jean-Jacques; Zhang, Peihong; Gale, Robert Peter; Mesa, Ruben A. (2017). Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: An analysis by the MPN QOL international working group. HAEMATOLOGICA, vol. 102, pp. 85-93, ISSN:0390-6078 DOI Accesso ONLINE all'editore

Scherber, Robyn Marie; Geyer, Holly Lynn; Dueck, Amylou C.; Kosiorek, Heidi E.; Finazzi, Guido; Cavazzina, Riccardo; Masciulli, Arianna; Scarano, Marco; Vannucchi, Alessandro M.; Mesa, Ruben A.; Barbui, Tiziano (2017). The potential role of hematocrit control on symptom burden among polycythemia vera patients: Insights from the CYTO-PV and MPN-SAF patient cohorts. LEUKEMIA & LYMPHOMA, vol. 58, pp. 1481-1487, ISSN:1042-8194 DOI

Vannucchi, Alessandro M.; Harrison, Claire N (2017). Emerging treatments for classical myeloproliferative neoplasms. BLOOD, vol. 129, pp. 693-703, ISSN:0006-4971 DOI Accesso ONLINE all'editore

Passamonti, Francesco; Griesshammer, Martin; Palandri, Francesca; Egyed, Miklos; Benevolo, Giulia; Devos, Timothy; Callum, Jeannie; Vannucchi, Alessandro M; Sivgin, Serdar; Bensasson, Caroline; Khan, Mahmudul; Mounedji, Nadjat; Saydam, Guray (2017). Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. THE LANCET ONCOLOGY, vol. 18, pp. 88-99, ISSN:1470-2045 DOI Accesso ONLINE all'editore

Vannucchi, Alessandro M (2017). From leeches to personalized medicine: Evolving concepts in the management of polycythemia vera. HAEMATOLOGICA, vol. 102, pp. 18-29, ISSN:0390-6078 DOI Accesso ONLINE all'editore

Verstovsek, Srdan; Harrison, Claire N.; Kiladjian, Jean-Jacques; Miller, Carole; Naim, Ahmad B.; Paranagama, Dilan C.; Habr, Dany; Vannucchi, Alessandro M. (2017). Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy. LEUKEMIA RESEARCH, vol. 56, pp. 52-59, ISSN:0145-2126 DOI Accesso ONLINE all'editore

Passamonti, F.; Giorgino, T.; Mora, B.; Guglielmelli, P.; Rumi, E.; Maffioli, M.; Rambaldi, A.; Caramella, M.; Komrokji, R.; Gotlib, J.; Kiladjian, J. J.; Cervantes, F.; Devos, T.; Palandri, F.; De Stefano, V.; Ruggeri, M.; Silver, R. T.; Benevolo, G.; Albano, F.; Caramazza, D.; Merli, M.; Pietra, D.; Casalone, R.; Rotunno, G.; Barbui, T.; Cazzola, M.; Vannucchi, A. M. (2017). A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. LEUKEMIA, vol. 31, pp. 2726-2731, ISSN:0887-6924 DOI Accesso ONLINE all'editore

Harrison, Claire N; Vannucchi, Alessandro M; Platzbecker, Uwe; Cervantes, Francisco; Gupta, Vikas; Lavie, David; Passamonti, Francesco; Winton, Elliott F; Dong, Hua; Kawashima, Jun; Maltzman, Julia D; Kiladjian, Jean-Jacques; Verstovsek, Srdan (2017). Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. THE LANCET. HAEMATOLOGY, pp. 00-01, ISSN:2352-3026 DOI

Ruberti, S; Bianchi, E; Guglielmelli, P; Rontauroli, S; Barbieri, G; Tavernari, L; Fanelli, T; Norfo, R; Pennucci, V; G. Corbizi, Fattori; Mannarelli, C; Bartalucci, N; Mora, B; Elli, L; Avanzini, M. A; Rossi, C; Salmoiraghi, S; Zini, R; Salati, S; Prudente, Z; Rosti, V; Passamonti, F; Rambaldi, A; Ferrari, S; Tagliafico, E; Vannucchi, A. M; Manfredini, R. (2017). Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients. LEUKEMIA, pp. 00-01, ISSN:0887-6924 DOI

Vannucchi, Alessandro M; Guglielmelli, Paola; Tefferi, Ayalew (2017). Polycythemia vera and essential thrombocythemia: algorithmic approach. CURRENT OPINION IN HEMATOLOGY, pp. 00-01, ISSN:1065-6251 DOI

Bartalucci, Niccolã²; Calabresi, Laura; Balliu, Manjola; Martinelli, Serena; Rossi, Maria Caterina; Villeval, Jean Luc; Annunziato, Francesco; Guglielmelli, Paola; Vannucchi, Alessandro M. (2017). Inhibitors of the PI3K/mTOR pathway prevent STAT5 phosphorylation in JAK2V617F mutated cells through PP2A/ CIP2A axis. ONCOTARGET, vol. 8, pp. 96710-96724, ISSN:1949-2553 DOI Accesso ONLINE all'editore

Ellis, Martin H.; Koren-Michowitz, Maya; Lavi, Noa; Vannucchi, Alessandro M; Mesa, Ruben; Harrison, Claire N. (2017). Ruxolitinib for the management of myelofibrosis: Results of an international physician survey. LEUKEMIA RESEARCH, vol. 61, pp. 6-9, ISSN:0145-2126 DOI Accesso ONLINE all'editore

Tefferi, Ayalew; Betti, Silvia; Barraco, Daniela; Mudireddy, Mythri; Shah, Sahrish; Hanson, Curtis A.; Ketterling, Rhett P.; Pardanani, Animesh; Gangat, Naseema; Coltro, Giacomo; Guglielmelli, Paola; Vannucchi, Alessandro M. (2017). Gender and survival in essential thrombocythemia: A two-center study of 1,494 patients. AMERICAN JOURNAL OF HEMATOLOGY, vol. 92, pp. 1193-1197, ISSN:0361-8609 DOI Accesso ONLINE all'editore

Erba, Benedetta Gaia; Gruppi, Cristian; Corada, Monica; Pisati, Federica; Rosti, Vittorio; Bartalucci, Niccoloâ ; Villeval, Jean-Luc; Vannucchi, Alessandro Maria; Barosi, Giovanni; Balduini, Alessandra; Dejana, Elisabetta (2017). Endothelial-to-Mesenchymal Transition in Bone Marrow and Spleen of Primary Myelofibrosis. THE AMERICAN JOURNAL OF PATHOLOGY, vol. 187, pp. 1879-1892, ISSN:0002-9440 DOI Accesso ONLINE all'editore

Verstovsek, Srdan; Passamonti, Francesco; Rambaldi, Alessandro; Barosi, Giovanni; Rumi, Elisa; Gattoni, Elisabetta; Pieri, Lisa; Zhen, Huiling; Granier, Muriel; Assad, Albert; Cazzola, Mario; Kantarjian, Hagop M.; Barbui, Tiziano; Vannucchi, Alessandro M. (2017). Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results. BLOOD, vol. 130, pp. 1768-1771, ISSN:0006-4971 DOI Accesso ONLINE all'editore

Harrison, Claire N; Schaap, Nicolaas; Vannucchi, Alessandro M; Kiladjian, Jean-Jacques; Tiu, Ramon V; Zachee, Pierre; Jourdan, Eric; Winton, Elliott; Silver, Richard T; Schouten, Harry C; Passamonti, Francesco; Zweegman, Sonja; Talpaz, Moshe; Lager, Joanne; Shun, Zhenming; Mesa, Ruben A. (2017). Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. THE LANCET. HAEMATOLOGY, vol. 4, pp. e317-e324, ISSN:2352-3026 DOI Accesso ONLINE all'editore

Barbui, Tiziano; Vannucchi, Alessandro Maria; Finazzi, Guido; Finazzi, Maria Chiara; Masciulli, Arianna; Carobbio, Alessandra; Ghirardi, Arianna; Tognoni, Gianni (2017). A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: A propensity-matched study. AMERICAN JOURNAL OF HEMATOLOGY, vol. 92, pp. 1131-1136, ISSN:0361-8609 DOI Accesso ONLINE all'editore

Vannucchi, Alessandro M.; Guglielmelli, Paola (2017). Traffic lights for ruxolitinib. BLOOD, vol. 130, pp. 1075-1077, ISSN:0006-4971 DOI Accesso ONLINE all'editore

Tefferi, Ayalew; Nicolosi, Maura; Mudireddy, Mythri; Szuber, Natasha; Finke, Christy M.; Lasho, Terra L.; Hanson, Curtis A.; Ketterling, Rhett P.; Pardanani, Animesh; Gangat, Naseema; Mannarelli, Carmela; Fanelli, Tiziana; Guglielmelli, Paola; Vannucchi, Alessandro M. (2017). Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients. AMERICAN JOURNAL OF HEMATOLOGY, pp. 00-01, ISSN:0361-8609 DOI Accesso ONLINE all'editore

Kvasnicka, Hans Michael; Orazi, Attilio; Thiele, Juergen; Barosi, Giovanni; Bueso-Ramos, Carlos E.; Vannucchi, Alessandro M.; Hasserjian, Robert P.; Kiladjian, Jean-Jacques; Gianelli, Umberto; Silver, Richard; Mughal, Tariq I.; Barbui, Tiziano (2017). European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia. AMERICAN JOURNAL OF HEMATOLOGY, vol. 92, pp. 1062-1067, ISSN:0361-8609 DOI Accesso ONLINE all'editore

Vannucchi, Alessandro M.; Guglielmelli, Paola (2017). What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia?. HEMATOLOGY, vol. 2017, pp. 480-488, ISSN:1520-4391 DOI Accesso ONLINE all'editore

Scotch, Allison H.; Kosiorek, Heidi; Scherber, Robyn; Dueck, Amylou C.; Slot, Stefanie; Zweegman, Sonja; Boekhorst, Peter A. W. te; Commandeur, Suzan; Schouten, Harry; Sackmann, Federico; Fuentes, Ana Kerguelen; HernÃ¡ndez-Maraver, Dolores; Pahl, Heike L.; Griesshammer, Martin; Stegelmann, Frank; Dã¶hner, Konstanze; Lehmann, Thomas; Bonatz, Karin; Reiter, Andreas; Boyer, Francoise; Etienne, Gabriel; Ianotto, Jean-Christophe; Ranta, Dana; Roy, Lydia; Cahn, Jean-Yves; Harrison, Claire N.; Radia, Deepti; Muxi, Pablo; Maldonado, Norman; Besses, Carlos; Cervantes, Francisco; Johansson, Peter L.; Barbui, Tiziano; Barosi, Giovanni; Vannucchi, Alessandro M.; Paoli, Chiara; Passamonti, Francesco; Andreasson, Bjorn; Ferrari, Maria L.; Rambaldi, Alessandro; Samuelsson, Jan; Birgegard, Gunnar; Xiao, Zhijian; Zefeng, Xu; Zhang, Yue; Sun, Xiujuan; Junqing, Xu; Kiladjian, Jean-Jacques; Zhang, Peihong; Gale, Robert Peter; Mesa, Ruben A.; Geyer, Holly L. (2017). Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs. LEUKEMIA RESEARCH, vol. 63, pp. 34-40, ISSN:0145-2126 DOI Accesso ONLINE all'editore

Zini, Roberta; Guglielmelli, Paola; Pietra, Daniela; Rumi, Elisa; Rossi, Chiara; Rontauroli, Sebastiano; Genovese, Elena; Fanelli, Tiziana; Calabresi, Laura; Bianchi, Elisa; Salati, Simona; Cazzola, Mario; Tagliafico, Enrico; Vannucchi, Alessandro M.; Manfredini, Rossella (2017). CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles. BLOOD CANCER JOURNAL, vol. 7, pp. 638-638, ISSN:2044-5385 DOI Accesso ONLINE all'editore

Verstovsek, Srdan; Gotlib, Jason; Mesa, Ruben A.; Vannucchi, Alessandro M.; Kiladjian, Jean-Jacques; Cervantes, Francisco; Harrison, Claire N.; Paquette, Ronald; Sun, William; Naim, Ahmad; Langmuir, Peter; Dong, Tuochuan; Gopalakrishna, Prashanth; Gupta, Vikas (2017). Long-Term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and-II pooled analyses. JOURNAL OF HEMATOLOGY & ONCOLOGY, vol. 10, pp. 156-156, ISSN:1756-8722 DOI Accesso ONLINE all'editore

Salati, Simona; Prudente, Zelia; Genovese, Elena; Pennucci, Valentina; Rontauroli, Sebastiano; Bartalucci, Niccolo'; Mannarelli, Carmela; Ruberti, Samantha; Zini, Roberta; Rossi, Chiara; Bianchi, Elisa; Guglielmelli, Paola; Tagliafico, Enrico; Vannucchi, Alessandro M; Manfredini, Rossella (2017). Calreticulin affects hematopoietic stem/progenitor cell fate by impacting erythroid and megakaryocytic differentiation. STEM CELLS AND DEVELOPMENT, pp. 00-01, ISSN:1547-3287 DOI

Tefferi, Ayalew; Lavu, Sravanthi; Mudireddy, Mythri; Lasho, Terra L; Finke, Christy M; Gangat, Naseema; Pardanani, Animesh; Hanson, Curtis A; Mannarelli, Carmela; Guglielmelli, Paola; Vannucchi, Alessandro M. (2017). JAK2 exon 12 mutated polycythemia vera: Mayo-Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2V617F mutated disease. AMERICAN JOURNAL OF HEMATOLOGY, pp. 00-01, ISSN:0361-8609 DOI

Loscocco, G. G.; Vannucchi, M.; Paoli, C.; Franci, A.; Pieri, L.; Annunziato, F.; Massi, D.; Vannucchi, A. M (2017). Kaposi Sarcoma in a patient treated with Ruxolitinib. ANNALS OF ONCOLOGY, pp. 1-5, ISSN:0923-7534 DOI

Mesa, Ruben A; Vannucchi, Alessandro M; Mead, Adam; Egyed, Miklos; Szoke, Anita; Suvorov, Aleksandr; Jakucs, Janos; Perkins, Andrew; Prasad, Ritam; Mayer, Jiri; Demeter, Judit; Ganly, Peter; Singer, Jack W; Zhou, Huafeng; Dean, James P; te Boekhorst, Peter A; Nangalia, Jyoti; Kiladjian, Jean-Jacques; Harrison, Claire N (2017). Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. THE LANCET. HAEMATOLOGY, vol. 4, pp. e225-e236, ISSN:2352-3026 DOI Accesso ONLINE all'editore

Goel, Swati; Paoli, Chiara; Iurlo, Alessandra; Pereira, Arturo; Efficace, Fabio; Barbui, Tiziano; Tefferi, Ayalew; Vannucchi, Alessandro M.; Cervantes, Francisco (2017). Socioeconomic burden of participation in clinical trials in patients with myeloproliferative neoplasms. EUROPEAN JOURNAL OF HAEMATOLOGY, pp. 1-6, ISSN:0902-4441 DOI

Coltro, Giacomo; Mannelli, Francesco; Guglielmelli, Paola; Pacilli, Annalisa; Bosi, Alberto; Vannucchi, Alessandro Maria (2017). A life-threatening ruxolitinib discontinuation syndrome. AMERICAN JOURNAL OF HEMATOLOGY, pp. 24775-24776, ISSN:0361-8609 DOI

Guglielmelli, Paola; Pietra, Daniela; Pane, Fabrizio; Pancrazzi, Alessandro; Cazzola, Mario; Vannucchi, Alessandro M.; Tura, Sante; Barosi, Giovanni (2017). Recommendations for molecular testing in classical Ph1-neg myeloproliferative disorders–A consensus project of the Italian Society of Hematology. LEUKEMIA RESEARCH, vol. 58, pp. 63-72, ISSN:0145-2126 DOI Accesso ONLINE all'editore

Pacilli, Annalisa; Fanelli, Tiziana; Mannarelli, Carmela; Rotunno, Giada; Pancrazzi, Alessandro; Vannucchi, Alessandro Maria; Guglielmelli, Paola (2017). Clonal architecture of JAK2V617F mutated cells during treatment with ruxolitinib. HEMATOLOGICAL ONCOLOGY, pp. 1-3, ISSN:0278-0232 DOI Accesso ONLINE all'editore

Rontauroli, Sebastiano; Norfo, Ruggiero; Pennucci, Valentina; Zini, Roberta; Ruberti, Samantha; Bianchi, Elisa; Salati, Simona; Prudente, Zelia; Rossi, Chiara; Rosti, Vittorio; Guglielmelli, Paola; Barosi, Giovanni; Vannucchi, Alessandro; Tagliafico, Enrico; Manfredini, Rossella (2017). miR-494-3p overexpression promotes megakaryocytopoiesis in primary myelofibrosis hematopoietic stem/progenitor cells by targeting SOCS6. ONCOTARGET, vol. 8, pp. 21380-21397, ISSN:1949-2553 DOI Accesso ONLINE all'editore

Barbui, Tiziano; Carobbio, Alessandra; Ghirardi, Arianna; Masciulli, Arianna; Rambaldi, Alessandro; Vannucchi, Alessandro M. (2017). No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from ECLAP and CYTO-PV clinical trials. HAEMATOLOGICA, pp. 1-9, ISSN:0390-6078 DOI

Al-Ali, Haifa Kathrin; Vannucchi, Alessandro M. (2017). Managing patients with myelofibrosis and low platelet counts. ANNALS OF HEMATOLOGY, vol. 96, pp. 537-548, ISSN:0939-5555 DOI Accesso ONLINE all'editore

Lussana, Federico; Carobbio, Alessandra; Salmoiraghi, Silvia; Guglielmelli, Paola; Vannucchi, Alessandro Maria; Bottazzi, Barbara; Leone, Roberto; Mantovani, Alberto; Barbui, Tiziano; Rambaldi, Alessandro (2017). Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera. JOURNAL OF HEMATOLOGY & ONCOLOGY, vol. 10, pp. 1-8, ISSN:1756-8722 DOI Accesso ONLINE all'editore

Marchetti, M; Barosi, G.; Cervantes, F.; Birgegård, G.; Griesshammer, M.; Harrison, C.; Hehlmann, R.; Kiladjian, J.-J.; Kröger, N.; Mcmullin, M.F.; Passamonti, F.; Vannucchi, A.; Barbui, T. (2017). Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations. LEUKEMIA, vol. 31, pp. 882-888, ISSN:0887-6924 DOI Accesso ONLINE all'editore

Mesa, Ruben; Vannucchi, Alessandro M.; Yacoub, Abdulraheem; Zachee, Pierre; Garg, Mamta; Lyons, Roger; Koschmieder, Steffen; Rinaldi, Ciro; Byrne, Jennifer; Hasan, Yasmin; Passamonti, Francesco; Verstovsek, Srdan; Hunter, Deborah; Jones, Mark M.; Zhen, Huiling; Habr, Dany; Martino, Bruno (2017). The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF). BRITISH JOURNAL OF HAEMATOLOGY, vol. 176, pp. 76-85, ISSN:0007-1048 DOI Accesso ONLINE all'editore

Guglielmelli, Paola; Lasho, Terra L; Rotunno, Giada; Mudireddy, Mythri; Mannarelli, Carmela; Nicolosi, Maura; Pacilli, Annalisa; Pardanani, Animesh; Rumi, Elisa; Rosti, Vittorio; Hanson, Curtis A; Mannelli, Francesco; Ketterling, Rhett P; Gangat, Naseema; Rambaldi, Alessandro; Passamonti, Francesco; Barosi, Giovanni; Barbui, Tiziano; Cazzola, Mario; Vannucchi, Alessandro M; Tefferi, Ayalew (2017). MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. JOURNAL OF CLINICAL ONCOLOGY, vol. 36, pp. 310-318, ISSN:0732-183X DOI Accesso ONLINE all'editore

Barbui, Tiziano; Thiele, Juergen; Gisslinger, Heinz; Carobbio, Alessandra; Vannucchi, Alessandro M.; Tefferi, Ayalew (2017). Diagnostic impact of the 2016 revised who criteria for polycythemia vera. AMERICAN JOURNAL OF HEMATOLOGY, vol. 92, pp. 417-419, ISSN:0361-8609 DOI Accesso ONLINE all'editore

Pieri, Lisa; Paoli, Chiara; Arena, Umberto; Marra, Fabio; Mori, Fabio; Zucchini, Mery; Colagrande, Stefano; Castellani, Alessandro; Masciulli, Arianna; Rosti, Vittorio; De Stefano, Valerio; Betti, Silvia; Finazzi, Guido; Ferrari, Maria Luisa; Rumi, Elisa; Ruggeri, Marco; Nichele, Ilaria; Guglielmelli, Paola; Fjerza, Rajmonda; Mannarelli, Carmela; Fanelli, Tiziana; Merli, Lucia; Corbizi Fattori, Giuditta; Massa, Margherita; Cimino, Giuseppe; Rambaldi, Alessandro; Barosi, Giovanni; Cazzola, Mario; Barbui, Tiziano; Vannucchi, Alessandro M. (2017). Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms. AMERICAN JOURNAL OF HEMATOLOGY, vol. 92, pp. 187-195, ISSN:0361-8609 DOI Accesso ONLINE all'editore

Passamonti, F; Mora, B.; Giorgino, T.; Guglielmelli, P.; Cazzola, M.; Maffioli, M.; Rambaldi, A.; Caramella, M.; Komrokji, R.; Gotlib, J.; Kiladjian, J.J.; Cervantes, F.; Devos, T.; Palandri, F.; de Stefano, V.; Ruggeri, M.; Silver, R.; Benevolo, G.; Albano, F.; Caramazza, D.; Rumi, E.; Merli, M.; Pietra, D.; Casalone, R.; Barbui, T.; Pieri, L.; Vannucchi, A.M. (2017). Driver mutations’ effect in secondary myelofibrosis: an international multicenter study based on 781 patients. LEUKEMIA, pp. 0-0, ISSN:0887-6924 DOI Accesso ONLINE all'editore

Bianchi, Elisa; Ruberti, Samantha; Rontauroli, Sebastiano; Guglielmelli, Paola; Salati, Simona; Rossi, Chiara; Zini, Roberta; Tagliafico, Enrico; Vannucchi, Alessandro Maria; Manfredini, Rossella (2017). Role of miR-34a-5p in hematopoietic progenitor cells proliferation and fate decision: Novel insights into the pathogenesis of primary myelofibrosis. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 18, pp. 145-167, ISSN:1661-6596 DOI Accesso ONLINE all'editore

Guglielmelli, Paola; Pacilli, Annalisa; Rotunno, Giada; Rumi, Elisa; Rosti, Vittorio; Delaini, Federica; Maffioli, Margherita; Fanelli, Tiziana; Pancrazzi, Alessandro; Pietra, Daniela; Salmoiraghi, Silvia; Mannarelli, Carmela; Franci, Annalisa; Paoli, Chiara; Rambaldi, Alessandro; Passamonti, Francesco; Barosi, Giovanni; Barbui, Tiziano; Cazzola, Mario; Vannucchi, Alessandro M (2017). Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. BLOOD, vol. 129, pp. 0-0, ISSN:0006-4971 DOI Accesso ONLINE all'editore

Tefferi A.; Vannucchi A.M. (2017). Genetic Risk Assessment in Myeloproliferative Neoplasms. MAYO CLINIC PROCEEDINGS, vol. 92, pp. 1283-1290, ISSN:0025-6196 DOI Accesso ONLINE all'editore

Tefferi, A; Al Ali, H. K; Barosi, G; Devos, T; Gisslinger, H; Jiang, Q; Kiladjian, J. J; Mesa, R; Passamonti, F; Mcmullin, M. F; Ribrag, V; Schiller, G; Vannucchi, ALESSANDRO MARIA; Zhou, D; Reiser, D; Zhong, J; Gale, R. P. (2017). Erratum: A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence. LEUKEMIA, vol. 31, pp. 1252-1252, ISSN:0887-6924 DOI

Barbui, Tiziano; Vannucchi, Alessandro M.; Carobbio, Alessandra; Rumi, Elisa; Finazzi, Guido; Gisslinger, Heinz; Ruggeri, Marco; Randi, Maria Luigia; Cazzola, Mario; Rambaldi, Alessandro; Gisslinger, Bettina; Pieri, Lisa; Thiele, Juergen; Pardanani, Animesh; Tefferi, Ayalew (2017). The effect of arterial hypertension on thrombosis in low-risk polycythemia vera. AMERICAN JOURNAL OF HEMATOLOGY, vol. 92, pp. E5-E6, ISSN:0361-8609 DOI Accesso ONLINE all'editore

Al-Ali, Haifa Kathrin; Griesshammer, Martin; le Coutre, Philipp; Waller, Cornelius F.; Liberati, Anna Marina; Schafhausen, Philippe; Tavares, Renato; Giraldo, Pilar; Foltz, Lynda; Raanani, Pia; Gupta, Vikas; Tannir, Bayane; Ronco, Julian Perez; Ghosh, Jagannath; Martino, Bruno; Vannucchi, Alessandro M. (2016). Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: A snapshot of 1144 patients in the JUMP trial. HAEMATOLOGICA, vol. 101, pp. 1065-1073, ISSN:0390-6078 DOI Accesso ONLINE all'editore

Pieri, Lisa; Rotunno, Giada; Gesullo, Francesca; Fanelli, Tiziana; Corbizi Fattori, Giuditta; Pacilli, Annalisa; Scarfì, Federica; Iorno, Maria Loredana; Almerigogna, Fabio; Salerno, Roberto; Guglielmelli, Paola; Zanotti, Roberta; Vannucchi, Alessandro M. (2016). Prognotic Impact of Mutations in Systemic Mastocytosis. BLOOD, vol. 128, pp. 1953-1953, ISSN:0006-4971 DOI

De Stefano, V.; Ruggeri, M.; Cervantes, F.; Alvarez-Larrán, A.; Iurlo, A.; Randi, M.L.; Elli, E.; Finazzi, M.C.; Finazzi, G.; Zetterberg, E.; Vianelli, N.; Gaidano, G.; Rossi, E.; Betti, S.; Nichele, I.; Cattaneo, D.; Palova, M.; Ellis, M.H.; Cacciola, R.; Tieghi, A.; Hernandez-Boluda, J.C.; Pungolino, E.; Specchia, G.; Rapezzi, D.; Forcina, A.; Musolino, C.; Carobbio, A.; Griesshammer, M.; Sant'Antonio, E.; Vannucchi, A.M.; Barbui, T (2016). High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with Vitamin K antagonists. LEUKEMIA, vol. 30, pp. 2032-2038, ISSN:0887-6924 DOI Accesso ONLINE all'editore

Pieri, Lisa; Vannucchi, Alessandro M. (2016). Improving prognostic tools in systemic mastocytosis: Insights from mutations. AMERICAN JOURNAL OF HEMATOLOGY, vol. 91, pp. 867-868, ISSN:0361-8609 DOI Accesso ONLINE all'editore

Barbui, T; Thiele, J.; Gisslinger, H.; Finazzi, G.; Vannucchi, A.M.; Tefferi, A. (2016). The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances. BLOOD REVIEWS, vol. 30, pp. 453-459, ISSN:0268-960X DOI Accesso ONLINE all'editore

Balliu, Manjola; Cellai, Cristina; Lulli, Matteo; Laurenzana, Anna; Torre, Eugenio; Vannucchi, Alessandro Maria; Paoletti, Francesco (2016). HDAC1 controls CIP2A transcription in human colorectal cancer cells. ONCOTARGET, vol. 7, pp. 25862-25871, ISSN:1949-2553 DOI

Pieri, Lisa; Bonadonna, Patrizia; Elena, Chiara; Papayannidis, Cristina; Grifoni, Federica Irene; Rondoni, Michela; Girlanda, Stefania; Mauro, Marina; Magliacane, Diomira; Elli, Elena Maria; Iorno, Maria Loredana; Almerigogna, Fabio; Scarfì, Federica; Salerno, Roberto; Fanelli, Tiziana; Gesullo, Francesca; Corbizi Fattori, Giuditta; Bonifacio, Massimiliano; Perbellini, Omar; Artuso, Anna; Soverini, Simona; De Benedittis, Caterina; Muratori, Simona; Pravettoni, Valerio; Cova, Vittoria; Cortellini, Gabriele; Ciceri, Fabio; Cortelezzi, Agostino; Martinelli, Giovanni; Triggiani, Massimo; Merante, Serena; Vannucchi, Alessandro Maria; Zanotti, Roberta (2016). Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients. AMERICAN JOURNAL OF HEMATOLOGY, vol. 91, pp. 692-699, ISSN:0361-8609 DOI Accesso ONLINE all'editore

Geyer, Holly L.; Andreasson, Bjorn; Kosiorek, Heidi E.; Dueck, Amylou C.; Scherber, Robyn M.; Martin, Kari A.; Butler, Kristina A.; Harrison, Claire N.; Radia, Deepti H.; Cervantes, Francisco; Kiladjian, Jean-Jacques; Reiter, Andreas; Birgegard, Gunnar; Passamonti, Francesco; Senyak, Zhenya; Vannucchi, Alessandro M.; Paoli, Chiara; Xiao, Zhijian; Samuelsson, Jan; Mesa, Ruben A (2016). The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group. CANCER, vol. 122, pp. 1888-1896, ISSN:0008-543X DOI Accesso ONLINE all'editore

Verstovsek, Srdan; Vannucchi, Alessandro M.; Griesshammer, Martin; Masszi, Tamas; Durrant, Simon; Passamonti, Francesco; Harrison, Claire N.; Pane, Fabrizio; Zachee, Pierre; Kirito, Keita; Besses, Carlos; Hino, Masayuki; Moiraghi, Beatriz; Miller, Carole B.; Cazzola, Mario; Rosti, Vittorio; Blau, Igor; Mesa, Ruben; Jones, Mark M.; Zhen, Huiling; Li, Jingjin; Francillard, Nathalie; Habr, Dany; Kiladjian, Jean-Jacques (2016). Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. HAEMATOLOGICA, vol. 101, pp. 821-829, ISSN:0390-6078 DOI Accesso ONLINE all'editore

Barbui, Tiziano; Thiele, Jürgen; Vannucchi, Alessandro M.; Tefferi, Ayalew (2016). Myeloproliferative neoplasms: Morphology and clinical practice. AMERICAN JOURNAL OF HEMATOLOGY, vol. 91, pp. 430-433, ISSN:0361-8609 DOI Accesso ONLINE all'editore

Harrison, Claire N.; Vannucchi, Alessandro M. (2016). Closing the gap: Genetic landscape of MPN. BLOOD, vol. 127, pp. 276-278, ISSN:0006-4971 DOI Accesso ONLINE all'editore

Engert, Andreas; Balduini, Carlo; Brand, Anneke; Coiffier, Bertrand; Cordonnier, Catherine; Döhner, Hartmut; De Wit, Thom Duyvené; Eichinger, Sabine; Fibbe, Willem; Green, Tony; De Haas, Fleur; Iolascon, Achille; Jaffredo, Thierry; Rodeghiero, Francesco; Sall Es, Gilles; Schuringa, Jan Jacob; André, Marc; Andre-Schmutz, Isabelle; Bacigalupo, Andrea; Bochud, Pierre-Yves; Den Boer, Monique; Bonini, Chiara; Camaschella, Clara; Cant, Andrew; Cappellini, Maria Domenica; Cazzola, Mario; Celso, Cristina Lo; Dimopoulos, Meletios; Douay, Luc; Dzierzak, Elaine; Einsele, Hermann; Ferreri, Andrés; De Franceschi, Lucia; Gaulard, Philippe; Gottgens, Berthold; Greinacher, Andreas; Gresele, Paolo; Gribben, John; De Haan, Gerald; Hansen, John-Bjarne; Hochhaus, Andreas; Kadir, Rezan; Kaveri, Srini; Kouskoff, Valerie; Kühne, Thomas; Kyrle, Paul; Ljungman, Per; Maschmeyer, Georg; Méndez-Ferrer, Simón; Milsom, Michael; Mummery, Christine; Ossenkoppele, Gert; Pecci, Alessandro; Peyvandi, Flora; Philipsen, Sjaak; Reitsma, Pieter; Ribera, José Maria; Risitano, Antonio; Rivella, Stefano; Ruf, Wolfram; Schroeder, Timm; Scully, Marie; Socie, Gerard; Staal, Frank; Stanworth, Simon; Stauder, Reinhard; Stilgenbauer, Stephan; Tamary, Hannah; Theilgaard-Mönch, Kim; Thein, Swee Lay; Tilly, Hervé; Trneny, Marek; Vainchenker, William; Vannucchi, Alessandro Maria; Viscoli, Claudio; Vrielink, Hans; Zaaijer, Hans; Zanella, Alberto; Zolla, Lello; Zwaginga, Jaap Jan; Martinez, Patricia Aguilar; Van Den Akker, Emile; Allard, Shubha; Anagnou, Nicholas; Andolfo, Immacolata; Andrau, Jean-Christophe; Angelucci, Emanuele; Anstee, David; Aurer, Igor; Avet-Loiseau, Hervé; Aydinok, Yesim; Bakchoul, Tamam; Balduini, Alessandra; Barcellini, Wilma; Baruch, Dominique; Baruchel, André; Bayry, Jagadeesh; Bento, Celeste; Van Den Berg, Anke; Bernardi, Rosa; Bianchi, Paola; Bigas, Anna; Biondi, Andrea; Bohonek, Milos; Bonnet, Dominique; Borchmann, Peter; Borregaard, Niels; Brækkan, Sigrid; Van Den Brink, Marcel; Brodin, Ellen; Bullinger, Lars; Buske, Christian; Butzeck, Barbara; Cammenga, Jörg; Campo, Elias; Carbone, Antonino; Cervantes, Francisco; Cesaro, Simone; Charbord, Pierre; Claas, Frans; Cohen, Hannah; Conard, Jacqueline; Coppo, Paul; Vives Corron, Joan-Lluis; Da Costa, Lydie; Davi, Frederic; Delwel, Ruud; Dianzani, Irma; Domanović, Dragoslav; Donnelly, Peter; Drnovšek, Tadeja Dovč; Dreyling, Martin; Du, Ming-Qing; Dufour, Carlo; Durand, Charles; Efremov, Dimitar; Eleftheriou, Androulla; Elion, Jacques; Emonts, Marieke; Engelhardt, Monika; Ezine, Sophie; Falkenburg, Fred; Favier, Remi; Federico, Massimo; Fenaux, Pierre; Fitzgibbon, Jude; Flygare, Johan; Foà, Robin; Forrester, Lesley; Galacteros, Frederic; Garagiola, Isabella; Gardiner, Chris; Garraud, Olivier; Van Geet, Christel; Geiger, Hartmut; Geissler, Jan; Germing, Ulrich; Ghevaert, Cedric; Girelli, Domenico; Godeau, Bertrand; Gökbuget, Nicola; Goldschmidt, Hartmut; Goodeve, Anne; Graf, Thomas; Graziadei, Giovanna; Griesshammer, Martin; Gruel, Yves; Guilhot, Francois; Von Gunten, Stephan; Gyssens, Inge; Halter, Jörg; Harrison, Claire; Harteveld, Cornelis; Hellström-Lindberg, Eva; Hermine, Olivier; Higgs, Douglas; Hillmen, Peter; Hirsch, Hans; Hoskin, Peter; Huls, Gerwin; Inati, Adlette; Johnson, Peter; Kattamis, Antonis; Kiefel, Volker; Kleanthous, Marina; Klump, Hannes; Krause, Daniela; Hovinga, Johanna Kremer; Lacaud, Georges; Lacroix-Desmazes, Sébastien; Landman-Parker, Judith; Legouill, Steven; Lenz, Georg; Von Lilienfeld-Toal, Marie; Von Lindern, Marieke; Lopez-Guillermo, Armando; Lopriore, Enrico; Lozano, Miguel; Macintyre, Elizabeth; Makris, Michael; Mannhalter, Christine; Martens, Joost; Mathas, Stephan; Matzdorff, Axel; Medvinsky, Alexander; Menendez, Pablo; Migliaccio, Anna Rita; Miharada, Kenichi; Mikulska, Malgorzata; Minard, Véronique; Montalbán, Carlos; De Montalembert, Mariane; Montserrat, Emili; Morange, Pierre-Emmanuel; Mountford, Joanne; Muckenthaler, Ma (2016). The european hematology association roadmap for european hematology research: A consensus document. HAEMATOLOGICA, vol. 101, pp. 115-208, ISSN:0390-6078 DOI Accesso ONLINE all'editore

Gugliotta, Luigi; Iurlo, Alessandra; Gugliotta, Gabriele; Tieghi, Alessia; Specchia, Giorgina; Gaidano, Gianluca; Scalzulli, Potito R.; Rumi, Elisa; Dragani, Alfredo; Martinelli, Vincenzo; Santoro, Cristina; Randi, Maria Luigia; Tagariello, Giuseppe; Candoni, Anna; Cattaneo, Daniele; Ricco, Alessandra; Palmieri, Raffaele; Liberati, Marina A.; Langella, Maria; Rago, Angela; Bergamaschi, Micaela; Monari, Paola; Miglio, Rossella; Santoro, Umberto; Cacciola, Rossella; Rupoli, Serena; Mastrullo, Lucia; Musto, Pellegrino; Mazzucconi, Maria Gabriella; Vignetti, Marco; Cortelezzi, Agostino; Vianelli, Nicola; Martino, Bruno; De Stefano, Valerio; Passamonti, Francesco; Vannucchi, Alessandro M. (2016). Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms. LEUKEMIA RESEARCH, vol. 46, pp. 18-25, ISSN:0145-2126 DOI Accesso ONLINE all'editore

Calistri, Linda; Pieri, Lisa; Santi, Raffaella; Nardi, Cosimo; Vannucchi, Alessandro Maria; Colagrande, Stefano (2016). MR imaging in non-hepatosplenic extramedullary hematopoiesis in primary myelofibrosis. AMERICAN JOURNAL OF HEMATOLOGY, pp. 0-0, ISSN:1096-8652 DOI

Rotunno, Giada; Pacilli, Annalisa; Artusi, Valentina; Rumi, Elisa; Maffioli, Margherita; Delaini, Federica; Brogi, Giada; Fanelli, Tiziana; Pancrazzi, Alessandro; Pietra, Daniela; Bernardis, Isabella; Belotti, Clara; Pieri, Lisa; Sant'Antonio, Emanuela; Salmoiraghi, Silvia; Cilloni, Daniela; Rambaldi, Alessandro; Passamonti, Francesco; Barbui, Tiziano; Manfredini, Rossella; Cazzola, Mario; Tagliafico, Enrico; Vannucchi, Alessandro M; Guglielmelli, Paola (2016). Epidemiology and clinical relevance of mutations in post-polycythemia vera and post-essential thrombocythemia myelofibrosis. A study on 359 patients of the AGIMM group. AMERICAN JOURNAL OF HEMATOLOGY, vol. ....., pp. n/a-n/a, ISSN:0361-8609 DOI

Tefferi, Ayalew; Lasho, Terra L; Guglielmelli, Paola; Finke, Christy M; Rotunno, Giada; Elala, Yoseph; Pacilli, Annalisa; Hanson, Curtis A; Pancrazzi, Alessandro; Ketterling, Rhett P; Mannarelli, Carmela; Barraco, Daniela; Fanelli, Tiziana; Pardanani, Animesh; Gangat, Naseema; Vannucchi, Alessandro M (2016). Targeted deep sequencing in polycythemia vera and essential thrombocythemia. BLOOD ADVANCES, vol. 1, pp. 21-30, ISSN:2473-9529 DOI Accesso ONLINE all'editore

Shimizu, Takafumi; Kubovcakova, Lucia; Nienhold, Ronny; Zmajkovic, Jakub; Meyer, Sara C.; Hao-Shen, Hui; Geier, Florian; Dirnhofer, Stephan; Guglielmelli, Paola; Vannucchi, Alessandro M.; Milosevic Feenstra, Jelena D.; Kralovics, Robert; Orkin, Stuart H.; Skoda, Radek C (2016). Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis. JOURNAL OF EXPERIMENTAL MEDICINE, vol. 213, pp. 1479-1496, ISSN:0022-1007 DOI Accesso ONLINE all'editore

Guglielmelli, Paola; Vannucchi, Alessandro M. (2016). The prognostic impact of bone marrow fibrosis in primary myelofibrosis. AMERICAN JOURNAL OF HEMATOLOGY, vol. 91, pp. E454-E455, ISSN:0361-8609 DOI Accesso ONLINE all'editore

Calura, E; Pizzini, S; Bisognin, A; Coppe, A; Sales, G; Gaffo, E; Fanelli, T; Mannarelli, C; Zini, R; Norfo, R; Pennucci, V; Manfredini, R; Romualdi, C; Guglielmelli, P; Vannucchi, A M; Bortoluzzi, S (2016). A data-driven network model of primary myelofibrosis: transcriptional and post-transcriptional alterations in CD34+ cells. BLOOD CANCER JOURNAL, vol. 6, pp. e439-e448, ISSN:2044-5385 DOI

De Luca, Francesca; Rotunno, Giada; Salvianti, Francesca; Galardi, Francesca; Pestrin, Marta; Gabellini, Stefano; Simi, Lisa; Mancini, Irene; Vannucchi, Alessandro Maria; Pazzagli, Mario; Di Leo, Angelo; Pinzani, Pamela (2016). Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer. ONCOTARGET, vol. 7, pp. 26107-26119, ISSN:1949-2553 DOI Accesso ONLINE all'editore

Alvarez-Larrán, Alberto; Pereira, Arturo; Guglielmelli, Paola; Hernández-Boluda, Juan Carlos; Arellano-Rodrigo, Eduardo; Ferrer-Marín, Francisca; Samah, Alimam; Griesshammer, Martin; Kerguelen, Ana; Andreasson, Bjorn; Burgaleta, Carmen; Schwarz, Jiri; García-Gutiérrez, Valentín; Ayala, Rosa; Barba, Pere; Gómez-Casares, María Teresa; Paoli, Chiara; Drexler, Beatrice; Zweegman, Sonja; Mcmullin, Mary F; Samuelsson, Jan; Harrison, Claire; Cervantes, Francisco; Vannucchi, Alessandro M; Besses, Carlos (2016). Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. HAEMATOLOGICA, vol. 101, pp. 926-931, ISSN:1592-8721 DOI

Loscocco, Giuseppe Gaetano; Mannarelli, Carmela; Pacilli, Annalisa; Fanelli, Tiziana; Rotunno, Giada; Gesullo, Francesca; Corbizi-Fattori, Giuditta; Vannucchi, Alessandro Maria; Guglielmelli, Paola (2016). Germline transmission of LNKE208Q variant in a family with myeloproliferative neoplasms. AMERICAN JOURNAL OF HEMATOLOGY, vol. 91, pp. E356-E356, ISSN:0361-8609 DOI Accesso ONLINE all'editore

Guglielmelli, Paola; Rotunno, Giada; Pacilli, Annalisa; Rumi, Elisa; Rosti, Vittorio; Delaini, Federica; Maffioli, Margherita; Fanelli, Tiziana; Pancrazzi, Alessandro; Pieri, Lisa; Fjerza, Rajmonda; Pietra, Daniela; Cilloni, Daniela; Sant'Antonio, Emanuela; Salmoiraghi, Silvia; Passamonti, Francesco; Rambaldi, Alessandro; Barosi, Giovanni; Barbui, Tiziano; Cazzola, Mario; Vannucchi, Alessandro M. (2016). Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients. AMERICAN JOURNAL OF HEMATOLOGY, vol. 91, pp. 918-922, ISSN:0361-8609 DOI Accesso ONLINE all'editore

De Stefano, V.; Vannucchi, A.M.; Ruggeri, M.; Cervantes, F.; Alvarez-Larrán, A.; Iurlo, A.; Randi, M.L.; Pieri, L.; Rossi, E.; Guglielmelli, P.; Betti, S.; Elli, E.; Finazzi, M.C.; Finazzi, G.; Zetterberg, E.; Vianelli, N.; Gaidano, G.; Nichele, I.; Cattaneo, D.; Palova, M.; Ellis, M.H.; Cacciola, E.; Tieghi, A.; Hernandez-Boluda, J.C.; Pungolino, E.; Specchia, G.; Rapezzi, D.; Forcina, A.; Musolino, C.; Carobbio, A.; Griesshammer, M.; Barbui, T (2016). Splanchnic vein thrombosis in myeloproliferative neoplasms: Risk factors for recurrences in a cohort of 181 patients. BLOOD CANCER JOURNAL, vol. 6, pp. e493-e500, ISSN:2044-5385 DOI Accesso ONLINE all'editore

Harrison, C.N; Vannucchi, A.M.; Kiladjian, J.-J.; Al-Ali, H.K.; Gisslinger, H.; Knoops, L.; Cervantes, F.; Jones, M.M.; Sun, K.; Mcquitty, M.; Stalbovskaya, V.; Gopalakrishna, P.; Barbui, T. (2016). Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. LEUKEMIA, vol. 30, pp. 1701-1707, ISSN:0887-6924 DOI Accesso ONLINE all'editore

Salati, Simona; Zini, Roberta; Nuzzo, Simona; Guglielmelli, Paola; Pennucci, Valentina; Prudente, Zelia; Ruberti, Samantha; Rontauroli, Sebastiano; Norfo, Ruggiero; Bianchi, Elisa; Bogani, Costanza; Rotunno, Giada; Fanelli, Tiziana; Mannarelli, Carmela; Rosti, Vittorio; Salmoiraghi, Silvia; Pietra, Daniela; Ferrari, Sergio; Barosi, Giovanni; Rambaldi, Alessandro; Cazzola, Mario; Bicciato, Silvio; Tagliafico, Enrico; Vannucchi, Alessandro M; Manfredini, Rossella (2015). Integrative analysis of copy number and gene expression data suggests novel pathogenetic mechanisms in Primary Myelofibrosis. INTERNATIONAL JOURNAL OF CANCER, vol. 138, pp. 1657-1669, ISSN:0020-7136 DOI

G. Barosi;A. Tefferi;C. Besses;G. Birgegard;F. Cervantes;G. Finazzi;H. Gisslinger;M. Griesshammer;C. Harrison;R. Hehlmann;S. Hermouet;J. Kiladjian;N. Kröger;R. Mesa;M. F. Mc;A. Pardanani;F. Passamonti;J. Samuelsson;A. M. Vannucchi;A. Reiter;R. T. Silver;S. Verstovsek;G. Tognoni;T. Barbui (2015). Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT).. LEUKEMIA, vol. 29, pp. 20-26, ISSN:0887-6924 DOI Accesso ONLINE all'editore

Pardanani, A; Tefferi, A; Guglielmelli, P; Bogani, C; Bartalucci, N; Rodríguez, J; Extremera, S; Pérez, I; Alfaro, V; Vannucchi, A M (2015). Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial. BLOOD CANCER JOURNAL, vol. 5, pp. e286-e286, ISSN:2044-5385 DOI

Chase, A.; Leung, W.; Tapper, W.; Jones, A.V.; Knoops, L.; Rasi, C.; Forsberg, L.A.; Guglielmelli, P.; Zoi, K.; Hall, V.; Chiecchio, L.; Eder-Azanza, L.; Bryant, C.; Lannfelt, L.; Docherty, L.; White, H.E.; Score, J.; Mackay, D.J.G.; Vannucchi, A.M.; Dumanski, J.P.; Cross, N.C.P. (2015). Profound parental bias associated with chromosome 14 acquired uniparental disomy indicates targeting of an imprinted locus. LEUKEMIA, vol. 29, pp. 2069-2074, ISSN:0887-6924 DOI Accesso ONLINE all'editore

Vannucchi, Alessandro M; Bartalucci, Niccolo; Pieri, Lisa; Guglielmelli, Paola (2015). Rationale for combination therapies in myelofibrosis. In: alessandro maria vannucchi, Niccolò bartalucci, Lisa Pieri, paola guglielmelli,. Novel Insights into Myelofibrosis Pathophysiology and Treatment, pp. 136-150 Future Medicine Ltd., ISBN:9781780845494. DOI Accesso ONLINE all'editore

Vannucchi, Alessandro M.* (2015). Ruxolitinib versus standard therapy for the treatment of polycythemia vera.. THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 372, pp. 1670-1671, ISSN:0028-4793 DOI Accesso ONLINE all'editore

Salvianti, F.; Rotunno, G.; Galardi, F. ; De Luca, F. ; Pestrin, M.; Vannucchi, A.M.; Di Leo, A.; Pazzagli, M.; Pinzani, P; (2015). Feasibility of a workflow for the molecular characterization of single cells by next generation sequencing. BIOMOLECULAR DETECTION AND QUANTIFICATION, vol. 5, pp. 23-29, ISSN:2214-7535 DOI Accesso ONLINE all'editore

L. Pieri;P. Guglielmelli;A. M. Vannucchi (2015). Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia.. AMERICAN JOURNAL OF HEMATOLOGY, vol. 90, pp. 82-83, ISSN:0361-8609 DOI Accesso ONLINE all'editore

Ortmann, Christina A.; Kent, David G.; Nangalia, Jyoti; Silber, Yvonne; Wedge, David C.; Grinfeld, Jacob; Baxter, E. Joanna; Massie, Charles E.; Papaemmanuil, Elli; Menon, Suraj; Godfrey, Anna L.; Dimitropoulou, Danai; Guglielmelli, Paola; Bellosillo, Beatriz; Besses, Carles; Döhner, Konstanze; Harrison, Claire N.; Vassiliou, George S.; Vannucchi, Alessandro; Campbell, Peter J.; Green, Anthony R. (2015). Effect of mutation order on myeloproliferative neoplasms. THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 372, pp. 601-612, ISSN:0028-4793 DOI Accesso ONLINE all'editore

Godfrey, Anna L; Chen, Edwin; Massie, Charles E; Silber, Yvonne; Pagano, Francesca; Bellosillo, Beatriz; Guglielmelli, Paola; Harrison, Claire N; Reilly, John T; Stegelmann, Frank; Bijou, Fontanet; Lippert, Eric; Boiron, Jean-Michel; Döhner, Konstanze; Vannucchi, Alessandro M; Besses, Carlos; Green, Anthony R (2015). STAT1 activation in association with JAK2 exon 12 mutations. HAEMATOLOGICA, vol. 101, pp. 15-19, ISSN:0390-6078 DOI Accesso ONLINE all'editore

Kröger, N.M; Deeg, J.H.; Olavarria, E.; Niederwieser, D.; Bacigalupo, A.; Barbui, T.; Rambaldi, A.; Mesa, R.; Tefferi, A.; Griesshammer, M.; Gupta, V.; Harrison, C.; Alchalby, H.; Vannucchi, A.M.; Cervantes, F.; Robin, M.; Ditschkowski, M.; Fauble, V.; Mclornan, D.; Ballen, K.; Popat, U.R.; Passamonti, F.; Rondelli, D.; Barosi, G. (2015). Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: A consensus process by an EBMT/ELN international working group. LEUKEMIA, vol. 29, pp. 2126-2133, ISSN:0887-6924 DOI Accesso ONLINE all'editore

Barbui, Tiziano; Masciulli, Arianna; Marfisi, Maria Rosa; Tognoni, Giovanni; Finazzi, Guido; Rambaldi, Alessandro; Vannucchi, Alessandro (2015). White blood cell counts and thrombosis in polycythemia vera: A subanalysis of the CYTO-PV study. BLOOD, vol. 126, pp. 560-561, ISSN:0006-4971 DOI Accesso ONLINE all'editore

Barbui, T; Thiele, J.; Vannucchi, A.M.; Tefferi, A. (2015). Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis. BLOOD CANCER JOURNAL, vol. 5, pp. e337-e345, ISSN:2044-5385 DOI Accesso ONLINE all'editore

Vannucchi, Alessandro M; Kantarjian, Hagop M.; Kiladjian, Jean-Jacques; Gotlib, Jason; Cervantes, Francisco; Mesa, Ruben A.; Sarlis, Nicholas J.; Peng, Wei; Sandor, Victor; Gopalakrishna, Prashanth; Hmissi, Abdel; Stalbovskaya, Viktoriya; Gupta, Vikas; Harrison, Claire; Verstovsek, Srdan (2015). A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. HAEMATOLOGICA, vol. 100, pp. 1139-1145, ISSN:0390-6078 DOI Accesso ONLINE all'editore

Pardanani, Animesh; Harrison, Claire; Cortes, Jorge E; Cervantes, Francisco; Mesa, Ruben A; Milligan, Donald; Masszi, Tamás; Mishchenko, Elena; Jourdan, Eric; Vannucchi, Alessandro M; Drummond, Mark W; Jurgutis, Mindaugas; Kuliczkowski, Kazimierz; Gheorghita, Emanuil; Passamonti, Francesco; Neumann, Frank; Patki, Abhay; Gao, Guozhi; Tefferi, Ayalew (2015). Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial. JAMA ONCOLOGY, vol. 1, pp. 643-51-651, ISSN:2374-2437 DOI

Vannucchi, Alessandro M; Kiladjian, Jean Jacques; Griesshammer, Martin; Masszi, Tamas; Durrant, Simon; Passamonti, Francesco; Harrison, Claire N.; Pane, Fabrizio; Zachee, Pierre; Mesa, Ruben; He, Shui; Jones, Mark M.; Garrett, William; Li, Jingjin; Pirron, Ulrich; Habr, Dany; Verstovsek, Srdan (2015). Ruxolitinib versus standard therapy for the treatment of polycythemia vera. THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 372, pp. 426-435, ISSN:0028-4793 DOI Accesso ONLINE all'editore

Emmi, Giacomo; Silvestri, Elena; Marconi, Roberto; Carrai, Valentina; Fanelli, Tiziana; Zucchini, Patrizia; Marasca, Roberto; Vannucchi, Alessandro Maria; Emmi, Lorenzo; Prisco, Domenico; Vaglio, Augusto (2015). First report of FIP1L1-PDGFR alpha-positive eosinophilic granulomatosis with polyangiitis. RHEUMATOLOGY, vol. 54, pp. 1751-1753, ISSN:1462-0324 DOI Accesso ONLINE all'editore

Tapper, William; Jones, Amy V.; Kralovics, Robert; Harutyunyan, Ashot S.; Zoi, Katerina; Leung, William; Godfrey, Anna L.; Guglielmelli, Paola; Callaway, Alison; Ward, Daniel; Aranaz, Paula; White, Helen E.; Waghorn, Katherine; Lin, Feng; Chase, Andrew; Joanna Baxter, E.; Maclean, Cathy; Nangalia, Jyoti; Chen, Edwin; Evans, Paul; Short, Michael; Jack, Andrew; Wallis, Louise; Oscier, David; Duncombe, Andrew S.; Schuh, Anna; Mead, Adam J.; Griffiths, Michael; Ewing, Joanne; Gale, Rosemary E.; Schnittger, Susanne; Haferlach, Torsten; Stegelmann, Frank; Döhner, Konstanze; Grallert, Harald; Strauch, Konstantin; Tanaka, Toshiko; Bandinelli, Stefania; Giannopoulos, Andreas; Pieri, Lisa; Mannarelli, Carmela; Gisslinger, Heinz; Barosi, Giovanni; Cazzola, Mario; Reiter, Andreas; Harrison, Claire; Campbell, Peter; Green, Anthony R.; Vannucchi, Alessandro; Cross, Nicholas C.P. (2015). Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms. NATURE COMMUNICATIONS, vol. 6, pp. 6691-6691, ISSN:2041-1723 DOI Accesso ONLINE all'editore

Geyer, Holly; Scherber, Robyn; Kosiorek, Heidi; Dueck, Amylou C; Kiladjian, Jean-Jacques; Xiao, Zhijian; Slot, Stefanie; Zweegman, Sonja; Sackmann, Federico; Fuentes, Ana Kerguelen; Hernández-Maraver, Dolores; Döhner, Konstanze; Harrison, Claire N; Radia, Deepti; Muxi, Pablo; Besses, Carlos; Cervantes, Francisco; Johansson, Peter L; Andreasson, Bjorn; Rambaldi, Alessandro; Barbui, Tiziano; Bonatz, Karin; Reiter, Andreas; Boyer, Francoise; Etienne, Gabriel; Ianotto, Jean-Christophe; Ranta, Dana; Roy, Lydia; Cahn, Jean-Yves; Maldonado, Norman; Barosi, Giovanni; Ferrari, Maria L; Gale, Robert Peter; Birgegard, Gunnar; Xu, Zefeng; Zhang, Yue; Sun, Xiujuan; Xu, Junqing; Zhang, Peihong; Te Boekhorst, Peter A W; Commandeur, Suzan; Schouten, Harry; Pahl, Heike L; Griesshammer, Martin; Stegelmann, Frank; Lehmann, Thomas; Senyak, Zhenya; Vannucchi, Alessandro M; Passamonti, Francesco; Samuelsson, Jan; Mesa, Ruben A (2015). Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease. JOURNAL OF CLINICAL ONCOLOGY, pp. N/A-N/A, ISSN:0732-183X DOI

Barbui, Tiziano; Vannucchi, Alessandro M.; Carobbio, Alessandra; Thiele, Jurgen; Rumi, Elisa; Gisslinger, Heinz; Rodeghiero, Francesco; Randi, Maria Luigia; Rambaldi, Alessandro; Pieri, Lisa; Pardanani, Animesh; Passamonti, Francesco; Finazzi, Guido; Tefferi, Ayalew (2015). Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis. AMERICAN JOURNAL OF HEMATOLOGY, vol. 90, pp. 434-437, ISSN:0361-8609 DOI Accesso ONLINE all'editore

Martinaud, Christophe; Desterke, Christophe; Konopacki, Johanna; Pieri, Lisa; Torossian, Frédéric; Golub, Rachel; Schmutz, Sandrine; Anginot, Adrienne; Guerton, Bernadette; Rochet, Nathalie; Albanese, Patricia; Henault, Emilie; Pierre-Louis, Olivier; Souraud, Jean-Baptiste; de Revel, Thierry; Dupriez, Brigitte; Ianotto, Jean-Christophe; Bourgeade, Marie-Françoise; Vannucchi, Alessandro M; Lataillade, Jean-Jacques; Le Bousse-Kerdilès, Marie-Caroline (2015). Osteogenic Potential of Mesenchymal Stromal Cells Contributes to Primary Myelofibrosis. CANCER RESEARCH, vol. 75, pp. 4753-65-4765, ISSN:0008-5472 DOI

Rago, Angela; Latagliata, Roberto; Montanaro, Marco; Montefusco, Enrico; Andriani, Alessandro; Crescenzi, Sabrina Leonetti; Mecarocci, Sergio; Spirito, Francesca; Spadea, Antonio; Recine, Umberto; Cicconi, Laura; Avvisati, Giuseppe; Cedrone, Michele; Breccia, Massimo; Porrini, Raffaele; Villivà, Nicoletta; De Gregoris, Cinzia; Alimena, Giuliana; D'Arcangelo, Enzo; Guglielmelli, Paola; Lo-Coco, Francesco; Vannucchi, Alessandro; Cimino, Giuseppe (2015). Hemoglobin levels and circulating blasts are two easily evaluable diagnostic parameters highly predictive of leukemic transformation in primary myelofibrosis. LEUKEMIA RESEARCH, vol. 39, pp. 314-317, ISSN:0145-2126 DOI Accesso ONLINE all'editore

Guglielmelli, P; Rotunno, G; Fanelli, T; Pacilli, A; Brogi, G; Calabresi, L; Pancrazzi, A; Vannucchi, A M (2015). Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis. BLOOD CANCER JOURNAL, vol. 5, pp. e360-e360, ISSN:2044-5385 DOI

Vannucchi, A.M.; Barbui, T.; Cervantes, F.; Harrison, C.; Kiladjian, J.-J.; Kröger, N.; Thiele, J.; Buske, C. (2015). Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ANNALS OF ONCOLOGY, vol. 26, pp. v85-v99, ISSN:0923-7534 DOI Accesso ONLINE all'editore

Barbui, T; Vannucchi, A M; Buxhofer-Ausch, V; De Stefano, V; Betti, S; Rambaldi, A; Rumi, E; Ruggeri, M; Rodeghiero, F; Randi, M L; Bertozzi, I; Gisslinger, H; Finazzi, G; Carobbio, A; Thiele, J; Passamonti, F; Falcone, C; Tefferi, A (2015). Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. BLOOD CANCER JOURNAL, vol. 5, pp. e369-e369, ISSN:2044-5385 DOI

Passamonti, F.; Vannucchi, A.M.; Cervantes, F.; Harrison, C.; Morra, E.; Kantarjian, H.; Verstovsek, S. (2015). Ruxolitinib and survival improvement in patients with myelofibrosis. LEUKEMIA, vol. 29, pp. 739-740, ISSN:0887-6924 DOI Accesso ONLINE all'editore

Cascavilla, Nicola; De Stefano, Valerio; Pane, Fabrizio; Pancrazzi, Alessandro; Iurlo, Alessandra; Gobbi, Marco; Palandri, Francesca; Specchia, Giorgina; Marina Liberati, A.; D’Adda, Mariella; Gaidano, Gianluca; Fjerza, Rajmonda; Achenbach, Heinrich; Smith, Jonathan; Wilde, Paul; Vannucchi, Alessandro M. (2015). Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: An observational, hypothesis-generating study. DRUG DESIGN, DEVELOPMENT AND THERAPY, vol. 9, pp. 2687-2694, ISSN:1177-8881 DOI Accesso ONLINE all'editore

Guglielmelli, Paola; Rotunno, Giada; Pacilli, Annalisa; Vannucchi, Alessandro Maria (2015). What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice?. CURRENT HEMATOLOGIC MALIGNANCY REPORTS, vol. 10, pp. 380-387, ISSN:1558-8211 DOI Accesso ONLINE all'editore

Mesa, Ruben; Verstovsek, Srdan; Kiladjian, Jean-Jacques; Griesshammer, Martin; Masszi, Tamas; Durrant, Simon; Passamonti, Francesco; Harrison, Claire N; Pane, Fabrizio; Zachee, Pierre; Zhen, Huiling; Jones, Mark M; Parasuraman, Shreekant; Li, Jingjin; Côté, Isabelle; Habr, Dany; Vannucchi, Alessandro M (2015). Changes in Quality of Life and Disease-Related Symptoms in Patients With Polycythemia Vera Receiving Ruxolitinib or Standard Therapy. EUROPEAN JOURNAL OF HAEMATOLOGY, pp. n/a-n/a, ISSN:0902-4441 DOI

Kröger, Nicolaus; Giorgino, Toni; Scott, Bart L.; Ditschkowski, Markus; Alchalby, Haefaa; Cervantes, Francisco; Vannucchi, Alessandro; Cazzola, Mario; Morra, Enrica; Zabelina, Tatjana; Maffioli, Margherita; Pereira, Arturo; Beelen, Dietrich; Deeg, H. Joachim; Passamonti, Francesco (2015). Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. BLOOD, vol. 125, pp. 3347-3350, ISSN:0006-4971 DOI Accesso ONLINE all'editore

Guglielmelli, Paola; Bisognin, Andrea; Saccoman, Claudia; Mannarelli, Carmela; Coppe, Alessandro; Vannucchi, Alessandro M; Bortoluzzi, Stefania (2015). Small RNA Sequencing Uncovers New miRNAs and moRNAs Differentially Expressed in Normal and Primary Myelofibrosis CD34+ Cells. PLOS ONE, vol. 10, pp. e0140445-e0140445, ISSN:1932-6203 DOI

Martinaud, Christophe; Desterke, Christophe; Konopacki, Johanna; Vannucchi, Alessandro M.; Pieri, Lisa; Guglielmelli, Paola; Dupriez, Brigitte; Ianotto, Jean-Christophe; Boutin, Laetitia; Lataillade, Jean-Jacques; Le Bousse-Kerdilès, Marie-Caroline (2015). Transcriptome analysis of bone marrow mesenchymal stromal cells from patients with primary myelofibrosis. GENOMICS DATA, vol. 5, pp. 1-2, ISSN:2213-5960 DOI Accesso ONLINE all'editore

Desterke, Christophe; Martinaud, Christophe; Guerton, Bernadette; Pieri, Lisa; Bogani, Costanza; Clay, Denis; Torossian, Frederic; Lataillade, Jean-Jacques; Hasselbach, Hans C.; Gisslinger, Heinz; Demory, Jean-Loup; Dupriez, Brigitte; Boucheix, Claude; Rubinstein, Eric; Amsellem, Sophie; Vannucchi, Alessandro M.; Le Bousse-Kerdiles, Marie-Caroline (2015). Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis. HAEMATOLOGICA, vol. 100, pp. 757-767, ISSN:0390-6078 DOI Accesso ONLINE all'editore

Pennucci, V1; Zini, R; Norfo, R; Guglielmelli, Paola; Bianchi, E; Salati, S; Sacchi, G; Prudente, Z; Tenedini, E; Ruberti, S; Paoli, C; Fanelli, Tiziana; Mannarelli, C; Tagliafico, E; Ferrari, S; Vannucchi, Am; Manfredini, R; Bogani, C; Bosi, Alberto; Fanelli, T; Fjerza, Rajmonda; Guglielmelli, P. (2015). Abnormal expression patterns of WT1-as, MEG3 and ANRIL long non-coding RNAs in CD34+ cells from patients with primary myelofibrosis and their clinical correlations.. LEUKEMIA & LYMPHOMA, pp. 492-496, ISSN:1042-8194

Sdan Verstovsek; Ben Y Zhang; Naseema Gangat; Francesco Passamonti; Domenica Caramazza; Barbara Mora; Margherita Maffioli; Paola Guglielmelli; Giada Rorunno; Annalisa Pacilli; Carmela Mannarelli; Holly L Geyer; Ruben A Mesa; Giovanni Barosi; Vittorio Rosti; Hans Carl Hasselbach; Kate J Newberry; Francisco Cervantes; Arturo Pereira; Alessandro M Vannucchi; Niccolò Bartalucci; Lisa Pieri; H Joachim Deeg; Olga Sala-Torra; Bart L Scott (2015). Novel insights into myelofibrosis pathophysiology and treatment. In: Sdan Verstovsek, Ben Y Zhang, Naseema Gangat, Francesco Passamonti, Domenica Caramazza, Barbara mora, Margherita Maffioli, Paola Guglielmelli, Giada Rorunno, Annalisa Pacilli, Carmela Mannarelli, Holly L Geyer, Ruben A Mesa, Giovanni Barosi, Vittorio Rosti, Hans Carl Hasselbach, Kate J Newberry, Francisco Cervantes, Arturo Pereira, Alessandro M Vannucchi, Niccolò Bartalucci, Lisa Pieri, H Joachim Deeg, Olga Sala-Torra, Bart L Scott. Novel Insights into Myelofibrosis Pathophysiology and Treatment, pp. 1-165 Future Medicine Ltd., ISBN:9781780845494. DOI Accesso ONLINE all'editore

Pieri, Lisa; Pancrazzi, Alessandro; Pacilli, Annalisa; Rabuzzi, Claudia; Rotunno, Giada; Fanelli, Tiziana; Guglielmelli, Paola; Fjerza, Rajmonda; Paoli, Chiara; Verstovsek, Srdan; Vannucchi, Alessandro M (2015). JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib. BLOOD, vol. 125, pp. 3352-3353, ISSN:0006-4971 DOI

Guglielmelli P;Lasho TL;Rotunno G;Score J;Mannarelli C;Pancrazzi A;Biamonte F;Pardanani A;Zoi K;Reiter A;Duncombe A;Fanelli T;Pietra D;Rumi E;Finke C;Gangat N;Ketterling RP;Knudson RA;Hanson CA;Bosi A;Pereira A;Manfredini R;Cervantes F;Barosi G;Cazzola M;Cross NC;Vannucchi AM;Tefferi A (2014). The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients.. LEUKEMIA, vol. 28, pp. 1804-1810, ISSN:0887-6924 DOI

Rumi E, Pietra D, Pascutto C, Guglielmelli P, Martínez-Trillos A, Casetti I, Colomer D, Pieri L, Pratcorona M, Rotunno G, Sant'Antonio E, Bellini M, Cavalloni C, Mannarelli C, Milanesi C, Boveri E, Ferretti V, Astori C, Rosti V, Cervantes F, Barosi G, Vannucchi AM, Cazzola M;Bisognin, A; Bogani, C; Bortoluzzi, S; Bosi, A (2014). Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.. BLOOD, pp. 1062-1069, ISSN:0006-4971

Mesa RA;Kiladjian JJ;Verstovsek S;Al-Ali HK;Gotlib J;Gisslinger H;Levy R;Siulnik A;Gupta V;Khan M;DiPersio JF;McQuitty M;Catalano JV;Hunter DS;Knoops L;Deininger M;Cervantes F;Miller C;Vannucchi AM;Silver RT;Barbui T;Talpaz M;Barosi G;Winton EF;Mendeson E;Harvey JH Jr;Arcasoy MO;Hexner E;Lyons RM;Paquette R;Raza A;Sun W;Sandor V;Kantarjian HM;Harrison C (2014). Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies.. HAEMATOLOGICA, vol. 99, pp. 292-298, ISSN:0390-6078 DOI

Rumi E;Pietra D;Pascutto C;Guglielmelli P;Martinez-Trillos A;Casetti I;Colomer D;Pieri L;Pratcorona M;Rotunno G;Sant'Antonio E;Bellini M;Cavalloni C;Mannarelli C;Milanesi C;Boveri E;Ferretti V;Astori C;Rosti V;Cervantes F;Barosi G;Vannucchi AM;Cazzola M. (2014). Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.. BLOOD, vol. 124, pp. 1062-1069, ISSN:0006-4971 DOI

Tefferi A;Guglielmelli P;Larson DR;Finke C;Wassie EA;Pieri L;Gangat N;Fjerza R;Belachew AA;Lasho TL;Ketterling RP;Hanson CA;Rambaldi A;Finazzi G;Thiele J;Barbui T;Pardanani A;Vannucchi AM (2014). Long-term survival and blast transformation in molecularly-annotated essential thrombocythemia, polycythemia vera and myelofibrosis.. BLOOD, vol. 124, pp. 2507-2513, ISSN:0006-4971 DOI

Barbui T;Thiele J;Kvasnicka HM;Carobbio A;Vannucchi AM;Tefferi A (2014). Essential thrombocythemia with high hemoglobin levels according to the revised WHO classification.. LEUKEMIA, vol. 28, pp. 2092-2094, ISSN:0887-6924 DOI

Tiziana Storlazzi C;Pieri L;Paoli C;Daniele G;Lasho T;Tefferi A;Vannucchi AM (2014). Complex karyotype in a polycythemia vera patient with a novel SETD1B/GTF2H3 fusion gene.. AMERICAN JOURNAL OF HEMATOLOGY, vol. 89, pp. 438-442, ISSN:0361-8609 DOI

Tefferi A;Thiele J;Vannucchi AM;Barbui T (2014). An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms.. LEUKEMIA, vol. 28, pp. 1407-1413, ISSN:0887-6924 DOI

Guglielmelli Paola; Vannucchi Alessandro Maria (2014). Essential Thrombocytosis. In: Abutalib SA and Markman M. Cancer Consult: Expertise for Clinical Practice, pp. 156-161 WILEY-BLACKWELL, COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA, ISBN:9781118589212. DOI Accesso ONLINE all'editore

T. Barbui;J. Thiele;A. Carobbio;A. M. Vannucchi;A. Tefferi (2014). The rate of transformation from JAK2-mutated ET to PV is influenced by an accurate WHO-defined clinico-morphological diagnosis.. LEUKEMIA, vol. 29, pp. 992-993, ISSN:0887-6924 DOI Accesso ONLINE all'editore

Pieri L, Bonadonnap; Elena, C; Papayannidis, C; Grifoni, Fi; Rondoni, M; Girlanda, S; Mauro, M; Magliacane, D; Elli, Em; Iorno, Ml; Severino, M; Almerigogna, F; Scarfì, F; Bonifacio, M; Perbellini, O; Artuso, A; Soverini, S; De Benedittis, C; Muratori, S; Lunardon, L; Cova, V; Cortellini, G; Bosi, A; Cortelezzi, A; Martinelli, G; Triggiani, M; Merante, S; Vannucchi, Am (2014). A Survey on Clinical and Biological Characteristic and Therapy Management of an Italian Series of 455 Adult Patients with Systemic Mastocytosis on Behalf of Italian Registry of Mastocytosis.. In: 56th Annual Meeting of the American-Society-of-Hematology, San Francisco, CA, DEC 06-09, 2014, American Society of Hematology, vol. 124, pp. 3188-3188. DOI Accesso ONLINE all'editore

Guglielmelli P;Nangalia J;Green AR;Vannucchi AM (2014). CALR mutations in myeloproliferative neoplasms: hidden behind the reticulum.. AMERICAN JOURNAL OF HEMATOLOGY, vol. 89, pp. 453-456, ISSN:0361-8609 DOI

M. C. Finazzi;A. Carobbio;F. Cervantes;I. M. Isola;A. M. Vannucchi;P. Guglielmelli;A. Rambaldi;G. Finazzi;G. Barosi;T. Barbui (2014). CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis.. LEUKEMIA, pp. 0-0, ISSN:0887-6924 DOI Accesso ONLINE all'editore

F. Lussana;A. Carobbio;M. L. Randi;C. Elena;E. Rumi;G. Finazzi;I. Bertozzi;L. Pieri;M. Ruggeri;F. Palandri;N. Polverelli;E. Elli;A. Tieghi;A. Iurlo;M. Ruella;M. Cazzola;A. Rambaldi;A. M. Vannucchi;T. Barbui (2014). A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera.. BRITISH JOURNAL OF HAEMATOLOGY, vol. 167, pp. 541-546, ISSN:0007-1048 DOI Accesso ONLINE all'editore

Passamonti F;Maffioli M;Cervantes F;Vannucchi AM;Morra E;Barbui T;Caramazza D;Pieri L;Rumi E;Gisslinger H;Knoops L;Kiladjian JJ;Mora B;Hollaender N;Pascutto C;Harrison C;Cazzola M (2014). Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts.. BLOOD, vol. 123, pp. 1833-1835, ISSN:0006-4971 DOI

Mughal TI;Vannucchi AM;Soverini S;Bazeos A;Tibes R;Saglio G;Abdel-Wahab O;Pardanani A;Hehlmann R;Barbui T;Van Etten R;Tefferi A;Goldman JM (2014). Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms.. HAEMATOLOGICA, vol. 99, pp. 797-801, ISSN:0390-6078 DOI

Barbui T;Thiele J;Gisslinger H;Finazzi G;Carobbio A;Rumi E;Luigia Randi M;Betozzi I;Vannucchi AM;Pieri L;Carrai V;Gisslinger B;Müllauer L;Ruggeri M;Rambaldi A;Tefferi A (2014). Masked polycythemia vera (mPV): results of an international study.. AMERICAN JOURNAL OF HEMATOLOGY, vol. 89, pp. 52-54, ISSN:0361-8609 DOI

Martinelli I;De Stefano V;Carobbio A;Randi ML;Santarossa C;Rambaldi A;Finazzi MC;Cervantes F;Arellano-Rodrigo E;Rupoli S;Canafoglia L;Tieghi A;Facchini L;Betti S;Vannucchi AM;Pieri L;Cacciola R;Cacciola E;Cortelezzi A;Iurlo A;Pogliani EM;Elli EM;Spadea A;Barbui T (2014). Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms An European Leukemia Net study.. AMERICAN JOURNAL OF HEMATOLOGY, vol. 89, pp. E200-E205, ISSN:0361-8609 DOI

A. M. Vannucchi (2014). How I treat polycythemia vera.. BLOOD, vol. 124, pp. 3212-3220, ISSN:0006-4971 DOI Accesso ONLINE all'editore

T. Barbui;A. Carobbio;E. Rumi;G. Finazzi;H. Gisslinger;F. Rodeghiero;M. L. Randi;A. Rambaldi;B. Gisslinger;L. Pieri;I. Bertozzi;I. Casetti;A. Pardanani;F. Passamonti;A. M. Vannucchi;A. Tefferi (2014). In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology.. BLOOD, vol. 124, pp. 3021-3023, ISSN:0006-4971 DOI Accesso ONLINE all'editore

M. H. Ellis;N. Lavi;A. Vannucchi;C. Harrison (2014). Treatment of thromboembolic events coincident with the diagnosis of myeloproliferative neoplasms: a physician survey.. THROMBOSIS RESEARCH, vol. 134, pp. 251-254, ISSN:0049-3848 DOI Accesso ONLINE all'editore

Barbui T;Thiele J;Carobbio A;Guglielmelli P;Rambaldi A;Vannucchi AM;Tefferi A (2014). Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients.. AMERICAN JOURNAL OF HEMATOLOGY, vol. 89, pp. 588-590, ISSN:0361-8609 DOI

Geyer HL;Scherber RM;Dueck AC;Kiladjian JJ;Xiao Z;Slot S;Zweegman S;Sackmann F;Fuentes AK;Hernández-Maraver D;Döhner K;Harrison CN;Radia D;Muxi P;Besses C;Cervantes F;Johansson PL;Andreasson B;Rambaldi A;Barbui T;Vannucchi AM;Passamonti F;Samuelsson J;Birgegard G;Mesa RA (2014). Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients.. BLOOD, vol. 123, pp. 3803-3810, ISSN:0006-4971 DOI

Francesco Epifani; Paola Guglielmelli; Idalba Loiacono; Andrea Epifani; Lisa Pieri; Alessandro Maria Vannucchi (2014). MPN Score.

Vannucchi, A.M.; Rotunno, G.; Bartalucci, N.; Raugei, G.; Carrai, V.; Balliu, M.; Mannarelli, C.; Pacilli, A.; Calabresi, L.; Fjerza, R.; Pieri, L.; Bosi, A.; Manfredini, R.; Guglielmelli, P. (2014). Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: Pathogenetic insight and diagnostic value. LEUKEMIA, vol. 28, pp. 1811-1818, ISSN:0887-6924 DOI Accesso ONLINE all'editore

Barosi G;Vannucchi AM;De Stefano V;Pane F;Passamonti F;Rambaldi A;Saglio G;Barbui T;Tura S (2014). Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: a consensus-based SIE, SIES, GITMO position paper.. LEUKEMIA RESEARCH, vol. 38, pp. 155-160, ISSN:0145-2126 DOI

Barbui T;Thiele J;Carobbio A;Gisslinger H;Finazzi G;Rumi E;Luigia Randi M;Vannucchi AM;Gisslinger B;Müllauer L;Ruggeri M;Rambaldi A;Tefferi A (2014). Masked polycythemia vera diagnosed according to WHO and BCSH classification.. AMERICAN JOURNAL OF HEMATOLOGY, vol. 89, pp. 199-202, ISSN:0361-8609 DOI

Barbui T;Thiele J;Vannucchi AM;Tefferi A (2014). Rethinking the diagnostic criteria of polycythemia vera.. LEUKEMIA, vol. 28, pp. 1191-1195, ISSN:0887-6924 DOI

Rondelli D;Goldberg JD;Isola L;Price LS;Shore TB;Boyer M;Bacigalupo A;Rambaldi A;Scarano M;Klisovic RB;Gupta V;Andreasson B;Mascarenhas J;Wetzler M;Vannucchi AM;Prchal JT;Najfeld V;Orazi A;Weinberg RS;Miller C;Barosi G;Silverman LR;Prosperini G;Marchioli R;Hoffman R (2014). MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis.. BLOOD, vol. 124, pp. 1183-1191, ISSN:0006-4971 DOI

Verstovsek S;Passamonti F;Rambaldi A;Barosi G;Rosen PJ;Rumi E;Gattoni E;Pieri L;Guglielmelli P;Elena C;He S;Contel N;Mookerjee B;Sandor V;Cazzola M;Kantarjian HM;Barbui T;Vannucchi AM (2014). A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.. CANCER, vol. 120, pp. 513-520, ISSN:0008-543X DOI

Tefferi A;Wassie EA;Guglielmelli P;Gangat N;Belachew AA;Lasho TL;Finke C;Ketterling RP;Hanson CA;Pardanani A;Wolanskyj AP;Maffioli M;Casalone R;Pacilli A;Vannucchi AM;Passamonti F (2014). Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients.. AMERICAN JOURNAL OF HEMATOLOGY, vol. 89, pp. e121-e124, ISSN:0361-8609 DOI

Tefferi A;Guglielmelli P;Lasho TL;Rotunno G;Finke C;Mannarelli C;Belachew AA;Pancrazzi A;Wassie EA;Ketterling RP;Hanson CA;Pardanani A;Vannucchi AM (2014). CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients.. LEUKEMIA, vol. 28, pp. 1494-1500, ISSN:0887-6924 DOI

Rotunno G;Mannarelli C;Guglielmelli P;Pacilli A;Pancrazzi A;Pieri L;Fanelli T;Bosi A;Vannucchi AM. (2014). Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia.. BLOOD, vol. 123, pp. 1552-1555, ISSN:0006-4971 DOI

Randi ML;Bertozzi I;Rumi E;Elena C;Finazzi G;Vianelli N;Polverelli N;Ruggeri M;Vannucchi AM;Antonioli E;Lussana F;Tieghi A;Iurlo A;Elli E;Ruella M;Fabris F;Cazzola M;Barbui T (2014). Pregnancy complications predict thrombotic events in young women with essential thrombocythemia.. AMERICAN JOURNAL OF HEMATOLOGY, vol. 89, pp. 306-309, ISSN:0361-8609 DOI

Tenedini E;Bernardis I;Artusi V;Artuso L;Roncaglia E;Guglielmelli P;Pieri L;Bogani C;Biamonte F;Rotunno G;Mannarelli C;Bianchi E;Pancrazzi A;Fanelli T;Malagoli Tagliazucchi G;Ferrari S;Manfredini R;Vannucchi AM;Tagliafico E. (2014). Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms.. LEUKEMIA, vol. 28, pp. 1052-1059, ISSN:0887-6924 DOI

Guglielmelli P;Biamonte F;Rotunno G;Artusi V;Artuso L;Bernardis I;Tenedini E;Pieri L;Paoli C;Mannarelli C;Fjerza R;Rumi E;Stalbovskaya V;Squires M;Cazzola M;Manfredini R;Harrison C;Tagliafico E;Vannucchi AM. (2014). Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study.. BLOOD, vol. 123, pp. 2157-2160, ISSN:0006-4971 DOI

Guglielmelli, P; Rotunno, G; Brogi, G; Pacilli, A; Bogani, C; Mannarelli, C; Pancrazzi, A; Fjerza, R; Pieri, L; Rumi, E; Pietra, D; Salmoiraghi, S; Provenzano, A; Giunti, L; Giglio, S; Maffioli, M; Bosi, A; Rambaldi, A; Barbui, T; Passamonti, F; Cazzola, M; Vannucchi, Am (2014). Calreticulin Mutation Is Associated with Milder Disease in Patients with Post Essential Thrombocythemia Myelofibrosis (PET-MF) Compared with JAK2V617F Mutation: A Study from the AGIMM Group. BLOOD, vol. 124, pp. 3179-3179, ISSN:0006-4971

Pennucci V;Zini R;Norfo R;Guglielmelli P;Bianchi E;Salati S;Sacchi G;Prudente Z;Tenedini E;Ruberti S;Paoli C;Fanelli T;Mannarelli C;Tagliafico E;Ferrari S;Vannucchi AM;Manfredini R. (2014). Abnormal expression patterns of WT1-as, MEG3 and ANRIL long non-coding RNAs in CD34+ cells from patients with primary myelofibrosis and their clinical correlations.. LEUKEMIA & LYMPHOMA, pp. 1-5, ISSN:1042-8194 DOI

Guglielmelli P;Bartalucci N;Rotunno G;Vannucchi AM (2014). Calreticulin: a new horizon for the testing and treatment of myeloproliferative neoplasms.. EXPERT REVIEW OF HEMATOLOGY, vol. 7, pp. 423-425, ISSN:1747-4086 DOI

Rotunno G;Guglielmelli P;Biamonte F;Rumi E;Cazzola M;Vannucchi AM (2014). Mutational analysis of BCORL1 in the leukemic transformation of chronic myeloproliferative neoplasms.. ANNALS OF HEMATOLOGY, vol. 93, pp. 523-524, ISSN:0939-5555 DOI

G. Finazzi;A. Carobbio;P. Guglielmelli;C. Cavalloni;S. Salmoiraghi;A. M. Vannucchi;M. Cazzola;F. Passamonti;A. Rambaldi;T. Barbui (2014). Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia.. BLOOD, vol. 124, pp. 2611-2612, ISSN:0006-4971 DOI Accesso ONLINE all'editore

Norfo R;Zini R;Pennucci V;Bianchi E;Salati S;Guglielmelli P;Bogani C;Fanelli T;Mannarelli C;Rosti V;Pietra D;Salmoiraghi S;Bisognin A;Ruberti S;Rontauroli S;Sacchi G;Prudente Z;Barosi G;Cazzola M;Rambaldi A;Bortoluzzi S;Ferrari S;Tagliafico E;Vannucchi AM;Manfredini R (2014). miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells unveils the role of miR-155/JARID2 axis in abnormal megakaryopoiesis.. BLOOD, vol. 124, pp. E21-E32, ISSN:0006-4971 DOI

R. Castelli;M. Cugno;U. Gianelli;A. Pancrazzi;A. M. Vannucchi (2014). Neutrophilic progression in a case of polycytemia vera mimicking chronic neutrophilic leukemia: Clinical and molecular characterization.. PATHOLOGY RESEARCH AND PRACTICE, vol. 14, pp. 287-288, ISSN:0344-0338 DOI Accesso ONLINE all'editore

Vannucchi AM;Rotunno G;Bartalucci N;Raugei G;Carrai V;Balliu M;Mannarelli C;Pacilli A;Calabresi L;Fjerza R;Pieri L;Bosi A;Manfredini R;Guglielmelli P (2014). Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value.. LEUKEMIA, vol. 28, pp. 1811-1818, ISSN:0887-6924 DOI

Klampfl T;Milosevic JD;Puda A;Schönegger A;Bagienski K;Berg T;Harutyunyan AS;Gisslinger B;Rumi E;Malcovati L;Pietra D;Elena C;Della Porta MG;Pieri L;Guglielmelli P;Bock C;Doubek M;Dvorakova D;Suvajdzic N;Tomin D;Tosic N;Racil Z;Steurer M;Pavlovic S;Vannucchi AM;Cazzola M;Gisslinger H;Kralovics R (2013). Complex patterns of chromosome 11 aberrations in myeloid malignancies target CBL, MLL, DDB1 and LMO2.. PLOS ONE, vol. 8, pp. e77819-e77826, ISSN:1932-6203 DOI

Vannucchi AM;Guglielmelli P (2013). JAK2 mutation-related disease and thrombosis.. SEMINARS IN THROMBOSIS AND HEMOSTASIS, vol. 39, pp. 496-506, ISSN:0094-6176 DOI

Tefferi A;Cervantes F;Mesa R;Passamonti F;Verstovsek S;Vannucchi AM;Gotlib J;Dupriez B;Pardanani A;Harrison C;Hoffman R;Gisslinger H;Kröger N;Thiele J;Barbui T;Barosi G (2013). Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report.. BLOOD, vol. 122, pp. 1395-1398, ISSN:0006-4971 DOI

Poletto V;Villani L;Catarsi P;Campanelli R;Massa M;Vannucchi AM;Rosti V;Barosi G (2013). No association between the XPD Lys751Gln (rs13181) polymorphism and disease phenotype or leukemic transformation in primary myelofibrosis.. HAEMATOLOGICA, vol. 98, pp. e83-e84, ISSN:0390-6078 DOI

Marchioli R; Specchia G; Finazzi G; Cacciola R; Cavazzina R; Cilloni D; De Stefano V; Elli E; Iurlo A; Latagliata R; Lunghi F; Marfisi RM; Musto P; Masciulli A; Musolino C; Cascavilla N; Quarta G; Randi ML; Rapezi Davide; Ruggeri M; Rumi E; Scortechini AR; Santini S; Scarano M; Siragusa S; Spadea A; Tieghi A; Angelucci E; Visani G; Vannucchi AM; Barbui T; CYTO-PV Collaborative Group (2013). Cardiovascular events and intensity of treatment in polycythemia vera.. THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 368, pp. 22-33, ISSN:0028-4793 DOI

Rumi E;Pietra D;Guglielmelli P;Bordoni R;Casetti I;Milanesi C;Sant'Antonio E;Ferretti V;Pancrazzi A;Rotunno G;Severgnini M;Pietrelli A;Astori C;Fugazza E;Pascutto C;Boveri E;Passamonti F;De Bellis G;Vannucchi A;Cazzola M. (2013). Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms.. BLOOD, vol. 121, pp. 4388-4395, ISSN:0006-4971 DOI

Susini MC;Guglielmelli P;Spolverini A;Biamonte F;Mannarelli C;Barosi G;Zoi K;Reiter A;Duncombe A;Cervantes F;Cazzola M;Cross N;Vannucchi AM. (2013). The ERCC2 Gln/Gln polymorphism at codon 751 is not associated with leukaemic transformation in primary myelofibrosis.. BRITISH JOURNAL OF HAEMATOLOGY, vol. 162, pp. 424-427, ISSN:0007-1048 DOI

Cervantes F;Vannucchi AM;Kiladjian JJ;Al-Ali HK;Sirulnik A;Stalbovskaya V;McQuitty M;Hunter DS;Levy RS;Passamonti F;Barbui T;Barosi G;Harrison CN;Knoops L;Gisslinger H; (2013). Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.. BLOOD, vol. 122, pp. 4047-4053, ISSN:0006-4971 DOI

Harrison CN;Mesa RA;Kiladjian JJ;Al-Ali HK;Gisslinger H;Knoops L;Squier M;Sirulnik A;Mendelson E;Zhou X;Copley-Merriman C;Hunter DS;Levy RS;Cervantes F;Passamonti F;Barbui T;Barosi G;Vannucchi AM (2013). Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy.. BRITISH JOURNAL OF HAEMATOLOGY, vol. 162, pp. 229-239, ISSN:0007-1048 DOI

Tefferi A;Rumi E;Finazzi G;Gisslinger H;Vannucchi AM;Rodeghiero F;Randi ML;Vaidya R;Cazzola M;Rambaldi A;Gisslinger B;Pieri L;Ruggeri M;Bertozzi I;Sulai NH;Casetti I;Carobbio A;Jeryczynski G;Larson DR;Müllauer L;Pardanani A;Thiele J;Passamonti F;Barbui T (2013). Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study.. LEUKEMIA, vol. 27, pp. 1874-1881, ISSN:0887-6924 DOI

Alessandro M. Vannucchi; Costanza Bogani; Niccolò Bartalucci (2013). JAK PI3K/mTOR COMBINATION THERAPY. Numero: US20130040973 A1 Incyte Corp., Novartis Pharma AG

Barbui T;Thiele J;Vannucchi AM;Tefferi A (2013). Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia.. LEUKEMIA, vol. 27, pp. 1953-1958, ISSN:0887-6924 DOI

Pieri L;Loiacono I;Vannucchi AM (2013). The burden of symptoms in myelofibrosis: from patient-reported outcomes to health economics.. LEUKEMIA RESEARCH, vol. 37, pp. 855-856, ISSN:0145-2126 DOI

Barosi G;Mesa R;Finazzi G;Harrison C;Kiladjian JJ;Lengfelder E;McMullin MF;Passamonti F;Vannucchi AM;Besses C;Gisslinger H;Samuelsson J;Verstovsek S;Hoffman R;Pardanani A;Cervantes F;Tefferi A;Barbui T (2013). Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project.. BLOOD, vol. 121, pp. 4778-4781, ISSN:0006-4971 DOI

Bartalucci N;Tozzi L;Bogani C;Martinelli S;Rotunno G;Villeval JL;Vannucchi AM (2013). Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms.. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, vol. 17, pp. 1385-1396, ISSN:1582-1838 DOI

Marchioli R;Vannucchi AM;Barbui T (2013). Treatment target in polycythemia vera.. THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 368, pp. 1556-1556, ISSN:0028-4793 DOI

Finazzi G;Vannucchi AM;Martinelli V;Ruggeri M;Nobile F;Specchia G;Pogliani EM;Olimpieri OM;Fioritoni G;Musolino C;Cilloni D;Sivera P;Barosi G;Finazzi MC;Di Tollo S;Demuth T;Barbui T;Rambaldi A (2013). A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy.. BRITISH JOURNAL OF HAEMATOLOGY, vol. 161, pp. 688-694, ISSN:0007-1048 DOI

Vannucchi AM;Lasho TL;Guglielmelli P;Biamonte F;Pardanani A;Pereira A;Finke C;Score J;Gangat N;Mannarelli C;Ketterling RP;Rotunno G;Knudson RA;Susini MC;Laborde RR;Spolverini A;Pancrazzi A;Pieri L;Manfredini R;Tagliafico E;Zini R;Jones A;Zoi K;Reiter A;Duncombe A;Pietra D;Rumi E;Cervantes F;Barosi G;Cazzola M;Cross NC;Tefferi A (2013). Mutations and prognosis in primary myelofibrosis.. LEUKEMIA, vol. 27, pp. 1861-1869, ISSN:0887-6924 DOI

Bogani C;Bartalucci N;Martinelli S;Tozzi L;Guglielmelli P;Bosi A;Vannucchi AM. (2013). mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms.. PLOS ONE, vol. 8, pp. e54826-e54826, ISSN:1932-6203 DOI

Bartalucci N;Guglielmelli P;Vannucchi AM (2013). Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms.. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol. 13 Suppl 2, pp. 307-309, ISSN:2152-2650 DOI

Nangalia J;Massie CE;Baxter EJ;Nice FL;Gundem G;Wedge DC;Avezov E;Li J;Kollmann K;Kent DG;Aziz A;Godfrey AL;Hinton J;Martincorena I;Van Loo P;Jones AV;Guglielmelli P;Tarpey P;Harding HP;Fitzpatrick JD;Goudie CT;Ortmann CA;Loughran SJ;Raine K;Jones DR;Butler AP;Teague JW;O'Meara S;McLaren S;Bianchi M;Silber Y;Dimitropoulou D;Bloxham D;Mudie L;Maddison M;Robinson B;Keohane C;Maclean C;Hill K;Orchard K;Tauro S;Du MQ;Greaves M;Bowen D;Huntly BJ;Harrison CN;Cross NC;Ron D;Vannucchi AM;Papaemmanuil E;Campbell PJ;Green AR (2013). Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.. THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 369, pp. 2391-2405, ISSN:0028-4793 DOI

Jovanovic JV;Ivey A;Vannucchi AM;Lippert E;Oppliger Leibundgut E;Cassinat B;Pallisgaard N;Maroc N;Hermouet S;Nickless G;Guglielmelli P;van der Reijden BA;Jansen JH;Alpermann T;Schnittger S;Bench A;Tobal K;Wilkins B;Cuthill K;McLornan D;Yeoman K;Akiki S;Bryon J;Jeffries S;Jones A;Percy MJ;Schwemmers S;Gruender A;Kelley TW;Reading S;Pancrazzi A;McMullin MF;Pahl HL;Cross NC;Harrison CN;Prchal JT;Chomienne C;Kiladjian JJ;Barbui T;Grimwade D (2013). Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study.. LEUKEMIA, vol. 27, pp. 2032-2039, ISSN:0887-6924 DOI

Spolverini A;Pieri L;Guglielmelli P;Pancrazzi A;Fanelli T;Paoli C;Bosi A;Nichele I;Ruggeri M;Vannucchi AM (2013). Infrequent occurrence of mutations in the PH domain of LNK in patients with JAK2 mutation-negative 'idiopathic' erythrocytosis.. HAEMATOLOGICA, vol. 98, pp. e101-e102, ISSN:0390-6078 DOI

Barbui T;Carobbio A;Finazzi G;Guglielmelli P;Salmoiraghi S;Rosti V;Rambaldi A;Vannucchi AM;Barosi G (2013). Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis.. LEUKEMIA, vol. 27, pp. 2084-2086, ISSN:0887-6924 DOI

Guglielmelli P;Vannucchi AM (2013). Struggling with myelofibrosis-associated anemia.. LEUKEMIA RESEARCH, vol. 37, pp. 1429-1431, ISSN:0145-2126 DOI

Bartalucci N;Bogani C;Vannucchi AM (2013). Preclinical models for drug selection in myeloproliferative neoplasms.. CURRENT HEMATOLOGIC MALIGNANCY REPORTS, vol. 8, pp. 317-324, ISSN:1558-8211 DOI

T. Barbui; J. Thiele; F. Passamonti; E. Rumi; E. Boveri; M.L. Randi; I. Bertozzi; F. Marino; A.M. Vannucchi; L. Pieri; G. Rotunno; H. Gisslinger; B. Gisslinger; L. Mullauer; G. Finazzi; A. Carobbio; A. Gianatti; M. Ruggeri; I. Nichele; E. D'Amore; A. Rambaldi; A. Tefferi (2012). Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. BLOOD, vol. 119, pp. 2239-2241, ISSN:0006-4971

Passamonti F;Thiele J;Girodon F;Rumi E;Carobbio A;Gisslinger H;Kvasnicka HM;Ruggeri M;Randi ML;Gangat N;Vannucchi AM;Gianatti A;Gisslinger B;Müllauer L;Rodeghiero F;d'Amore ES;Bertozzi I;Hanson CA;Boveri E;Marino F;Maffioli M;Caramazza D;Antonioli E;Carrai V;Buxhofer-Ausch V;Pascutto C;Cazzola M;Barbui T;Tefferi A (2012). A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment.. BLOOD, vol. 120, pp. 1197-1201, ISSN:0006-4971 DOI

R.P. Gale; G. Barosi; T. Barbui; F. Cervantes; K. Dohner; B. Dupriez; V. Gupta; C. Harrison; R. Hoffman; J.J. Kiladjian; R. Mesa; M.F. Mc Mullin; F. Passamonti; V. Ribrag; G. Roboz; G. Saglio; A.M. Vannucchi; S. Verstovsek (2012). RBC-transfusion guidelines update. LEUKEMIA RESEARCH, vol. 36, pp. 659-660, ISSN:0145-2126

Antonioli, E; Guglielmelli, P; Pieri, L; Finazzi, M; Rumi, E; Martinelli, V; Vianelli, N; Randi, Ml; Bertozzi, I; De Stefano, V; Za, T; Rossi, E; Ruggeri, M; Elli, E; Cacciola, R; Cacciola, E; Pogliani, E; Rodeghiero, F; Baccarani, M; Passamonti, F; Finazzi, G; Rambaldi, A; Bosi, A; Cazzola, M; Barbui, T; Vannucchi, Am (2012). Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN. AMERICAN JOURNAL OF HEMATOLOGY, vol. 87, pp. 552-554, ISSN:0361-8609 DOI

Spolverini A; Pieri L; Guglielmelli P; Pancrazzi A; Fanelli T; Paoli C;Bosi A; Vannucchi AM (2012). LNK MUTATIONS IN JAK2 NEGATIVE ERYTHROCYTOSIS. In: XII Congress of the Italian Society of Experimental Hematology, Roma, Ferrata Storti Foundation, pp. 128-128.

Vannucchi AM; Fanci R (2012). Fisiopatologia e morfologia del sangue e degli organi emopoietici. In: Bosi A, De Stefano V, Di Raimondo F, La Nasa G. Manuale di malattie del sangue, pp. 1-20, Milano: Elsevier, ISBN:9788821432620.

Vannucchi AM; Guglielmelli P (2012). Neoplasie mieloproliferative croniche Ph negative. In: Bosi A, De Stefano V, Di raimondo F, La Nasa G. Manuale di malattie del sangue, pp. 70-75, Milano: Elsevier, ISBN:9788821432620.

Buxhofer-Ausch V; Gisslinger H; Thiele J; Gisslinger B; Kvasnicka HM; Müllauer L; Frantal S; Carobbio A; Passamonti F; Rumi E; Ruggeri M; Rodeghiero F; Randi ML; Bertozzi I; Vannucchi AM; Antonioli E; Finazzi G; Gangat N; Tefferi A; Barbui T. (2012). Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: An international study of 264 patients.. AMERICAN JOURNAL OF HEMATOLOGY, vol. 87, pp. 669-672, ISSN:0361-8609

S. Bortoluzzi; A. Bisognin; M. Biasolo; P. Guglielmelli; F. Biamonte; R. Norfo; R. Manfredini; AM. Vannucchi (2012). Characterisation and discovery of novel miRNAs andmoRNAs in JAK2V617F mutated SET2 cells. BLOOD, vol. 119, pp. e120-e130, ISSN:0006-4971

Vittorio Rosti; Laura Villani; Roberta Riboni; Valentina Poletto; Elisa Bonetti; L. Tozzi; Gaetano Bergamaschi; Paolo Catarsi; Elena Dallera; Francesca Novara; Margherita Massa; Rita Campanelli; Gabriela Fois; Benedetta Peruzzi; Marco Lucioni; Paola Guglielmelli; Alessandro Pancrazzi; Giacomo Fiandrino; Orsetta Zuffardi; Umberto Magrini; Marco Paulli; A.M. Vannucchi ; Giovanni Barosi; (2012). Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation. BLOOD, vol. 0, pp. 0-0, ISSN:0006-4971 DOI

Susini MC; Masala G; Antonioli E; Pieri L; Guglielmelli P; Palli D; Bosi A; Vannucchi AM (2012). Risk of second cancers in chronic myeloproliferative neoplasms. BLOOD, vol. 119, pp. 3861-3862, ISSN:0006-4971 DOI

Milosevic JD; Puda A; Malcovati L; Berg T; Hofbauer M; Stukalov A; Klampf T; Harutyunyan AS; Gisslinger H; Gisslinger B; Burjanivova T; Rumi E; Pietra D; Elena C; Vannucchi AM; Doubek M; Dvorakova D; Robesova B; Wieser R; Koller E; Suvajdzic N; Tomin D; Tosic N; Colinge J; Racil Z; Steurer M; Pavlovic S; Cazzola M; Kralovics R (2012). Clinical significance of genetic aberrations in secondary acute myeloid leukemia. AMERICAN JOURNAL OF HEMATOLOGY, vol. 87, pp. 1010-1016, ISSN:1096-8652 DOI

A.Puda;J.D. Milosevic;T. Berg;T. Klampfl;A.S. Harutyunyan;B. Gisslinger;E. Rumi;D. Pietra;L. Malcovati;C. Elena;M. Doubek;M. Steurer;N. Tosic;S. Pavlovic;P. Guglielmelli;L. Pieri;A.M. Vannucchi;H. Gisslinger;M. Cazzola;R. Kralovics. (2012). Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies.. AMERICAN JOURNAL OF HEMATOLOGY, vol. 87, pp. 245-250, ISSN:0361-8609 DOI

G. Finazzi;A. Carobbio;J. Thiele;F. Passamonti;E. Rumi;M. Ruggeri;F. Rodeghiero;M.L. Randi;I. Bertozzi;A.M. Vannucchi;E. Antonioli;H. Gisslinger;V. Buxhofer-Ausch;N. Gangat;A. Rambaldi;A. Tefferi;T. Barbui (2012). Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria.. LEUKEMIA, vol. 26, pp. 716-719, ISSN:0887-6924

Emanuel RM; Dueck AC; Geyer HL; Kiladjian JJ; Slot S; Zweegman S; Te Boekhorst PA; Commandeur S; Schouten HC; Sackmann F; Kerguelen Fuentes A; Hernández-Maraver D; Pahl HL; Griesshammer M; Stegelmann F; Doehner K; Lehmann T; Bonatz K; Reiter A; Boyer F; Etienne G; Ianotto JC; Ranta D; Roy L; Cahn JY; Harrison CN; Radia D; Muxi P; Maldonado N; Besses C; Cervantes F; Johansson PL; Barbui T; Barosi G; Vannucchi AM; Passamonti F; Andreasson B; Ferarri ML; Rambaldi A; Samuelsson J; Birgegard G; Tefferi A; Mesa RA. (2012). Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs.. JOURNAL OF CLINICAL ONCOLOGY, vol. 0, pp. 0-0, ISSN:0732-183X DOI

L. Pieri; M.L. Iorno; E. DiFonzo; F. Almerigogna; N. Pimpinelli; C. Cardinali; E. Antonioli; P. Guglielmelli; A. Bosi; P. Fabbri; A.M. Vannucchi (2012). Mastocitosi: approccio multidisciplinare a una patologia misconoscciuta. TOSCANA MEDICA, vol. XXIX (1), pp. 47-49, ISSN:2611-9412

T. Barbui; G. Barosi; V. De Stefabo; A. Falanga; G. Finazzi; F. Passamonti; M. Ruggeri; A.M. Vannucchi (2012). Le Neoplasie Mieloproliferative Philadelphia negative. Un approccio per problemi. In: T. Barbui, G. Barosi, V. De Stefabo, A. Falanga, G. Finazzi, F. Passamonti, M. Ruggeri, A.M. Vannucchi. Le Neoplasie Mieloproliferative Philadelphia negative. Un approccio per problemi, pp. 1-255, Milano: Oxys.

A.M. VANNUCCHI; C. BOGANI; P. GUGLIELMELLI; NOVARTIS PHARMA AG; INCYTE CORP. (2012). mTOR/JAK INHIBITOR COMBINATION THERAPY. Numero: 20120214825 A.M. VANNUCCHI, C. BOGANI, P. GUGLIELMELLI, NOVARTIS PHARMA AG, INCYTE CORP.

Godfrey AL; Chen E; Pagano F; Ortmann CA; Silber Y; Bellosillo B; Guglielmelli P; Harrison CN; Reilly T; Stegelman F; Bijoux F; Lippert E; McMullin MF; Boiron JM; Dohner K; Vannucchi AM; Besses C; Camplbell PJ; Green AR (2012). JAK2V617F-homozigosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant clone. BLOOD, vol. 120, pp. 2704-2707, ISSN:0006-4971

Cervantes F; Dupriez B; Passamonti F; Vannucchi AM; Morra E; Reilly JT; Demory JL; Rumi E; Guglielmelli P; Roncoroni E; Tefferi A; Pereira A (2012). Improving survival trends in primary myelofibrosis: an international study. JOURNAL OF CLINICAL ONCOLOGY, vol. 30, pp. 2981-2987, ISSN:0732-183X DOI

C. Harrison; J.J. Kiladjian;H.K. Al-Ali; H.Gisslinger; R. Waltzman; V. Stalbovskaya; M. McQuitty; D. S. Hunter; R. Levy; L. Knoops; F. Cervantes; A.M. Vannucchi; T. Barbui; G. Barosi (2012). JAK Inhibition with Ruxolitinib versus Best Available Therapyfor Myelofibrosis. THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 366(9), pp. 787-798, ISSN:0028-4793 DOI Accesso ONLINE all'editore

Abdel-Wahab O; Pardanani A; Bernard OA; Finazzi G; Crispino JD; Gisslinger H; Kralovics R; Odenike O; Bhalla K; Gupta V; Barosi G; Gotlib J; Guglielmelli P; Kiladjian JJ; Noel P; Cazzola M; Vannucchi AM; Hoffman R; Barbui T; Thiele J; Van Etten RA; Mughal T; Tefferi A. (2012). Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium. AMERICAN JOURNAL OF HEMATOLOGY, vol. 87, pp. 562-568, ISSN:0361-8609 DOI

C. Harrison; A.M. Vannucchi (2012). Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians.. THERAPEUTIC ADVANCES IN HEMATOLOGY, vol. 3, pp. 341-354, ISSN:2040-6207 DOI

L. Villani;G. Bergamaschi;M. Primignani;V. Rosti;A. Carolei;V. Poletto;P. Catarsi;A. Spolverini;A.M. Vannucchi;G. Barosi. (2012). JAK2 46/1 haplotype predisposes tosplanchnic vein thrombosis-associated BCR-ABL negative classic myeloproliferativeneoplasms.. LEUKEMIA RESEARCH, vol. 36(1), pp. 7-9, ISSN:0145-2126

A. Tefferi; A. Pardanani; N. Gangat; K.H. Begna; C.A. Hanson; D.L. Van Dyke; D. Caramazza; A.M. Vannucchi; E. Morra; M. Cazzola; A. Pereira; F. Cervantes; F. Passamonti (2012). Leukemia risk models in primary myelofibrosis: an International Working Group study. LEUKEMIA, vol. 26, pp. 1439-1441, ISSN:0887-6924

A.M. Vannucchi (2012). Polycythemia Vera and Essential Thrombocythemia: When to Change Therapy - Second-Line Options. In: T. Barbui, A. Tefferi. Myeloproliferative Neoplasms. Critical Concepts and Management, pp. 119-129, Heidelberg: Springer, ISBN:9783642249884.

Barbui T; Finazzi G; Carobbio A; Thiele J; Passamonti F; Rumi E; Ruggeri M; Rodeghiero F; Randi ML; Bertozzi I; Gisslinger H; Buxhofer-Ausch V; De Stefano V; Betti S; Rambaldi A; Vannucchi AM; Tefferi A (2012). Development and validation of an International Prognostic Score of thrombosis in WHO-Essential thrombocythemia (IPSET-thrombosis. BLOOD, vol. 0, pp. 0-0, ISSN:0006-4971 DOI

Barbui T; Thiele J; Carobbio A; Passamonti F; Rumi E; Randi ML; Bertozzi I; Vannucchi AM; Gisslinger H; Gisslinger B; Finazzi G; Ruggeri M; Rodeghiero F; Rambaldi A; Gangat N; Tefferi A. (2012). Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early /prefibrotic primary myelofibrosis. BLOOD, vol. 120, pp. 569-571, ISSN:0006-4971 DOI

Vannucchi AM; Pieri L; Susini MC; Guglielmelli P (2012). BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques. FUTURE ONCOLOGY, vol. 8, pp. 575-593, ISSN:1479-6694

Susini, Mc; Masala, G; Antonioli, Elisabetta; Pieri, Lisa; Guglielmelli, P; Palli, D; Bosi, Alberto; Vannucchi, Am (2012). Risk of second cancers in chronic myeloproliferative neoplasms.. BLOOD, vol. 119, pp. 3861-3862, ISSN:0006-4971 DOI

A. Carobbio; G. Finazzi; J. Thiele; H.M. Kvasnicka; F. Passamonti; E. Rumi; M. Ruggeri; F. Rodeghiero; M.L. Randi; I. Bertozzi; A.M. Vannucchi; E. Antonioli; H. Gisslinger; V. Buxhofer-Ausch; N. Gangat; A. Rambaldi; A. Tefferi; T. Barbui (2012). Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia.. AMERICAN JOURNAL OF HEMATOLOGY, vol. 87, pp. 203-204, ISSN:0361-8609

A.M. Vannucchi (2011). Management of myelofibrosis.. HEMATOLOGY, vol. 2011, pp. 222-230, ISSN:1520-4391

Vannucchi AM (2011). Management of myelofibrosis. In: 53rd Annual Meeting of the American Society of Hematology, pp. 222-228.

A.M. Vannucchi; E. Antonioli; P. Guglielmelli; L. Pieri; A. Pancrazzi; A. Bosi (2011). Percorsi diagnostici-terapeutici per le neoplasie mieloproliferative nella AOU Careggi. TOSCANA MEDICA, vol. xxix(4), pp. 46-48, ISSN:2611-9412

R.P. Gale;G. Barosi;T. Barbui;F. Cervantes;K. Dohner;B. Dupriez; V. Gupta;C. Harrison;R. Hoffman;J.J. Kiladjian;R. Mesa;M.F. Mc Mullin;F. Passamonti;V. Ribrag;G. Roboz;G. Saglio;A.M. Vannucchi;S.Verstovsek (2011). What are RBC-transfusion-dependence and -independence?. LEUKEMIA RESEARCH, vol. 35(1), pp. 8-11, ISSN:0145-2126

Guglielmelli P; Biamonte F; Score J; Hidalgo-Curtis C; Cervantes F; Maffioli M; Fanelli T; Ernst T; Winkelman N; Jones AV; Zoi K; Reiter A; Duncombe A; Villani L; Bosi A; Barosi G; Cross NC; Vannucchi AM (2011). EZH2 mutational status predicts poor survival in myelofibrosis.. BLOOD, vol. 2011 Nov 10;118(19):5227-34., pp. 5227-5234, ISSN:0006-4971 DOI Accesso ONLINE all'editore

A. Pardanani;A.M. Vannucchi;F. Passamonti;F. Cervantes;T. Barbui;A. Tefferi (2011). JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations.. LEUKEMIA, vol. 25(2), pp. 218-225, ISSN:0887-6924

Barbui, T; Carobbio, A; Finazzi, G; Vannucchi, Am; Barosi, G; Antonioli, E; Guglielmelli, P; Pancrazzi, A; Salmoiraghi, S; Zilio, P (2011). Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3.. HAEMATOLOGICA, vol. 96(2), pp. 315-318, ISSN:0390-6078 DOI

Biamonte F;Guglielmelli P;Fanelli T;Pancrazzi A;Villani L;Bosi A;Barosi G;Vannucchi AM (2011). ANALYSIS OF ASXL1 MUTATIONS IN 215 PATIENTS WITH MYELOFIBROSIS : IMPACT ON DISEASE PHENOTYPE AND PROGNOSIS. In: 43° Congress of the Italian Society of Hematology, Ferrata Storti Foundation, pp. 31-31.

R. Scherber;A.C. Dueck;P. Johansson;T. Barbui;G. Barosi;A.M. Vannucchi;F. Passamonti;B. Andreasson;M.L. Ferarri;A. Rambaldi;J. Samuelsson;G. Birgegard;A. Tefferi;C.N. Harrison;D. Radia;R.A. Mesa (2011). The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients.. BLOOD, vol. 118(2), pp. 401-408, ISSN:0006-4971

G. Barosi;V. Rosti;A.M. Vannucchi (2011). Therapeutic approaches in myelofibrosis.. EXPERT OPINION ON PHARMACOTHERAPY, vol. 12(10), pp. 1597-1611, ISSN:1465-6566

L. Gugliotta; A. Tieghi; G. Tortorella; P.R. Scalzulli;R. Ciancia;M. Lunghi; E. Cacciola; R. Cacciola; A. Candoni;M. Crugnola; K. Codeluppi; E. Usala;G. Specchia;V. Martinelli;F. Palmieri;I. Pierri;AM Liberati; A. Iurlo; A. Grossi; A.M. Vannucchi; N. Vianelli; M.G. Mazzucconi. (2011). Low impact of cardiovascular adverse events onanagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia.. LEUKEMIA RESEARCH, vol. 35(12), pp. 1557-1563, ISSN:0145-2126

A.M. Vannucchi (2011). Diagnosis and treatment of polcythenia vera and essential thrombocythemia. In: 16th congress of the European Hematology Association, pp. 255-263.

L. Pieri; A. Spolverini;B. Scappini;U. Occhini;S. Birtolo;A. Bosi;F. Albano;C. Fava;A.M. Vannucchi (2011). Concomitant occurrence of BCR-ABL and JAK2V617F mutation.. BLOOD, vol. 118(12), pp. 3445-3446, ISSN:0006-4971

Spolverini A; Jones AV; Hochhaus A; Pieri L; Cross NC; Vannucchi AM. (2011). The myeloproliferative neoplasm-associated JAK2 46/1 haplotype is not overrepresented in chronic myelogenous leukemia.. ANNALS OF HEMATOLOGY, vol. 90(3), pp. 365-366, ISSN:0939-5555

L. Varricchio;E. Masselli;E. Alfani;A. Battistini;G. Migliaccio;A.M. Vannucchi;W. Zhang;D. Rondelli;J. Godbold;B. Ghinassi;C. Whitsett; R. Hoffman; A.R.Migliaccio (2011). The dominant negative β isoform of the glucocorticoid receptor is uniquely expressed in erythroid cells expanded from polycythemia vera patients.. BLOOD, vol. 118(2), pp. 425-436, ISSN:0006-4971

T. Klampfl;A. Harutyunyan;T. Berg;B. Gisslinger;M. Schalling;K. Bagienski;D. Olcaydu;F. Passamonti;E. Rumi;D. Pietra;R. Jäger;L. Pieri;P. Guglielmelli; I. Iacobucci;G. Martinelli;M. Cazzola;A.M. Vannucchi;H. Gisslinger;R. Kralovics. (2011). Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression.. BLOOD, vol. 118(1), pp. 167-176, ISSN:0006-4971 DOI

T. Barbui;J. Thiele;F. Passamonti;E. Rumi;E. Boveri;M. Ruggeri;F. Rodeghiero;E.S. d'Amore;M.L. Randi;I. Bertozzi;F. Marino;A.M. Vannucchi;E. Antonioli;V. Carrai;H. Gisslinger;V. Buxhofer-Ausch;L. Müllauer;A. Carobbio;A. Gianatti;N. Gangat;C.A. Hanson;A. Tefferi (2011). Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis:an international study.. JOURNAL OF CLINICAL ONCOLOGY, vol. 29, pp. 3179-3184, ISSN:0732-183X DOI

Guglielmelli, Paola; Barosi, Giovanni; Rambaldi, Alessandro; Marchioli, Roberto; Masciulli, Arianna; Tozzi, Lorenzo; Biamonte, Flavia; Bartalucci, Niccolò; Gattoni, Elisabetta; Lupo, Maria Letizia; Finazzi, Guido; Pancrazzi, Alessandro; Antonioli, Elisabetta; Susini, Maria Chiara; Pieri, Lisa; Malevolti, Elisa; Usala, Emilio; Occhini, Ubaldo; Grossi, Alberto; Caglio, Silvia; Paratore, Simona; Bosi, Alberto; Barbui, Tiziano; Vannucchi, Alessandro M (2011). Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. BLOOD, vol. 118, pp. 2069-2076, ISSN:0006-4971 DOI Accesso ONLINE all'editore

Tiziano Barbui; Giovanni Barosi; Gunnar Birgegard; Francisco Cervantes; Guido Finazzi; Martin Griesshammer; Claire Harrison; Hans Carl Hasselbalch; Rudiger Hehlmann; Ronald Hoffman; Jean-Jacques Kiladjian; Nicolaus Kröger; Ruben Mesa; Mary F. McMullin; Animesh Pardanani; Francesco Passamonti; Alessandro M. Vannucchi; Andreas Reiter; Richard T. Silver; Srdan Verstovsek; Ayalew Tefferi (2011). Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.. JOURNAL OF CLINICAL ONCOLOGY, vol. 29, pp. 761-770, ISSN:0732-183X DOI

A.M. Vannucchi;F. Biamonte (2011). Epigenetics and mutations in chronic myeloproliferative neoplasms.. HAEMATOLOGICA, vol. 96(10), pp. 1398-1402, ISSN:0390-6078

F. Passamonti;C. Elena;S. Schnittger;R.C. Skoda;A.R. Green;F. Girodon;J.J. Kiladjian;M.F. McMullin;M. Ruggeri;C. Besses;A.M. Vannucchi;E. Lippert;H. Gisslinger;E. Rumi;T. Lehmann;C.A. Ortmann;D. Pietra;C. Pascutto;T. Haferlach;M. Cazzola (2011). Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations.. BLOOD, vol. 117(10), pp. 2813-2816, ISSN:0006-4971

A. Carobbio;J. Thiele;F. Passamonti;E. Rumi;M. Ruggeri; F. Rodeghiero;M.L. Randi;I. Bertozzi;A.M. Vannucchi;E. Antonioli;H. Gisslinger;V. Buxhofer-Ausch;G. Finazzi;N. Gangat;A. Tefferi;T. Barbui (2011). Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients.. BLOOD, vol. 117(22), pp. 5857-5859, ISSN:0006-4971

Guglielmelli, P.; Tozzi, L.; Bogani, C.; Iacobucci, I.; Ponziani, V.; Martinelli, G.; Bosi, A.; Vannucchi, A.M. . (2011). Overexpression of microRNA-16-2 contributes to the abnormalerythropoiesis in polycythemia vera.. BLOOD, vol. 117(25), pp. 6923-6927, ISSN:0006-4971 DOI Accesso ONLINE all'editore

A. M. Vannucchi;L. Pieri;P. Guglielmelli (2011). JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment.. THERAPEUTIC ADVANCES IN HEMATOLOGY, vol. 2, pp. 21-32, ISSN:2040-6207 DOI Accesso ONLINE all'editore

C. Desterke;C. Bilhou-Nabéra;B. Guerton;C. Martinaud;C. Tonetti;D. Clay;P. Guglielmelli;A.M. Vannucchi;D. Bordessoule;H. Hasselbalch;B. Dupriez;N. Benzoubir;M.F. Bourgeade;O. Pierre-Louis;V. Lazar;W. Vainchenker;A. Bennaceur-Griscelli;H. Gisslinger;S. Giraudier;M.C. Le Bousse-Kerdilès. (2011). FLT3-mediated p38-MAPK activation participates in the control ofmegakaryopoiesis in primary myelofibrosis.. CANCER RESEARCH, vol. 71(11), pp. 4049-4050, ISSN:0008-5472 DOI

A. Pardanani;P. Guglielmelli;T. Lasho;A. Pancrazzi;C.M. Finke;A.M. Vannucchi;A. Tefferi (2011). Primary myelofibrosis with or without mutant MPL: comparison ofsurvival and clinical features involving 603 patients.. LEUKEMIA, vol. 25(12), pp. 1834-1839, ISSN:0887-6924 DOI

l. Pieri;P. Guglielmelli;A.M. Vannucchi (2010). Chronic myeloproliferative neoplasms: a collaborative approach.. MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, vol. 2(2), pp. e2010017-0, ISSN:2035-3006

Vannucchi AM; Guglielmelli P. (2010). Advances in understanding and management of polycythemia vera.. CURRENT OPINION IN ONCOLOGY, vol. 22(6), pp. 636-641, ISSN:1040-8746 DOI

Rinaldi CR; Rinaldi P; Gemei M; Grimaldi F; Battipaglia G; Del Vecchio L; Martino B; Specchia G; Candoni A; Gugliotta L; Vannucchi AM; Barbui T; Pane F. (2010). JAK2V617F mutation persists in blasts and mature cells of transformed JAK2V617F-positive-myeloproliferative neoplasia: a European Leukemia Net (ENL) study.. AMERICAN JOURNAL OF HEMATOLOGY, vol. 85(5), pp. 383-386, ISSN:0361-8609

V. Rosti; E. Bonetti; G. Bergamaschi; R. Campanelli; P. Guglielmelli; M. Maestri;U. Magrini; M. Massa; C. Tinelli; G. Viarengo; L. Villani; M. Primignani; A.M. Vannucchi; F. Frassoni; G. Barosi. (2010). High frequency of endothelial colony forming cells marks a non-active myeloproliferative neoplasm with high risk ofsplanchnic vein thrombosis.. PLOS ONE, vol. 5, pp. e15277-e15277, ISSN:1932-6203

P. Guglielmelli; A.M. Vannucchi (2010). Recent advances in diagnosis and treatment of chronic myeloproliferative neoplasms. F1000 MEDICINE REPORTS, vol. 2, pp. pii:16-pii:16, ISSN:1757-5931

Jones AV; Campbell PJ; Beer PA; Schnittger S; Vannucchi AM; Zoi K; Percy MJ; McMullin MF; Scott LM; Tapper W; Silver RT; Oscier D; Harrison CN; Grallert H; Kisialiou A; Strike P; Chase AJ; Green AR; Cross NC. (2010). The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms.. BLOOD, vol. 115(22), pp. 4517-4523, ISSN:0006-4971

Barosi G; Birgegard G; Finazzi G; Griesshammer M; Harrison C; Hasselbalch H; Kiladijan JJ; Lengfelder E; Mesa R; Mc Mullin MF; Passamonti F; Reilly JT; Vannucchi AM; Barbui T. (2010). A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process.. BRITISH JOURNAL OF HAEMATOLOGY, vol. 148(6), pp. 961-963, ISSN:0007-1048

Beer PA; Delhommeau F; Lecouedic JP; Dawson MA; Chen E; Bareford D; Kusec R; McMullin MF; Harrison CN; Vannucchi AM; Vainchenker W; Green AR. (2010). Two routes to leukemic transformation following a JAK2 mutation-positive myeloproliferative neoplasm. BLOOD, vol. 115(14), pp. 2891-2900, ISSN:0006-4971

De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Leone G; Barbui T. (2010). Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia.. AMERICAN JOURNAL OF HEMATOLOGY, vol. 85(2), pp. 97-100, ISSN:0361-8609 DOI

Vannucchi AM. (2010). JAK2 mutation and thrombosis in the myeloproliferative neoplasms.. CURRENT HEMATOLOGIC MALIGNANCY REPORTS, vol. 5(1), pp. 22-28, ISSN:1558-8211

Ghinassi B; Martelli F; Verrucci M; D'Amore E; Migliaccio G; Vannucchi AM; Hoffman R; Migliaccio AR. (2010). Evidence for organ-specific stem cell microenvironments.. JOURNAL OF CELLULAR PHYSIOLOGY, vol. 223(2), pp. 460-470, ISSN:0021-9541

Carobbio A; Finazzi G; Antonioli E; Vannucchi AM; Barosi G; Ruggeri M; Rodeghiero F; Delaini F; Rambaldi A; Barbui T. (2010). Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria.. BLOOD, vol. 116(7), pp. 1051-1055, ISSN:0006-4971

Vannucchi AM. (2010). From palliation to targeted therapy in myelofibrosis.. THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 363(12), pp. 1180-1182, ISSN:0028-4793

Passamonti F; Cervantes F; Vannucchi AM; Morra E; Rumi E; Cazzola M; Tefferi A. (2010). Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis.. BLOOD, vol. 116(15), pp. 2857-2858, ISSN:0006-4971

P. Guglielmelli;F. Biamonte;A. Spolverini;L. Pieri;A. Isgrò;E. Antonioli;A. Pancrazzi;A. Bosi;G. Barosi;A.M. Vannucchi (2010). Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis.. LEUKEMIA, vol. 24(8), pp. 1533-1537, ISSN:0887-6924

Vannucchi AM. (2010). Insights into pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia. Internal and Emergency medicine. INTERNAL AND EMERGENCY MEDICINE, vol. 5(3), pp. 177-184, ISSN:1970-9366

Gianfaldoni G; Mannelli F; Ponziani V; Longo G; Bencini S; Bosi A; Vannucchi AM. (2010). Early reduction of WT1 transcripts during induction chemotherapy predicts for longer disease free and overall survival in acute myeloid leukemia.. HAEMATOLOGICA, vol. 95(8), pp. 1435-1438, ISSN:0390-6078

Gianfaldoni G;Mannelli F;Ponziani V;Longo G;Bencini S;Bosi A;Vannucchi AM (2010). Early reduction of WT1 transcripts during induction chemotherapy predicts for longer disease free and overall survival in acute myeloid leukemia.. HAEMATOLOGICA, vol. 95, pp. 833-836, ISSN:0390-6078 DOI

Antonioli E; Carobbio A; Pieri L; Pancrazzi A; Guglielmelli P; Delaini F; Ponziani V; Bartalucci N; Tozzi L; Bosi A; Rambaldi A; Barbui T; Vannucchi A (2010). Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia.. HAEMATOLOGICA, vol. 95, pp. 1435-1438, ISSN:0390-6078 DOI

Barosi G; Gattoni E; Guglielmelli P; Campanelli R; Facchetti F; Fisogni S; Goldberg J; Marchioli R; Hoffman R; Vannucchi AM. (2010). Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition.. AMERICAN JOURNAL OF HEMATOLOGY, vol. 85(8), pp. 616-619, ISSN:0361-8609 DOI

Beer PA; Ortmann CA; Stegelmann F; Guglielmelli P; Reilly JT; Larsen TS; Hasselbalch H; Vannucchi AM; Moller P; Dohner K; Green A. (2010). Molecular mechanisms associated with leukaemic transformation of MPL-mutant myeloproliferative neoplasms.. HAEMATOLOGICA, vol. 95(12), pp. 2153-2156, ISSN:0390-6078 DOI

Barbui T; Carobbio A; Cervantes F; Vannucchi AM; Guglielmelli P; Antonioli E; Alvarez-Larran A; Rambaldi A; Finazzi G; Barosi G. (2010). Thrombosis in primary myelofibrosis: incidence and risk factors.. BLOOD, vol. 115, pp. 778-782, ISSN:0006-4971 DOI

Passamonti F; Cervantes F; Vannucchi AM; Morra E; Rumi E; Pereira A; Guglielmelli P; Pungolino E; Caramella M; Maffioli M; Pascutto C; Lazzarino M; Cazzola M; Tefferi A. (2010). A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).. BLOOD, vol. 115, pp. 1703-1708, ISSN:0006-4971 DOI

Verrucci M; Pancrazzi A; Aracil M; Martelli F; Guglielmelli P; Zingariello M; Ghinassi B; D'Amore E; Jimeno J; Vannucchi AM; Migliaccio AR. (2010). CXCR4-independent rescue of the myeloproliferative defect of the Gata1low myelofibrosis mouse model by Aplidin.. JOURNAL OF CELLULAR PHYSIOLOGY, vol. 225(2), pp. 490-499, ISSN:0021-9541 DOI

Tefferi A; Lasho TL; Abdel-Wahab O; Guglielmelli P; Patel J; Caramazza D; Pieri L; Finke CM; Kilpivaara O; Wadleigh M; Mai M; McClure RF; Gilliland DG; Levine RL; Pardanani A; Vannucchi AM. (2010). IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.. LEUKEMIA, vol. 24(7), pp. 1302-1309, ISSN:0887-6924 DOI

Rambaldi A; Dellacasa CM; Finazzi G; Carobbio A; Ferrari ML; Guglielmelli P; Gattoni E; Salmoiraghi S; Finazzi MC; Di Tollo S; D'Urzo C; Vannucchi AM; Barosi G; Barbui T. (2010). A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms.. BRITISH JOURNAL OF HAEMATOLOGY, vol. 150(4), pp. 446-455, ISSN:0007-1048 DOI

Pieri L; Bosi A; Vannucchi AM. (2010). Imatinib and cardiac failure in idiopathic hypereosinophilic syndrome.. ANNALS OF HEMATOLOGY, vol. 89(7), pp. 745-746, ISSN:0939-5555

Barbara Ghinassi; Maria Zingariello; Fabrizio Martelli; Rodolfo Lorenzini; Alessandro M Vannucchi; Rosa Alba Rana; Mitsuo Nishikawa; Giovanni Migliaccio; John Mascarenhas; Anna Rita Migliaccio (2009). Increased differentiation of dermal mast cells in mice lacking the Mpl gene.. STEM CELLS AND DEVELOPMENT, vol. 18, pp. 1081-1092, ISSN:1547-3287

Migliaccio AR; Martelli F; Verrucci M; Sanchez M; Valeri M; Migliaccio G; Vannucchi AM; Zingariello M; Di Baldassarre A; Ghinassi B; Rana RA; van Hensbergen Y; Fibbe WE. (2009). GATA1 expression driven by the alternative hs2 enhancer in the spleen rescues the hematopoietic failure induced by the hypomorphic GATA1low mutation. BLOOD, vol. 114, pp. 2107-2120, ISSN:0006-4971

Barosi G; Birgegard G; Finazzi G; Griesshammer M; Harrison C; Hasselbalch HC; Kiladjian JJ; Lengfelder E; McMullin MF; Passamonti F; Reilly JT; Vannucchi AM; Barbui T. (2009). Response criteria for essential thrombocythemia and polycythemia vera. Result of a European LeukemiaNet (ELN) consensus conference. BLOOD, vol. 113, pp. 4829-4833, ISSN:0006-4971

L. Pieri ; C. Bogani ; P. Guglielmelli ; M. Zingariello ; RA. Rana ; N. Bartalucci ;A Bosi ; AM. Vannucchi (2009). The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils of polycythemia vera.. HAEMATOLOGICA, vol. 94, pp. 1537-1545, ISSN:0390-6078 DOI

Olcaydu D; Skoda RC; Looser R; Li S; Cazzola M; Pietra D; Passamonti F; Lippert E; Carillo S; Girodon F; Vannucchi A; Reading NS; Prchal JT; Ay C; Pabinger I; Gisslinger H; Kralovics R. (2009). The “GGCC” haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation positive polycythemia vera. LEUKEMIA, vol. 23, pp. 1924-1926, ISSN:0887-6924

Vannucchi AM. (2009). How JAK2-inhibitors work in myelofibrosis: an alternative hypothesis.. LEUKEMIA RESEARCH, vol. 33, pp. 1581-1583, ISSN:0145-2126

A.M. Vannucchi; P. Guglielmelli; A. Tefferi (2009). Advances in understanding and management of myeloproliferative neoplasms. CA, vol. 59, pp. 171-191, ISSN:0007-9235

L. Catani; R. Zini; D. Solazzo; E. Ottaviani; A.M. Vannucchi; S. ferrari; M. Baccarani; N. Vianelli; R.M. Lemoli; R. Manfredini (2009). Molecular profile of CD34+ stem/progenitor cells according to JAK2V617F mutation status in essential thrombocythemia.. LEUKEMIA, vol. 23, pp. 997-1000, ISSN:0887-6924

Vannucchi AM; Guglielmelli P; Rambaldi A; Bogani C; Barbui T. (2009). Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, vol. 13, pp. 1437-1450, ISSN:1582-1838

Goldman JM; Green AR; Holyoake T; Jamieson C; Mesa R; Mughal T; Pellicano F; Perrotti D; Skoda R; Vannucchi AM. (2009). Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues.. LEUKEMIA, vol. 23, pp. 1708-1715, ISSN:0887-6924

P. Guglielmelli; C. Fatini; M. Lenti; A. Bosi; A.M. Vannucchi (2009). JAK2V617F mutational screening in patients with retinal vein thrombosis or recurrent fetal loss.. THROMBOSIS RESEARCH, vol. 124, pp. 377-378, ISSN:0049-3848 DOI

A.M. Vannucchi; P. Guglielmelli; L. Pieri; E. Antonioli; A. Bosi (2009). Treatment options for essential thrombocythemia and polycythemia vera. EXPERT REVIEW OF HEMATOLOGY, vol. 2, pp. 41-55, ISSN:1747-4086 DOI

Vannucchi AM; Masala G; Antonioli E; Chiara Susini M; Guglielmelli P; Pieri L; Maggi L; Caini S; Palli D; Bogani C; Ponziani V; Pancrazzi A; Annunziato F; Bosi A. (2009). Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms.. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, vol. 18(7), pp. 2068-2073, ISSN:1055-9965

M. Verrucci; A.R. Migliaccio; A.M. Vannucchi; J.M. Jimeno Donaque (2009). Aplidine in the treatment of chronic myeloproliferative disorders. PHARMA MAR S.A., M. Verrucci, A.R. Migliaccio, A.M. Vannucchi, J.M. Jimeno Donaque

Guglielmelli P; Barosi G; Specchia G; Rambaldi A; Lo Coco F; Antonioli E; Pieri L; Pancrazzi A; Ponziani V; Delaini F; Longo G; Ammatuna E; Liso V; Bosi A; Barbui T; Vannucchi AM. (2009). Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele.. BLOOD, vol. 114, pp. 1477-1483, ISSN:0006-4971

Martelli F; Verrucci M; Migliaccio G; Zingariello M; Rana RA; Vannucchi AM; Migliaccio AR. (2009). Removal of the spleen in mice alters the cytokine expression profile of the marrow micro-environment and increases bone formation.. ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 1176, pp. 77-86, ISSN:0077-8923

Intermesoli T; Delaini F; Acerboni S; Salmoiraghi S; Spinelli O; Guerini V; Vannucchi AM; Mappa S; Rossi G; Rossi V; Di Bona E; Paratore S; Carobbio A; Rambaldi A; Barbui T; Bassan R. (2009). A short low-dose imatinib trial allows rapid identification of responsive patients in hypereosinophilic syndromes.. BRITISH JOURNAL OF HAEMATOLOGY, vol. 147, pp. 681-685, ISSN:0007-1048

C. Cellai; A. Laurenzana; E. Bianchi; S. Sdelci; R. Manfredini; A.M. Vannucchi; R. Caporale; M. Balliu; F. Mannelli; S. Ferrari; A. Bosi; D. Miniat; P.L. Cocco; S. Veronneau; J. Stankova; F. Paoletti (2009). Mechanistic insight into WEB-2170-induced apoptosis in human acute myelogenous leukemia cells: the crucial role of PTEN. EXPERIMENTAL HEMATOLOGY, vol. 37, pp. 1176-1185, ISSN:0301-472X DOI Accesso ONLINE all'editore

P. Guglielmelli; G. Barosi; L. Pieri; E. Antonioli; A. Bosi; A.M. Vannucchi (2009). JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis. HAEMATOLOGICA, vol. 94, pp. 144-146, ISSN:0390-6078 DOI

De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Cacciola E; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Leone G; Barbui T (2009). Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation. ANNALS OF HEMATOLOGY, vol. 89, pp. 141-146, ISSN:0939-5555 DOI

Carobbio A; Finazzi G; Antonioli E; Guglielmelli P; Vannucchi AM; Dellacasa CM; Salmoiraghi S; Delaini F; Rambaldi A; Barbui T. (2009). JAK2V617F allele burden and thrombosis: a direct comparison in Essential Thrombocythemia and Polycythemia Vera. EXPERIMENTAL HEMATOLOGY, vol. 37, pp. 1016-1021, ISSN:0301-472X DOI

De Stefano, V; Za, T; Rossi, E; Vannucchi, Am; Ruggeri, M; Elli, E; Micò, C; Tieghi, A; Cacciola, Rr; Santoro, C; Vianelli, N; Guglielmelli, P; Pieri, L; Scognamiglio, F; Cacciola, E; Rodeghiero, F; Pogliani, Em; Finazzi, G; Gugliotta, L; Leone, G; Barbui, T; Bosi, A; Ruggeri, M; Scognamiglio, F (2009). Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation.. ANNALS OF HEMATOLOGY, pp. 141-146, ISSN:0939-5555

Pieri L1; Bogani C; Guglielmelli P; Zingariello M; Rana RA; Bartalucci N; Bosi A; Vannucchi AM (2009). The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera.. HAEMATOLOGICA, pp. 1537-1545, ISSN:0390-6078

Francisco Cervantes; Brigitte Dupriez; Arturo Pereira; Francesco Passamonti; John T Reilly; Enrica Morra; Alessandro M Vannucchi; Ruben A Mesa; Jean-Loup Demory; Giovanni Barosi; Elisa Rumi; Ayalew Tefferi (2009). A new prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.. BLOOD, vol. 113, pp. 2895-2901, ISSN:0006-4971

Anna Rita Migliaccio; Fabrizio Martelli; Maria Verrucci; Giovanni Migliaccio; Alessandro Maria Vannucchi; Hongyu Ni; Mingjiang Xu; Yi Jiang; Betty Nakamoto; Thalia Papayannopoulou; Ronald Hoffman (2008). Altered SDF-1/CXCR4 axis in patients with primary myelofibrosis and in the Gata1 low mouse model of the disease.. EXPERIMENTAL HEMATOLOGY, vol. 36, pp. 158-171, ISSN:0301-472X

A.M. Vannucchi (2008). JAK2: how many faces in MPDs?. BLOOD, vol. 111, pp. 2499-2499, ISSN:0006-4971

Marco Ruggeri; Francesco Rodeghiero; Alberto Tosetto; Giancarlo Castaman; Francesca Scognamiglio; Guido Finazzi; Federica Delaini; Caterina Micò; Alessandro M Vannucchi; Elisabetta Antonioli; Valerio De Stefano; Tommaso Za; Luigi Gugliotta; Alessia Tieghi; Maria Gabriella Mazzucconi; Cristina Santoro; Tiziano Barbui; (2008). Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey.. BLOOD, vol. 111, pp. 666-671, ISSN:0006-4971

G. Barosi; R. A. Mesa; J. Thiele; F. Cervantes; P. J. Campbell; S. Verstovsek; B. Dupriez; R. L. Levine; F. Passamonti; J. Gotlib; J. T. Reilly; A. M. Vannucchi; C. A. Hanson; L. A. Solberg; A. Orazi; A. Tefferi; International Working Group; Treatment (IWG-MRT) (2008). Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment.. LEUKEMIA, vol. 22, pp. 437-438, ISSN:0887-6924

A. Carobbio; G. Finazzi; E. Antonioli; P. Guglielmelli; A.M. Vannucchi; F. Delaini; V. Guerini; M. Ruggeri; F. Rodeghiero; A. Rambaldi; T. Barbui (2008). Thrombocytosis and leukocytosis interactions in vascular complications of essential thrombocythemia. BLOOD, vol. 112(8), pp. 3135-3137, ISSN:0006-4971 DOI

Elisabetta Antonioli; Paola Guglielmelli; Giada Poli; Costanza Bogani; Alessandro Pancrazzi; Giovanni Longo; Vanessa Ponziani; Lorenzo Tozzi; Lisa Pieri; Valeria Santini; Alberto Bosi; Alessandro M Vannucchi. (2008). Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia.. HAEMATOLOGICA, vol. 93, pp. 41-48, ISSN:0390-6078 DOI

V. Ponziani; F. Mannelli; N. Bartalucci; G. Gianfaldoni; F. Leoni; E. Antonioli; P. Guglielmelli; S. Ciolli; A. Bosi; A. M. Vannucchi (2008). No role for CXCL12-G801A polymorphism in the development of extramedullary disease in acute myeloid leukemia.. LEUKEMIA, vol. 22, pp. 669-671, ISSN:0887-6924, Macmillan Magazines Limited:Porters South Crinian Street, London N1 9XW United Kingdom:011 44 207 8334000, 011 44 171 8434982, Fax: 011 44 207 812358: DOI

Alessandra Carobbio; Elisabetta Antonioli; Paola Guglielmelli; Alessandro M Vannucchi; Federica Delaini; Vittoria Guerini; Guido Finazzi; Alessandro Rambaldi; Tiziano Barbui (2008). Leukocytosis and risk stratification assessment in essential thrombocythemia.. JOURNAL OF CLINICAL ONCOLOGY, vol. 26, pp. 2732-2736, ISSN:0732-183X DOI

Alessandro M Vannucchi; Paola Guglielmelli (2008). Molecular pathophysiology of Philadelphia-negative myeloproliferative disorders: beyond JAK2 and MPL mutations.. HAEMATOLOGICA, vol. 93, pp. 972-976, ISSN:0390-6078 DOI

Alessandro M Vannucchi; Elisabetta Antonioli; Paola Guglielmelli; Alessandro Pancrazzi; Vittoria Guerini; Giovanni Barosi; Marco Ruggeri; Giorgina Specchia; Francesco Lo-Coco; Federica Delaini; Laura Villani; Silvia Finotto; Emanuele Ammatuna; Renato Alterini; Valentina Carrai; Gloria Capaccioli; Simonetta Di Lollo; Vincenzo Liso; Alessandro Rambaldi; Alberto Bosi; Tiziano Barbui (2008). Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia.. BLOOD, vol. 112, pp. 844-847, ISSN:0006-4971

Alessandro Pancrazzi; Paola Guglielmelli; Vanessa Ponziani; Gaetano Bergamaschi; Alberto Bosi; Giovanni Barosi; Alessandro M Vannucchi (2008). A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction.. THE JOURNAL OF MOLECULAR DIAGNOSTICS, vol. 10, pp. 435-441, ISSN:1525-1578

Lisa Pieri; Paola Guglielmelli; Costanza Bogani; Alberto Bosi; Alessandro M Vannucchi; (2008). Mesenchymal stem cells from JAK2(V617F) mutant patients with primary myelofibrosis do not harbor JAK2 mutant allele.. LEUKEMIA RESEARCH, vol. 32, pp. 516-517, ISSN:0145-2126 DOI

A. M. Vannucchi; E. Antonioli; P. Guglielmelli; A. Pardanani; A. Tefferi (2008). Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.. LEUKEMIA, vol. 22, pp. 1299-1307, ISSN:0887-6924 DOI

Costanza Bogani; Vanessa Ponziani; Paola Guglielmelli; Cristophe Desterke; Vittorio Rosti; Alberto Bosi; Marie-Caroline Le Bousse-Kerdilès; Giovanni Barosi; Alessandro M Vannucchi. (2008). Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis.. STEM CELLS, vol. 26, pp. 1920-1930, ISSN:1066-5099

De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T (2008). Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.. HAEMATOLOGICA, vol. 93, pp. 372-380, ISSN:0390-6078 DOI Accesso ONLINE all'editore

PANCRAZZI A; AM VANNUCCHI; V. PONZIANI; P. GUGLIELMELLI (2008). ANALISI MUTAZIONALI DELLE MALATTIE MIELOPROLIFERTAIVE CRONICHE. Università di Firenze

A.M. Vannucchi; T. Barbui (2008). Startified management of essential thrombocythemia and polycythemia vera. In: 13th Congress of the European Society of Hematology association, pp. 201-208.

Fabrizio Martelli; Barbara Ghinassi; Rodolfo Lorenzini; Alessandro M Vannucchi; Rosa Alba Rana; Mitsuo Nishikawa; Sandra Partamian; Giovanni Migliaccio; Anna Rita Migliaccio (2008). Thrombopoietin inhibits murine mast cell differentiation.. STEM CELLS, vol. 26, pp. 912-919, ISSN:1066-5099

Vannucchi AM; Barbui T (2007). Thrombocytosis and thrombosis. In: 49th Annual Meeting of the American Society of Hematology, pp. 363-369.

A.M. Vannucchi; J-L- Villeval; O. Wagner-Ballon; P. Guglielmelli; A.R. Migliaccio (2007). Animal models of myelofibrosis. In: M.P. Conn. Sourcebook of models for biomedical research, pp. 713-723, Totowa NJ, Human Press Inc.: P.M. Conn, ISBN:978-1-59745-285-4. DOI

Barbara Ghinassi; Massimo Sanchez; Fabrizio Martelli; Giovanni Amabile; Alessandro Maria Vannucchi; Giovanni Migliaccio; Stuart H Orkin; Anna Rita Migliaccio (2007). The hypomorphic Gata1low mutation alters the proliferation/differentiation potential of the common megakaryocytic-erythroid progenitor.. BLOOD, vol. 109, pp. 1460-1471, ISSN:0006-4971

Vannucchi Alessandro Maria; Pancrazi Alessandro; Guglielmelli Paola; Ponziani Vanessa (2007). MPL mutational analysis in chronic myeloproliferative disorders. Numero: WO2009072084 A2 Vannucchi Alessandro Maria, Pancrazi Alessandro, Guglielmelli Paola, Ponziani Vanessa

Ruben A Mesa; Srdan Verstovsek; Francisco Cervantes; Giovanni Barosi; John T Reilly; Brigitte Dupriez; Ross Levine; Marie-Caroline Le Bousse-Kerdiles; Martha Wadleigh; Peter J Campbell; Richard T Silver; Alessandro M Vannucchi; H. Joachim Deeg; Heinz Gisslinger; Deborah Thomas; Olatoyosi Odenike; Lawrence A Solberg; Jason Gotlib; Elizabeth Hexner; Stephen D Nimer; Hagop Kantarjian; Attilio Orazi; James W Vardiman; Juergen Thiele; Ayalew Tefferi; (2007). Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT).. LEUKEMIA RESEARCH, vol. 31, pp. 737-740, ISSN:0145-2126

Costanza Bogani; Paola Guglielmelli; Elisabetta Antonioli; Alessandro Pancrazzi; Alberto Bosi; Alessandro Maria Vannucchi (2007). B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis.. HAEMATOLOGICA, vol. 92, pp. 258-259, ISSN:0390-6078 DOI

A. M. Vannucchi; E. Antonioli; P. Guglielmelli; G. Longo; A. Pancrazzi; V. Ponziani; C. Bogani; P. R. Ferrini; A. Rambaldi; V. Guerini; A. Bosi; T. Barbui. (2007). Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden.. LEUKEMIA, vol. 21, pp. 1952-1959, ISSN:0887-6924 DOI

Paola Guglielmelli; Lorenzo Tozzi; Alessandro Pancrazzi; Costanza Bogani; Elisabetta Antonioli; Vanessa Ponziani; Giada Poli; Roberta Zini; Sergio Ferrari; Rossella Manfredini; Alberto Bosi; Alessandro M Vannucchi. (2007). MicroRNA expression profile in granulocytes from primary myelofibrosis patients.. EXPERIMENTAL HEMATOLOGY, vol. 35, pp. 1708-1718, ISSN:0301-472X DOI

Paola Guglielmelli; Alessandro Pancrazzi; Gaetano Bergamaschi; Vittorio Rosti; Laura Villani; Elisabetta Antonioli; Alberto Bosi; Giovanni Barosi; Alessandro M Vannucchi; (2007). Anaemia characterises patients with myelofibrosis harbouring Mpl mutation.. BRITISH JOURNAL OF HAEMATOLOGY, vol. 137, pp. 244-247, ISSN:0007-1048 DOI

Monica Bocchia; Alessandro M Vannucchi; Alessandro Gozzetti; Paola Guglielmelli; Giada Poli; Rosaria Crupi; Marzia Defina; Alberto Bosi; Lauria Francesco (2007). Insights into JAK2-V617F mutation in CML.. THE LANCET ONCOLOGY, vol. 8, pp. 864-866, ISSN:1470-2045 DOI

Alessandro M Vannucchi; Tiziano Barbui (2007). Thrombocytosis and thrombosis.. HEMATOLOGY, vol. 2007, pp. 363-370, ISSN:1520-4391

Alessandro M Vannucchi; Elisabetta Antonioli; Paola Guglielmelli; Alessandro Rambaldi; Giovanni Barosi; Roberto Marchioli; Rosa Maria Marfisi; Guido Finazzi; Vittoria Guerini; Fabrizio Fabris; Maria Luigia Randi; Valerio De Stefano; Sabrina Caberlon; Agostino Tafuri; Marco Ruggeri; Giorgina Specchia; Vincenzo Liso; Edoardo Rossi; Enrico Pogliani; Luigi Gugliotta; Alberto Bosi; Tiziano Barbui (2007). Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia.. BLOOD, vol. 110, pp. 840-846, ISSN:0006-4971

Ayalew Tefferi; Juergen Thiele; Attilio Orazi; Hans Michael Kvasnicka; Tiziano Barbui; Curtis A Hanson; Giovanni Barosi; Srdan Verstovsek; Gunnar Birgegard; Ruben Mesa; John T Reilly; Heinz Gisslinger; Alessandro M Vannucchi; Francisco Cervantes; Guido Finazzi; Ronald Hoffman; D. Gary Gilliland; Clara D Bloomfield; James W Vardiman (2007). Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.. BLOOD, vol. 110, pp. 1092-1097, ISSN:0006-4971

Anna Rita Migliaccio; Rosa Alba Rana; Alessandro M Vannucchi; Francesco A Manzoli (2007). Role of thrombopoietin in mast cell differentiation.. ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 1106, pp. 152-174, ISSN:0077-8923

A.M. Vannucchi; P. Guglielmelli (2007). Regolazione dell’emopoiesi. In: A. Bosi. Il sangue cordonale, pp. 41-63, Firenze, SEE Editrice: A. Bosi.

Paola Guglielmelli; Roberta Zini; Costanza Bogani; Simona Salati; Alessandro Pancrazzi; Elisa Bianchi; Francesco Mannelli; Sergio Ferrari; Marie-Caroline Le Bousse-Kerdilès; Alberto Bosi; Giovanni Barosi; Anna Rita Migliaccio; Rossella Manfredini; Alessandro M Vannucchi (2007). Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1).. STEM CELLS, vol. 25, pp. 165-173, ISSN:1066-5099 DOI

Marcello Di Nisio; Tiziano Barbui; Leonardo Di Gennaro; Giovanna Borrelli; Guido Finazzi; Raffaele Landolfi; Giuseppe Leone; Rosamaria Marfisi; Ettore Porreca; Marco Ruggeri; Anne W S; Gianni Tognoni; Alessandro M Vannucchi; Roberto Marchioli; (2007). The haematocrit and platelet target in polycythemia vera.. BRITISH JOURNAL OF HAEMATOLOGY, vol. 136, pp. 249-259, ISSN:0007-1048

Vittorio Rosti; Margherita Massa; Alessandro M Vannucchi; Gaetano Bergamaschi; Rita Campanelli; Alessandro Pecci; Gianluca Viarengo; Valentina Meli; Monia Marchetti; Paola Guglielmelli; Edward Bruno; Mingjiang Xu; Ronald Hoffman; Giovanni Barosi. (2007). The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia.. BLOOD CELLS, MOLECULES, & DISEASES, vol. 38, pp. 280-286, ISSN:1079-9796 DOI

A.M. Vannucchi (2007). Biologia molecolare delle malattie mieloproliferative croniche Ph Negative tipiche. In: 41° Congresso Nazionale Società Italiana di Ematologia, vol. Libro degli atti, pp. 164-172.

Alessandro M. Vannucchi; Alessandro Pancrazzi; paola guglielmelli; Vanessa Ponziani (2007). Analisi mutazionale delle malattie mieloproliferative croniche. Numero: FI2007A000274; PCT IB2008/055122 Università di Firenze

PIERI L; GUGLIELMELLI P; BOGANI C; A. BOSI; VANNUCCHI AM; FOR THE MYELOPROLIFERATIVE DISORDERS RESEARCH CONSORTIUM MPD-RC (2007). Mesenchymal stem cells from JAK2(V617F) mutant patients with primary myelofibrosis do not harbor JAK2 mutant allele. LEUKEMIA RESEARCH, vol. 32, pp. 516-517, ISSN:0145-2126, Elsevier Science Limited:Oxford Fulfillment Center, PO Box 800, Kidlington Oxford OX5 1DX United Kingdom:011 44 1865 843000, 011 44 1865 843699, EMAIL: asianfo@elsevier.com, tcb@elsevier.co.UK, INTERNET: http://www.elsevier.com, http://www.elsevier.com/locate/shpsa/, Fax: 011 44 1865 843010:

Giovanni Barosi; Gaetano Bergamaschi; Monia Marchetti; Alessandro M Vannucchi; Paola Guglielmelli; Elisabetta Antonioli; Margherita Massa; Vittorio Rosti; Rita Campanelli; Laura Villani; Gianluca Viarengo; Elisabetta Gattoni; Giancarla Gerli; Giorgina Specchia; Carmine Tinelli; Alessandro Rambaldi; Tiziano Barbui. (2007). JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis.. BLOOD, vol. 110, pp. 4030-4036, ISSN:0006-4971 DOI

Elisabetta Antonioli; Paola Guglielmelli; Giada Poli; Valeria Santini; Alberto Bosi; Alessandro M Vannucchi (2007). Polycythemia vera following autologous transplantation for AML: insights on the kinetics of JAK2V617F clonal dominance.. BLOOD, vol. 110, pp. 4620-4621, ISSN:0006-4971 DOI

A. M. Vannucchi; S. Guidi; P. Guglielmelli; S. Glinz; L. Lombardini; A. Busca; F. Locatelli; A. M. Dall'Omo; A. Bosi (2007). Significance of CTLA-4 and CD14 genetic polymorphisms in clinical outcome after allogeneic stem cell transplantation.. BONE MARROW TRANSPLANTATION, vol. 40, pp. 1001-1002, ISSN:0268-3369 DOI

Eva Zetterberg; Alessandro M Vannucchi; Anna Rita Migliaccio; William Vainchenker; Micheline Tulliez; Renée Dickie; Hans Hasselbalch; Rick Rogers; Jan Palmblad (2007). Pericyte coverage of abnormal blood vessels in myelofibrotic bone marrows.. HAEMATOLOGICA, vol. 92, pp. 597-604, ISSN:0390-6078

A. MIGLIACCIO; A. VANNUCCHI; G. MIGLIACCIO; R. HOFFMAN (2006). MOLECULAR ADVANCES TOWARD THE UNDERSTANDING OF THE PATHO-BIOLOGY OF IDIOPATHIC MYELOFIBROSIS. CURRENT IMMUNOLOGY REVIEW, vol. 2, pp. 169-186, ISSN:1573-3955 DOI Accesso ONLINE all'editore

M. SANCHEZ; I. WEISSMAN; M. PALLAVICINI; M. VALERI; P. GUGLIELMELLI; G. MIGLIACCIO; A. VANNUCCHI; A. MIGLIACCIO (2006). Differential amplification of murine bipotent megakaryocytic/erythroid progenitor and precursor cells during recovery from acute and chronic erythroid stress. STEM CELLS, vol. 24, pp. 337-348, ISSN:1066-5099 DOI

V. Ponziani;G. Gianfaldoni;F. Mannelli;F. Leoni;S. Ciolli;P. Guglielmelli;E. Antonioli;G. Longo;A. Bosi;A. M. Vannucchi (2006). The size of duplication does not add to the prognostic significance of FLT3 internal tandem duplication in acute myeloid leukemia patients.. LEUKEMIA, vol. 20, pp. 2074-2076, ISSN:0887-6924 DOI Accesso ONLINE all'editore

Vannucchi, A.; Guglielmelli, P.; Antonioli, E.; Mappa, S.; Pancrazzi, A.; Bogani, C.; Ponziani, V.; Bosi, A. (2006). Inconsistencies in the association between the JAL2V617F mutation and PRV-1 over-expression among the chronic myeloproliferative diseases. BRITISH JOURNAL OF HAEMATOLOGY, vol. 132, pp. 651-654, ISSN:0007-1048

CELLAI C; LAURENZANA A; VANNUCCHI AM; CAPORALE R; PAGLIERANI M; DI LOLLO S; PANCRAZZI A; PAOLETTI F (2006). GROWTH INHIBITION AND DIFFERENTIATION OF HUMAN BREAST CANCER CELLS BY THE PAFR ANTAGONIST WEB-2086. BRITISH JOURNAL OF CANCER, vol. 94, pp. 1637-1642, ISSN:0007-0920 DOI Accesso ONLINE all'editore

Ponziani V; Porfirio B; Guglielminelli P; Poli G; Guidi S; Nozzoli C; Lombardini L; Vannucchi AM; Bosi A. (2006). Development of a quantitative real time PCR assay for chimerism monitoring after sex-mismatched stem cell transplantation. Haematologica 91(s3) 2006, p. 20.. HAEMATOLOGICA, pp. 20-20, ISSN:0390-6078

Nozzoli C; Bartolozzi B; Guidi S; Orsi A; Vannucchi AM; Leoni F; Bosi A. (2006). Epstein-Barr virus-associated post-transplant lymphoproliferative disease with central nervous system involvement after unrelated allogeneic hematopoietic stem cell transplantation.. LEUKEMIA & LYMPHOMA, vol. 47(1), pp. 167-169, ISSN:1042-8194

A. M. Vannucchi;P. Guglielmelli;E. Antonioli;S. Mappa;A. Pancrazzi;C. Bogani;V. Ponziani;A. Bosi (2006). Inconsistencies in the association between the JAK2(V617F) mutation and PRV-1 over-expression among the chronic myeloproliferative diseases.. BRITISH JOURNAL OF HAEMATOLOGY, vol. 132, pp. 652-4; author reply 654, ISSN:0007-1048 DOI Accesso ONLINE all'editore

A. VANNUCCHI; A. PANCRAZZI; C. BOGANI; E. ANTONIOLI; P. GUGLIELMELLI (2006). A QUANTITATIVE ASSAY FOR JAK2V617F MUTATION IN MYELOPROLIFERATIVE DISORDERS BY ARMS-PCR AND CAPILLARY ELECTROPHORESIS. LEUKEMIA, vol. 20, pp. 1055-1060, ISSN:0887-6924 DOI

MARTELLI F.; GHINASSI B.; ALFANI E.; GATTA V.; PANETTA B.; PANCRAZZI A.; BOGANI C.; VANNUCCHI A.M.; F. PAOLETTI; MIGLIACCIO G.; MIGLIACCIO A.R. (2005). Variegation of the phenotype induced by the GATA-1low mutation in mice of different genetic backgrounds.. BLOOD, vol. 106, pp. 4102-4113, ISSN:0006-4971 DOI

Antonioli E; Guglielmelli P; Pancrazzi A; Bogani C; Verrucci M; Ponziani V; Longo G; Bosi A; Vannucchi AM. (2005). Clinical implications of the JAK2 V617F mutation in essential thrombocythemia.. LEUKEMIA, vol. 19(10), pp. 1847-1849, ISSN:0887-6924 DOI Accesso ONLINE all'editore

A. MIGLIACCIO; R. RANA; A. VANNUCCHI; F. MANZOLI (2005). ROLE OF GATA-1 IN NORMAL AND NEOPLASTIC HEMATOPOIESIS. In: Orkin SH. HEMATOPOIETIC STEM CELLS V, pp. 142-158, New York: KANZ L, WEISEL KC, ORLIC D, FIBBE WE.

MIGLIACCIO AR; RANA RA; A. VANNUCCHI; MANZOLI FA (2005). Role of GATA-1 in normal and neoplastic hemopoiesis. ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 1044, pp. 142-158, ISSN:0077-8923, New York Academy of Sciences:Subscription Services Department, 2 East 63rd Street:New York, NY 10021:(800)843-6927, (212)838-0230, EMAIL: publications@nyas.org, INTERNET: http://www.nyas.org, Fax: (212)888-2894:

A. VANNUCCHI; A. MIGLIACCIO; F. PAOLETTI; H. CHAGRAUOI; F. WENDLING (2005). Pathogenesis of myelofibrosis with myeloid metaplasia: lesson from mouse models of disease. SEMINARS IN ONCOLOGY, vol. 32, pp. 365-372, ISSN:0093-7754

A. Laurenzana; C. Cellai; A. Vannucchi; A. Pancrazzi; M. Romanelli; F. Paoletti (2005). WEB-2086 and WEB-2170 trigger apoptosis in both ATRA-sensitive and -resistant promyelocytic leukemia cells and greatly enhance ATRA differentiation potential. LEUKEMIA, vol. 19, pp. 390-395, ISSN:0887-6924

Vannucchi, ALESSANDRO MARIA; Ficarra, G.; Antonioli, E.; Bosi, Alberto (2005). Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma.. BRITISH JOURNAL OF HAEMATOLOGY, vol. 128, pp. 738-738, ISSN:0007-1048

E. ANTONIOLI; A. VANNUCCHI; A. BOSI; G. GIANFALDONI; F. MANNELLI (2005). Chronic relapsing thrombotic thrombocytopenic purpura succesfully treated with rituximab: case report. JOURNAL OF CHEMOTHERAPY, vol. 17, pp. 449-451, ISSN:1120-009X

A. M. Vannucchi;A. Pancrazzi;P. Guglielmelli;S. D. Lollo;C. Bogani;G. Baroni;L. Bianchi;A. R. Migliaccio;A. Bosi;F. Paoletti (2005). Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis.. THE AMERICAN JOURNAL OF PATHOLOGY, vol. 167, pp. 849-858, ISSN:0002-9440 DOI Accesso ONLINE all'editore

AM. Vannucchi; F.Martelli; A.Pancrazzi; P.Guglielmelli; F.Almerigogna; M.Valeri; E.Alfani; G.Migliaccio; AR. Migliaccio. (2005). Splenectomy favours development of extramedullary hematopoiesis in the GATA-1low model of myelofibrosis.. BLOOD, vol. 106, pp. 3513-3513, ISSN:0006-4971

VANNUCCHI AM.; BIANCHI L.; F. PAOLETTI; PANCRAZZI A.; TORRE E.; NISHIKAWA M.; ZINGARIELLO M.; DI BALDASSARRE A.; RANA RA.; LORENZINI R.; ALFANI E.; MIGLIACCIO G.; MIGLIACCIO AR. (2005). A pathobiological pathway linking thrombopoietin, GATA1 and TGFbeta1 in the development of myelofibrosis. BLOOD, vol. 105, pp. 3493-3501, ISSN:0006-4971

G.FICARRA; F.BENINATI; I.RUBINO; A.VANNUCCHI; G.LONGO; P. TONELLI; G.PINI PRATO (2005). Osteonecrosis of the jaws in periodontal patients with a history of biphosphonates treatment. JOURNAL OF CLINICAL PERIODONTOLOGY, vol. 32, pp. 1125-1128, ISSN:0303-6979

Gianfaldoni, G; Antonioli, E; Mannelli, F; Vannucchi, Am; Bosi, A. (2005). Chronic relapsing thrombotic thrombocytopenic purpura successfully treated with rituximab: case report.. JOURNAL OF CHEMOTHERAPY, pp. 449-451, ISSN:1973-9478

AMABILE G; DI NOIA A; ALFANI E; A. VANNUCCHI; SANCHEZ M; BOSCO D; MIGLIACCIO AR; MIGLIACCIO G (2005). Isolation of TPO-dependent subclones from the multipotent 32D cell line. BLOOD CELLS, MOLECULES, & DISEASES, vol. 35, pp. 241-252, ISSN:1079-9796

A. VANNUCCHI; L. BIANCHI ; F. PAOLETTI; V. DI GIACOMO; G. MIGLIACCIO; A.R.MIGLIACCIO (2004). Impaired GATA-1 expression and myelofibrosis in an animal model. PATHOLOGIE BIOLOGIE, vol. 52, pp. 275-279, ISSN:0369-8114

A. M. Vannucchi;A. Grossi;A. Pancrazzi;E. Antonioli;P. Guglielmelli;F. Balestri;M. Biscardi;S. Bulgarelli;G. Longo;C. Graziano;L. Gugliotta;A. Bosi (2004). PRV-1, erythroid colonies and platelet Mpl are unrelated to thrombosis in essential thrombocythaemia.. BRITISH JOURNAL OF HAEMATOLOGY, vol. 127, pp. 214-219, ISSN:0007-1048 DOI Accesso ONLINE all'editore

CIOLLI S; A. VANNUCCHI; LEONI F; NOZZOLI C; LONGO G; SALATI A; PANCRAZZI A; BIANCHI L; BOSI A; ROSSI FERRINI P. (2004). Internal tandem duplication of FLT3 gene (FLT3/TID) predicts a poor post-remission outcome in adult patients witha cute non-promyelocytic leukemia. LEUKEMIA & LYMPHOMA, vol. 45, pp. 73-78, ISSN:1042-8194

CENTURIONE L; DI BALDASSARRE A; ZINGARIELLO M; BOSCO D; GATTA V; RANA RA; LANGELLA V; DI VIRGILIO A; A. VANNUCCHI; MIGLIACCIO AR (2004). Increased and pathological emperipolesis of neutrophils within megakaryocytes associated with marrow fibrosis in GATA-1low mice. BLOOD, vol. 104, pp. 3573-3580, ISSN:0006-4971

A. MIGLIACCIO; R. LORENZINI; A. VANNUCCHI; G. MIGLIACCIO; G. SPANGRUDE (2003). Robust levels of long term multilineage reconstitution in the absence of stem cell self-replication in W/Wv mice transplanted with purified stem cells. JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH, vol. 12, pp. 409-424, ISSN:1525-8165

A. VANNUCCHI; A. MIGLIACCIO (2003). Little steps toward the identification of the myelofibrotic locus. BLOOD, vol. 101, pp. 5088-5089, ISSN:0006-4971

A. MIGLIACCIO; R. RANA; R. LORENZINI; L. BIANCHI; A. VANNUCCHI;G. MIGLIACCIO; M. SANCHEZ; L. CENTURIONE; S. ORKIN (2003). GATA-1 as a regulator of mast cell differentiation revealed by the phenotype of the GATA-1low mouse mutant.. JOURNAL OF EXPERIMENTAL MEDICINE, vol. 197, pp. 281-296, ISSN:0022-1007

Bosi A; Bartolozzi B; Vannucchi AM; Orsi A; Guidi S; Rossi Ferrini P. (2002). Polymerase chain reaction-based "pre-emptive" therapy with cidofovir for cytomegalovirus reactivation in allogeneic hematopoietic stem cells transplantation recipients: a prospective study.. HAEMATOLOGICA, vol. 87(4), pp. 446-447, ISSN:0390-6078

F. PAOLETTI; A. VANNUCCHI; L. BIANCHI; N. DELLA MALVA; C. CELLAI; A. LAURENZANA (2002). Specific PAF antagonist WEB-2086 induces terminal differentiation of murine and human leukemia cells. THE FASEB JOURNAL, vol. 16, pp. 733-735, ISSN:0892-6638

A. VANNUCCHI; L. BIANCHI; C. CELLAI; F. PAOLETTI; R. RANA; R. LORENZINI; G. MIGLIACCIO; A. MIGLIACCIO (2002). DEVELOPMENT OF MYELOFIBROSIS IN MICE GENETICALLY IMPAIRED FOR GATA-1 EXPRESSION (GATA-1LOW) MICE.. BLOOD, vol. 100, pp. 1123-1132, ISSN:0006-4971

A. VANNUCCHI; L. BIANCHI; C. CELLAI; F. PAOLETTI; V. CARRAI; A. CALZOLARI; L. CENTURIONE; R. LORENZINI; C. CARTA; E. ALFANI; M. SANCHEZ; G. MIGLIACCIO; A. MIGLIACCIO (2001). Accentuated response to phenylhydrazine and erythropoietin in mice genetically impaired for their Gata-1 expressione (GATA-1low mice).. BLOOD, vol. 97, pp. 3040-3050, ISSN:0006-4971

A. VANNUCCHI; GLINZ S; BOSI A; CAPORALE R; ROSSI FERRINI P (2001). Selective ex vivo expansion of cytomegalovirus/specific CD4 and CD8 T lymphocytes using dendritic cells pulsed with a human leukocyte antigen A201 restricted peptide. BRITISH JOURNAL OF HAEMATOLOGY, vol. 113, pp. 479-482, ISSN:0007-1048

A. VANNUCCHI; F. PAOLETTI; C. CELLAI; R. CAPORALE; M. SANCHEZ; S. LINARI; P. ROSSI FERRINI; G. MIGLIACCIO; A. MIGLIACCIO (2000). Identification and characterization of a bipotent (eryhtroid and megakaryocytic) cell precursor from the spleen of phenylhydrazine-treated mice.. BLOOD, vol. 95, pp. 2559-2568, ISSN:0006-4971

C. Cellai; R. Matucci; A. M. Vannucchi; F. Paoletti (1999). Constitutive muscarinic receptors are involved in the growth and differentiation of friend erythroleukemia cells.. JOURNAL OF CELLULAR PHYSIOLOGY, vol. 178, pp. 333-340, ISSN:0021-9541 Accesso ONLINE all'editore

A. Bosi; D. Laszlo; S. Bacci; R. Fanci; S. Guidi; R. Saccardi; A. M. Vannucchi; P. Rossi-Ferrini (1999). An open evaluation of triple antibiotic therapy including vancomycin for febrile bone marrow transplant recipients with severe neutropenia.. JOURNAL OF CHEMOTHERAPY, vol. 11, pp. 287-292, ISSN:1120-009X

A. M. Vannucchi; S. Glinz; A. Bosi; C. Fallai; P. Rossi-Ferrini (1999). Detection of contaminating tumor cells by RT-PCR in breast cancer patients.. BONE MARROW TRANSPLANTATION, vol. 24, pp. 228-229, ISSN:0268-3369

A. VANNUCCHI; LINARI S.; LIN C-S.; KOURY M.J.; BONDURANT M.C.; MIGLIACCIO A.R. (1999). Increased expression of the distal, but not of the proximal, Gata1 transcripts during differentiation of primary erythroid cells.. JOURNAL OF CELLULAR PHYSIOLOGY, vol. 180, pp. 390-401, ISSN:0021-9541, John Wiley & Sons Incorporated:Customer Service, 111 River Street:Hoboken, NJ 07030:(800)225-5945, (201)748-6000, EMAIL: societyinfo@wiley.com, INTERNET: http://www.wiley.com, Fax: (212)748-6551:

S. Linari; A. M. Vannucchi; S. Ciolli; F. Leoni; R. Caporale; A. Grossi; G. Pagliai; V. Santini; F. Paoletti; P. R. Ferrini (1998). Coexpression of erythroid and megakaryocytic genes in acute erythroblastic (FAB M6) and megakaryoblastic (FAB M7) leukaemias.. BRITISH JOURNAL OF HAEMATOLOGY, vol. 102, pp. 1335-1337, ISSN:0007-1048

Rossi Ferrini P; Grossi A; Vannucchi AM; Barosi G; Guarnone R; Piva N; Musto P; Balleari E (1998). A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes.. BRITISH JOURNAL OF HAEMATOLOGY, vol. 103, pp. 1070-1074, ISSN:1365-2141

A. M. Vannucchi; A. Bosi; S. Glinz; P. Pacini; S. Linari; R. Saccardi; R. Alterini; L. Rigacci; S. Guidi; L. Lombardini; G. Longo; M. P. Mariani; P. Rossi-Ferrini (1998). Evaluation of breast tumour cell contamination in the bone marrow and leukapheresis collections by RT-PCR for cytokeratin-19 mRNA.. BRITISH JOURNAL OF HAEMATOLOGY, vol. 103, pp. 610-617, ISSN:0007-1048

A. Bosi; M. Zazzi; A. Amantini; M. Cellerini; A. M. Vannucchi; A. De Milito; S. Guidi; R. Saccardi; L. Lombardini; D. Laszlo; P. Rossi Ferrini (1998). Fatal herpesvirus 6 encephalitis after unrelated bone marrow transplant.. BONE MARROW TRANSPLANTATION, vol. 22, pp. 285-288, ISSN:0268-3369

GROSSI A.; A. VANNUCCHI; BACCI P.; CAPORALE R.; CAPPELLI G.; VISCONTI G.; PAGLIAI G.; FERRINI PR. (1998). Erythropoietin upregulates the expression of its own receptor in TF-1 cell line. LEUKEMIA RESEARCH, vol. 22(2), pp. 145-151, ISSN:0145-2126, Elsevier Science Limited:Oxford Fulfillment Center, PO Box 800, Kidlington Oxford OX5 1DX United Kingdom:011 44 1865 843000, 011 44 1865 843699, EMAIL: asianfo@elsevier.com, tcb@elsevier.co.UK, INTERNET: http://www.elsevier.com, http://www.elsevier.com/locate/shpsa/, Fax: 011 44 1865 843010:

A. M. Vannucchi; A. Bosi; S. Linari; S. Guidi; G. Longo; L. Lombardini; M. P. Mariani; R. Saccardi; D. Laszlo; P. Rossi Ferrini (1997). High doses of recombinant human erythropoietin fail to accelerate platelet reconstitution in allogeneic bone marrow transplantation. Results of a pilot study.. HAEMATOLOGICA, vol. 82, pp. 53-56, ISSN:0390-6078

D. Laszlo; S. Bacci; A. Bosi; R. Fanci; S. Guidi; R. Saccardi; A. M. Vannucchi; P. Rossi Ferrini (1997). Randomized trial comparing netilmicin plus imipenem-cilastatin versus netilmicin plus ceftazidime as empiric therapy for febrile neutropenic bone marrow transplant recipients.. JOURNAL OF CHEMOTHERAPY, vol. 9, pp. 95-101, ISSN:1120-009X

ASHIHARA E.; A. VANNUCCHI; MIGLIACCIO G.; MIGLIACCIO A.R. (1997). Growth factor receptor expression during in vitro differentiation of partially purified populations containing murine stem cells.. JOURNAL OF CELLULAR PHYSIOLOGY, vol. 171(3), pp. 343-356, ISSN:0021-9541, John Wiley & Sons Incorporated:Customer Service, 111 River Street:Hoboken, NJ 07030:(800)225-5945, (201)748-6000, EMAIL: societyinfo@wiley.com, INTERNET: http://www.wiley.com, Fax: (212)748-6551:

G. Longo; E. Filimberti; S. Cinotti; A. M. Vannucchi; L. Lombardini; P. R. Ferrini (1997). Pretransplant factor XII levels correlate with prognosis in patients undergoing autologous graft for hematological malignancies.. HAEMATOLOGICA, vol. 82, pp. 360-361, ISSN:0390-6078

A. VANNUCCHI; LINARI S.; CELLAI C.; KOURY M.J.; PAOLETTI F. (1997). Constitutive and inducible expression of megakaryocyte-specific genes in Friend erythroleukaemia cells.. BRITISH JOURNAL OF HAEMATOLOGY, vol. 99, pp. 500-508, ISSN:0007-1048

BONSI L.; GROSSI A.; STRIPPOLI P.; TUMIETTO F.; TONELLI R.; A. VANNUCCHI; RONCHI A.; OTTOLENGHI S.; VISCONTI G.; AVANZI G.C.; PEGORARO L.; BAGNARA G.P. (1997). An erythroid and megakaryocytic common precursor cell line (B1647) expressing both c-mpl and erythropoietin receptor (Epo-R) proliferates and modifies globin chain synthesis in response to megakaryocyte growth and development factor (MGDF) but not to erythropoietin (Epo).. BRITISH JOURNAL OF HAEMATOLOGY, vol. 98(3), pp. 549-559, ISSN:0007-1048, Blackwell Science Limited:PO Box 88, Oxford OX2 0NE United Kingdom:011 44 1865 776868, 011 44 1865 206038, EMAIL: journals.cs@blacksci.co.uk, INTERNET: http://www.blackwell-science.com, Fax: 011 44 1865 721205:

A. M. Vannucchi; A. Bosi; A. Ieri; S. Guidi; R. Saccardi; L. Lombardini; S. Linari; D. Laszlo; G. Longo; P. Rossi-Ferrini (1996). Combination therapy with G-CSF and erythropoietin after autologous bone marrow transplantation for lymphoid malignancies: a randomized trial.. BONE MARROW TRANSPLANTATION, vol. 17, pp. 527-531, ISSN:0268-3369

F. Paoletti; A. Mocali; C. Cellai; R. Caporale; A. M. Vannucchi (1996). Megakaryocyte-like increase in ploidy of Friend's erythroleukemia cells induced to endoreplication by colcemid.. EXPERIMENTAL HEMATOLOGY, vol. 24, pp. 1441-1448, ISSN:0301-472X

V. Santini; A. Zoccolante; A. Bosi; S. Guidi; R. Saccardi; A. M. Vannucchi; G. Martinazzo; P. A. Bernabei; P. R. Ferrini (1996). Detection of bcr/abl transcripts by RT-PCR and their colorimetric evaluation in chronic myeloid leukemia patients receiving allogeneic bone marrow transplantation.. HAEMATOLOGICA, vol. 81, pp. 201-207, ISSN:0390-6078

A. R. Migliaccio; A. M. Vannucchi; G. Migliaccio (1996). Molecular control of erythroid differentiation.. INTERNATIONAL JOURNAL OF HEMATOLOGY, vol. 64, pp. 1-29, ISSN:0925-5710

F. PAOLETTI; A. VANNUCCHI; A. MOCALI; R. CAPORALE; S. BURSTEIN (1995). Identification and conditions for selective expression of megakaryocytic markers in Friend erythroleukemia cells. BLOOD, vol. 86, pp. 2624-2631, ISSN:0006-4971

D.Laszlo ; A. Bosi ; S. Guidi ; R. Saccardi R; A. M .Vannucchi ; L.Lombardini;G. Longo ; R.Fanci ; A. Azzi ;R. De Santis ; PL . Rossi Ferrini. (1995). Prostaglandin E2 bladder instillation for the treatment of hemorrhagic cystitis after allogeneic bone marrow transplantation.. HAEMATOLOGICA, vol. 80 (5), pp. 421-425, ISSN:0390-6078

GROSSI A.; A. VANNUCCHI; BACCI P.; LONGO G.; RAFANELLI D.; ALTERINI R.; ROSSI FERRINI P. (1995). In vivo administration of stem cell factor enhances both proliferation and maturation of murine megakaryocytes.. HAEMATOLOGICA, vol. 80(1), pp. 18-24, ISSN:0390-6078, Fondaz Ferrata Storti:Strada Nuova 134, 27100 Pavia Italy:011 39 0382 531182, EMAIL: office@haematologica.it, Fax: 011 39 0382 27721:

A. M. Vannucchi; A. Bosi; L. Lombardini; A. Grossi; P. Bacci; S. Guidi; R. Saccardi; P. Rossi-Ferrini (1995). Circulating CFU-E during hematopoietic recovery after allogeneic bone marrow transplantation: relationship to erythroid engraftment.. EXPERIMENTAL HEMATOLOGY, vol. 23, pp. 1337-1340, ISSN:0301-472X

A. M. Vannucchi; A. Bosi; D. Laszlo; S. Guidi; R. Saccardi; P. Rossi-Ferrini (1995). Treatment of a delayed graft failure after allogeneic bone marrow transplantation with IL-3 and GM-CSF.. HAEMATOLOGICA, vol. 80, pp. 341-343, ISSN:0390-6078

A. M. Vannucchi; D. Rafanelli; G. Longo; A. Bosi; S. Guidi; R. Saccardi; E. Filimberti; S. Cinotti; A. Grossi; M. Morfini (1994). Early hemostatic alterations following bone marrow transplantation: a prospective study.. HAEMATOLOGICA, vol. 79, pp. 519-525, ISSN:0390-6078

A. M. Vannucchi; A. Bost; A. Grossi; S. Guidi; R. Saccardi; P. Rossi-Ferrini (1994). Down-modulation of serum erythropoietin levels following cyclosporin A infusion.. BONE MARROW TRANSPLANTATION, vol. 13, pp. 497-498, ISSN:0268-3369

A. M. Vannucchi; A. Grossi; D. Rafanelli; M. Statello; S. Cinotti; P. Rossi-Ferrini (1994). Inhibition of erythropoietin production in vitro by human interferon gamma.. BRITISH JOURNAL OF HAEMATOLOGY, vol. 87, pp. 18-23, ISSN:0007-1048

P. Rossi Ferrini; A.M. Vannucchi (1994). Malattie dell'emostasi e della trombosi. di W.E. Hathaway, S.H. Goodnight, Milano: Mc-Graw Hill, 883862240X.

S. Porciani; A. Becciolini; A. Lanini; M. Storto; R. Saccardi; A. Bosi; S. Guidi; A.M. Vannucchi; L. Lombardini (1994). Erythrocyte polyamines in the monitoring of bone marrow transplantation.. In: Convegno, vol. Int. J. Biol. Markers vol. 9, pp. 160-160.

A. Azzi; R. Fanci; A. Bosi; S. Ciappi; K. Zakrzewska; R. de Santis; D. Laszlo; S. Guidi; R. Saccardi; A. M. Vannucchi (1994). Monitoring of polyomavirus BK viruria in bone marrow transplantation patients by DNA hybridization assay and by polymerase chain reaction: an approach to assess the relationship between BK viruria and hemorrhagic cystitis.. BONE MARROW TRANSPLANTATION, vol. 14, pp. 235-240, ISSN:0268-3369

P.L. Rossi Ferrini; A.M.Vannucchi (1994). Terapia con eritropoietina dopo trapianto di midollo osseo. In: C. Bernasconi. Citochine emopoietiche: Impiego clinico, pp. 115-121, Pavia: Edizioni Medico-Scientifiche Pavia.

A. VANNUCCHI; PAOLETTI F.; GROSSI A. (1994). A common megakaryocytic and erythrocytic precursor in murine erythroleukemia (Friend) cells?. EXPERIMENTAL HEMATOLOGY, vol. 22(2), pp. 110-110, ISSN:0301-472X, Elsevier Science Incorporated / NY Journals:Madison Square Station, PO Box 882:New York, NY 10159:(212)633-3730, EMAIL: usinfo-f@elsevier.com, INTERNET: http://www.elsevier.com, Fax: (212)633-3680:

A. M. Vannucchi; A. Bosi; A. Grossi; S. Guidi; R. Saccardi; P. Bacci; L. Lombardini; P. Rossi-Ferrini (1993). The use of erythropoietin in the treatment of post-bone marrow transplantation anemia.. INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, vol. 16 Suppl 5, pp. 8-12, ISSN:0391-3988

S. Porciani; A. Lanini; P. Comeglio; A. Tani; R. Saccardi; A. Bosi; S. Guidi; A.M. Vannucchi; A. Becciolini (1993). Significance of erythrocyte polyamines in bone marrow transplantation.. THE INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, vol. Int. J. Biol. Markers vol. 8, pp. 46-47, ISSN:0393-6155

Rossi Ferrini P; Santini V; Ciolli S; Grossi A; Leoni F; Rafanelli D; Vannucchi AM. (1993). The role of haematopoietic growth factors in the treatment of myelodysplastic syndromes.. HEMATOLOGICAL ONCOLOGY, vol. 11, pp. 32-35, ISSN:0278-0232

A. Bosi; S. Guidi; A. Messori; R. Saccardi; L. Lombardini; A. M. Vannucchi; R. Fanci; P. Rossi-Ferrini (1993). Ondansetron versus chlorpromazine for preventing emesis in bone marrow transplant recipients: a double-blind randomized study.. JOURNAL OF CHEMOTHERAPY, vol. 5, pp. 191-196, ISSN:1120-009X

A. M. Vannucchi; A. Grossi; A. Bosi; D. Rafanelli; M. Statello; S. Guidi; R. Saccardi; P. Rossi-Ferrini (1993). Effects of cyclosporin A on erythropoietin production by the human Hep3B hepatoma cell line.. BLOOD, vol. 82, pp. 978-984, ISSN:0006-4971

A. Grossi; A.M. Vannucchi; D. Rafanelli; P.L. Rossi Ferrini (1993). The humoral regulation of normal and pathological erythropoieisis. In: P.P. Foà. Humoral factors in the regulation of tissue growth, pp. 47-70, New York: Sringer-Verlag, ISBN:0387978798.

A. Bosi; R. Fanci; P. Pecile; S. Guidi; R. Saccardi; A. M. Vannucchi; G. Longo; E. Donnini; A. Orsi; P. Rossi-Ferrini (1992). Aztreonam versus colistin-neomycin for selective decontamination of the digestive tract in patients undergoing bone marrow transplantation: a randomized study.. JOURNAL OF CHEMOTHERAPY, vol. 4, pp. 30-34, ISSN:1120-009X

D. Rafanelli; A. Grossi; G. Longo; A. M. Vannucchi; P. Bacci; P. R. Ferrini (1992). Recombinant human erythropoietin for treatment of myelodysplastic syndromes.. LEUKEMIA, vol. 6, pp. 323-327, ISSN:0887-6924

P. Bacci; A. Grossi; A. M. Vannucchi; D. Rafanelli; A. Casini; M. De Luca (1992). Effects of miocamycin and erythromycin on polymorphonuclear cell function.. JOURNAL OF CHEMOTHERAPY, vol. 4, pp. 268-270, ISSN:1120-009X

A. Messori; A. Bosi; S. Guidi; G. Longo; C. Pistolesi; R. Saccardi; T. Valenza; A. M. Vannucchi (1992). PKRD: a pharmacokinetic program for least-squares and bayesian analysis of repeated-dose pharmacokinetic curves.. COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE, vol. 38, pp. 27-35, ISSN:0169-2607

F. PAOLETTI; MOCALI A.; VANNUCCHI A.M. (1992). Acetylcholinesterase in murine erythroleukemia (Friend) cells: evidence for megakaryocyte-like expression and potential growt-regulatory role of enzyme activity. BLOOD, vol. 79, pp. 2873-2879, ISSN:0006-4971

A. M. Vannucchi; A. Bosi; A. Grossi; S. Guidi; R. Saccardi; L. Lombardini; P. Rossi-Ferrini (1992). Stimulation of erythroid engraftment by recombinant human erythropoietin in ABO-compatible, HLA-identical, allogeneic bone marrow transplant patients.. LEUKEMIA, vol. 6, pp. 215-219, ISSN:0887-6924

A. VANNUCCHI; GROSSI A.; PAOLETTI F.; RAFANELLI D.; BACCI P.; FERRINI P.R. (1992). Constitutive expression of a megakaryocytic functional property by murine erythroleukemia (Friend) cells: the incorporation of serotonin.. EXPERIMENTAL HEMATOLOGY, vol. 20, pp. 1296-1301, ISSN:0301-472X

A. Bosi; A. M. Vannucchi; A. Grossi; S. Guidi; R. Saccardi; D. Rafanelli; G. Longo; P. R. Ferrini (1991). Inadequate erythropoietin production in allogeneic bone marrow transplant patients.. HAEMATOLOGICA, vol. 76(4), pp. 280-284, ISSN:0390-6078

A. M. Vannucchi; G. Longo; A. Bosi; S. Cinotti; E. Filimberti; S. Guidi; R. Saccardi; M. Morfini; E. Boni; P. Rossi Ferrini (1991). Early haemostatic modifications following cryopreserved graft infusion.. BONE MARROW TRANSPLANTATION, vol. 8, pp. 171-176, ISSN:0268-3369

A. M. Vannucchi; A. Grossi; A. Bosi; D. Rafanelli; S. Guidi; R. Saccardi; R. Alterini; P. R. Ferrini (1991). Impaired erythropoietin production in mice treated with cyclosporin A.. BLOOD, vol. 78, pp. 1615-1618, ISSN:0006-4971

A. Bosi; A. M. Vannucchi; A. Grossi; S. Guidi; D. Rafanelli; R. Saccardi; P. R. Ferrini (1991). Serum erythropoietin levels in allogeneic, non T-depleted bone marrow transplantation, and the effects of rhEpo administration.. BONE MARROW TRANSPLANTATION, vol. 7 Suppl 2, pp. 87-87, ISSN:0268-3369

J. H. Amuasi; P. Ferri; A. Grossi; L. Vannucchi; A. M. Vannucchi; P. R. Ferrini (1991). Quantitative platelet imaging and comparison of four mathematical models for the evaluation of platelet mean life span in patients with chronic immune thrombocytopenia.. HAEMATOLOGICA, vol. 76, pp. 104-108, ISSN:0390-6078

A. Grossi; A. M. Vannucchi; G. Longo; D. Rafanelli; P. Rossi Ferrini (1991). [Essential thrombocythemia: conventional therapy]. HAEMATOLOGICA, vol. 76 Suppl 3, pp. 368-370, ISSN:0390-6078

A. Bosi; A. M. Vannucchi; A. Grossi; S. Guidi; L. Vannucchi; R. Saccardi; P. A. Bernabei; G. Longo; D. Rafanelli; P. Rossi-Ferrini (1991). Serum erythropoietin levels in patients undergoing autologous bone marrow transplantation.. BONE MARROW TRANSPLANTATION, vol. 7, pp. 421-425, ISSN:0268-3369

Kimmel M; Grossi A; Amuasi J; Vannucchi AM. (1990). Non-parametric analysis of platelet lifespan.. CELL AND TISSUE KINETICS, vol. 23(3), pp. 191-202, ISSN:0008-8730

D. Rafanelli; A. Grossi; A. M. Vannucchi; S. Cinotti; M. Morfini; P. R. Ferrini (1990). The effect of picotamide on platelet function in patients with myeloproliferative disorders.. THROMBOSIS AND HAEMOSTASIS, vol. 63, pp. 525-526, ISSN:0340-6245

Vannucchi AM; Grossi A; Rafanelli D; Vannucchi L; Rossi Ferrini P. (1990). Binding of recombinant human 125I-erythropoietin to CFU-E from the spleen of anemic mice.. HAEMATOLOGICA, vol. 75(1), pp. 21-26, ISSN:0390-6078

A. VANNUCCHI; GROSSI A.; RAFANELLI D.; FERRINI P.R. (1990). In vivo stimulation of megakaryocytopoiesis by recombinant murine granulocyte-macrophage colony-stimulating factor.. BLOOD, vol. 76(8), pp. 1473-1480, ISSN:0006-4971, American Society of Hematology:1900 M Street Northwest, Suite 200:Washington, DC 20036:(800)633-4931, (202)776-0544, EMAIL: publishing@hematology.org, ash@hematology.org, INTERNET: http://www.hematology.org, Fax: (202)776-0551:

A. Bosi; E. De Majo; S. Guidi; F. Parri; R. Saccardi; A. M. Vannucchi; R. Fanci; P. R. Ferrini (1990). Kinetics of anti-CMV antibodies after administration of intravenous immunoglobulins to bone marrow transplant recipients.. HAEMATOLOGICA, vol. 75, pp. 109-112, ISSN:0390-6078

GROSSI A.; A. VANNUCCHI; ROSSI FERRINI P. (1990). Humoral regulation of megakaryocytopoiesis.. BIOTHERAPY, vol. 2(4), pp. 375-385, ISSN:0921-299X, Kluwer Academic Publishers:Journals Department, PO Box 322, 3300 AH Dordrecht Netherlands:011 31 78 6576050, EMAIL: frontoffice@wkap.nl, kluweronline@wkap.nl, INTERNET: http://www.kluwerlaw.com, Fax: 011 31 78 6576254:

P. Rossi Ferrini; A. Grossi; V. Santini; A. M. Vannucchi (1989). [GM-CSF: its clinical administration; the treatment of aplasia]. HAEMATOLOGICA, vol. 74, pp. 489-500, ISSN:0390-6078

A. M. Vannucchi; A. Grossi; D. Rafanelli; L. Vannucchi; P. R. Ferrini (1989). A dot assay for the erythropoietin receptor using human recombinant 125I-erythropoietin.. ANALYTICAL BIOCHEMISTRY, vol. 182, pp. 182-186, ISSN:0003-2697

GROSSI A.; A. VANNUCCHI; RAFANELLI D.; ROSSI FERRINI P. (1989). Recombinant human erythropoietin has little influence on megakaryocytopoiesis in mice.. BRITISH JOURNAL OF HAEMATOLOGY, vol. 71(4), pp. 463-468, ISSN:0007-1048, Blackwell Science Limited:PO Box 88, Oxford OX2 0NE United Kingdom:011 44 1865 776868, 011 44 1865 206038, EMAIL: journals.cs@blacksci.co.uk, INTERNET: http://www.blackwell-science.com, Fax: 011 44 1865 721205:

A. Grossi; S. Rosseti; A. M. Vannucchi; D. Rafanelli; P. R. Ferrini (1988). Occurrence of haemorrhagic and thrombotic events in myeloproliferative disorders: a retrospective study of 108 patients.. CLINICAL AND LABORATORY HAEMATOLOGY, vol. 10, pp. 167-175, ISSN:0141-9854

A. M. Vannucchi; A. Grossi; D. Rafanelli; P. Rossi Ferrini; G. Ramponi (1988). Partial purification and biochemical characterization of human plasma thrombopoietin.. LEUKEMIA, vol. 2, pp. 236-240, ISSN:0887-6924

A. VANNUCCHI; GROSSI A.; RAFANELLI D.; VANNUCCHI L.; FERRINI P.R. (1988). Serotonin incorporation as a marker of murine megakaryocyte proliferation in liquid cultures.. EXPERIMENTAL HEMATOLOGY, vol. 16(11), pp. 916-921, ISSN:0301-472X, Elsevier Science Incorporated / NY Journals:Madison Square Station, PO Box 882:New York, NY 10159:(212)633-3730, EMAIL: usinfo-f@elsevier.com, INTERNET: http://www.elsevier.com, Fax: (212)633-3680:

GROSSI A.; A. VANNUCCHI; RAFANELLI D.; VANNUCCHI L.; FERRINI P.R. (1987). Megakaryocyte progenitors in the bone marrow and peripheral blood of patients with myeloproliferative diseases.. AMERICAN JOURNAL OF HEMATOLOGY, vol. 25(4), pp. 371-376, ISSN:0361-8609, John Wiley & Sons Incorporated:Customer Service, 111 River Street:Hoboken, NJ 07030:(800)225-5945, (201)748-6000, EMAIL: societyinfo@wiley.com, INTERNET: http://www.wiley.com, Fax: (212)748-6551:

A. Grossi; A. M. Vannucchi; D. Rafanelli; P. R. Ferrini (1987). Biological characterization of partially purified human urinary thrombopoietin.. HAEMATOLOGICA, vol. 72, pp. 291-295, ISSN:0390-6078

A.M. Vannucchi; A. grossi; D. Rafanelli; S. Di Lollo; C. Bertani; P.L. Rossi Ferrini (1986). Partial purification of thrombopoietic stimulating activity from human urine. In: R.R. Levine, N. Williams, J. Levin, B.L. Evatt. Megakayocyte development and function, pp. 221-226, New York: Alan R. Liss, Inc, ISBN:0845150650.

A. Grossi; A. M. Vannucchi; P. Casprini; M. Morfini; P. R. Ferrini (1986). Effects of high-dose intravenous gammaglobulin on kinetic parameters of 51Cr-labelled platelets in chronic ITP.. HAEMATOLOGICA, vol. 71, pp. 123-127, ISSN:0390-6078

A. M. Vannucchi; A. Grossi; D. Rafanelli; S. DiLollo; C. Bertani; P. RossiFerrini (1986). Partial purification of a thrombopoietic stimulating activity from human urine.. PROGRESS IN CLINICAL AND BIOLOGICAL RESEARCH, vol. 215, pp. 221-225, ISSN:0361-7742

GROSSI A.; A. VANNUCCHI; RAFANELLI D.; FILIMBERTI E.; ROSSI FERRINI P. (1986). Beta-thromboglobulin content in megakaryocytes of patients with myeloproliferative diseases.. THROMBOSIS RESEARCH, vol. 43(3), pp. 367-374, ISSN:0049-3848, Elsevier Science Limited:Oxford Fulfillment Center, PO Box 800, Kidlington Oxford OX5 1DX United Kingdom:011 44 1865 843000, 011 44 1865 843699, EMAIL: asianfo@elsevier.com, tcb@elsevier.co.UK, INTERNET: http://www.elsevier.com, http://www.elsevier.com/locate/shpsa/, Fax: 011 44 1865 843010:

M. Morfini; A. M. Vannucchi; A. Grossi; S. Cinotti; D. Rafanelli; P. R. Ferrini (1985). Direct evidence that high dose intravenous gammaglobulin blocks splenic and hepatic sequestration of 51Cr-labeled platelets in ITP.. THROMBOSIS AND HAEMOSTASIS, vol. 54, pp. 554-554, ISSN:0340-6245

GROSSI A.; A. VANNUCCHI; RAFANELLI D.; FERRINI P.R. (1985). Megakaryocyte enrichment procedures.. BLOOD, vol. 65(2), pp. 506-507, ISSN:0006-4971, American Society of Hematology:1900 M Street Northwest, Suite 200:Washington, DC 20036:(800)633-4931, (202)776-0544, EMAIL: publishing@hematology.org, ash@hematology.org, INTERNET: http://www.hematology.org, Fax: (202)776-0551:

A. Grossi; A. M. Vannucchi; D. Rafanelli; P. Rossi Ferrini (1984). Transient remission of chronic idiopathic thrombocytopenic purpura during septic abscess and pneumothorax.. HAEMATOLOGICA, vol. 69, pp. 572-575, ISSN:0390-6078

G. Longo; F. Cecchi; A. Grossi; M. Matucci; D. Rafanelli; A. M. Vannucchi; P. Casprini; S. Vannini; M. Morfini; A. Dolara (1984). Coagulation and platelet function in hypertrophic cardiomyopathy.. THROMBOSIS AND HAEMOSTASIS, vol. 51, pp. 299-299, ISSN:0340-6245

A. Grossi; A. M. Vannucchi; P. Casprini; S. Guidi; D. Rafanelli; M. G. Pecchioli; P. Rossi Ferrini (1983). Different patterns of platelet turnover in chronic idiopathic thrombocytopenic purpura.. SCANDINAVIAN JOURNAL OF HAEMATOLOGY, vol. 31, pp. 206-214, ISSN:0036-553X